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Cardiac injury is increased following ischemia-reperfusion. Mitochondria are the
“effector organelles” that are damaged during ischemia (ISC) when there is no blood
flow. Resumption of metabolism by damaged mitochondria during reperfusion (REP)
results in increased cell injury. Current therapeutic interventions to pre-condition and
post-condition the heart during ISC are ineffective during certain conditions like aging
and diabetes due to defects in the signaling cascades. In contrast, mitochondrial-based
strategies are effective in protecting the heart during ISC-REP. Hence direct therapeutic
targeting of dysfunctional mitochondria will provide the potential to bypass the upstream
signaling defects and intervene directly upon the effector organelle.
Novel mitochondrial-targeted therapy relies on understanding the sites in the electron
transport chain (ETC) that are damaged by ISC and produce cell-injury during REP.
This project identifies a novel pathological role of cytochrome c in depleting cardiolipin
during ischemia after which the mitochondria are in a defective condition that leads to
additional cell death during reperfusion. During ischemia oxidants from complex III
oxidize cytochrome c, forming a peroxidase, which causes oxidative damage and
depletion of cardiolipin. Depletion of cardiolipin disrupts normal physiology and
augments cell death. Identification of the innovative pathobiology during ISC-REP
recognizes a novel therapeutic target, cytochrome c peroxidase, which can be a focal
point for new therapeutic interventions to decrease cardiac injury.
In order to maintain homeostatis, living organisms have the methionine sulfoxide
reductase system, which reduce both free and protein bound Met(O) back to methionine
(Met) in the presence of thioredoxin. Oxidized Trx is inactive and unable to bind to
ASK1 thereby activating ASK1 and causing cell death via p38/JNK pathways thereby
xxvi

contributing to the pathogenesis of myocardial ISC-REP injury. In this study we have
shown that inhibition of ASK1 protects the heart during REP via the modulation of
mitochondria that sustained damage during ISC. The mitochondrial-based mechanism
of cardioprotection with ASK1 inhibition enhanced the functional integrity of the inner
mitochondrial membrane retaining cytochrome c thereby decreasing cell death. This
therapeutic intervention is a key step to achieve the ultimate goal to improve clinical
outcomes

in

patients

that

suffer

xxvii

an

acute

myocardial

infarction.

CHAPTER I: INTRODUCTION

I. 1. Mitochondria biology and structure
Mitochondria are distinct, membrane-bound organelles found in most eukaryotic cells.
The size of these organelles range from 0.5 to 1.0 μm in diameter and their number in a
cell varies in each organism and tissue type from one to over a thousand. Since
mitochondria generate most of the cell’s adenosine triphosphate (ATP), they are often
termed “powerhouse of the cell”. In addition to generating energy, mitochondria are
involved in other cellular processes such as calcium homeostasis, ammonia
detoxification (urea cycle), fatty acid oxidation, certain heme synthesis reactions, steroid
synthesis, cell signaling, cellular differentiation and cell death [1, 2]. Mitochondria are
implicated in diseased conditions including cardiac dysfunction, neurodegeneration and
congenital metabolic disorders, as well as, aging [3-5]. The mitochondrion has its own
independent genome that is replicated and transcribed entirely in this organelle similar
to bacterial genome, presumably due to the bacterial origin of mitochondria [6-8]. As
1

shown in Figure 1.1, the organelle is composed of compartments that include the outer
membrane, the intermembrane space, the inner membrane, the cristae and the matrix,
each responsible for specialized functions. Both the outer and inner membranes are
made

of

phospholipid

bilayers

and

2

have

different

properties

[6-8].

Figure 1.1. Schematic depiction of a mitochondrion. The organelle is composed of
compartments that include the outer membrane, the intermembrane space, the inner
membrane, the cristae and the matrix [8].

3

The outer mitochondrial membrane (OMM) encloses the entire organelle and has a 1:1
weight ratio of protein: phospholipid which is similar to that of the plasma membrane [6,
8]. The membrane allows passage of molecules 5000 Daltons or less through channels
which are formed by a large variety of integral proteins called porins. Larger proteins are
transported across the outer membrane by binding to the multisubunit protein complex
called translocase of the outer membrane (TOM) [9]. Studies have been reported that
the outer membrane associates with the endoplasmic reticulum (ER) forming a structure
called MAM (mitochondria-associated ER-membrane) which is involved in lipid transfer
between ER and mitochondria and also in calcium signaling [10-12].
The space between the outer membrane and the inner membrane is termed the
mitochondrial intermembrane space (IMS). IMS contains small molecules including ions,
carbohydrates and sugars that are permeable to the outer membrane resulting in a
similar concentration as the cytosol. However, large proteins like cytochrome c are
transported across the outer membrane via the TOM complex [6, 13-15].
The inner mitochondrial membrane (IMM) has numerous invaginations called cristae
which increase the surface area of the inner membrane. Proteins are embedded in the
inner membrane that perform important functions including oxidative phosphorylation,
specific transport of proteins that regulate metabolite passage, protein import and
mitochondrial fusion. The IMM is enriched with phospholipids, particularly cardiolipin,
which makes the membrane impermeable to molecules [6, 16]. Proteins are transported
across the inner membrane using translocase of inner membrane (TIM) and metabolite
transporters comprising malate-aspartate shuttle system and

4

glycerol-3-phosphate

shuttle that allow tightly controlled exchange of metabolites and protein import across
the IMM [9].
The space enclosed by the inner membrane is called the matrix. It contains proteins,
enzymes, special mitochondrial ribosomes (rRNAs), transfer RNAs (tRNAs), and
circular forms of mitochondrial DNA (mtDNA) present in two to ten copies per
mitochondrion [17]. Some key functions of matrix localized enzymes include oxidation of
pyruvate and fatty acids, the citric acid cycle and the urea cycle (in liver and kidney
mitochondria) [6].
Mitochondria have their own genetic material and fully functional machinery to
synthesize their own RNAs and proteins. Mitochondrial DNA is a double-stranded
circular sequence which consists of 16,569 base pairs that encodes a total of 37 genes:
22 tRNA, 2 rRNA, and 13 polypeptides. The thirteen polypeptides encode for the
subunits of electron transport chain complexes I, III, IV, and ATP synthase (Table 1.1).
The rest of the mitochondrial proteins are encoded by nuclear DNA which are
subsequently translocated and integrated into the mitochondria using TOM/TIM system
[17, 18].
Significant oxidative stress generates reactive oxygen species (ROS) from the electron
transport chain (ETC) which result in spontaneous and relatively frequent mutations in
mtDNA due to close proximity of mtDNA to the electron transport chain (ETC) and due
to the lack of the efficient defense mechanisms [19, 20]. Mitochondrial DNA mutations
trigger a vicious cycle that lead to enzymatic abnormalities and further oxidative stress.
Such mutations are inherited (only maternal mtDNA is passed to the offspring) and lead
5

to diseases that include Kearns-Sayre syndrome, MELAS syndrome and Leber's
hereditary optic neuropathy [21]. However, mutations in nuclear genes lead to
mitochondrial abnormalities such as coenzyme Q10 deficiency, Barth syndrome and a
wide variety of clinical disease phenotypes, including certain mitochondrial myopathies
[22, 23].

6

Table 1.1. The mtDNA encodes proteins of the electron transport chain
complexes

Complex

Number of subunits

Subunits encoded by mtDNA

Complex I

46

ND1, ND2, ND3, ND4, ND4L, ND5, ND6

Complex III

11

CytB

Complex IV

13

COX1, COX2, COX3

Complex V

8

Atp6, Atp8

COX- Cyclooxygenase; ND- NADH dehydrogenase; Cyt- Cytochrome; ATPadenosine triphosphate.
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I. 2. Cellular respiration and oxidative phosphorylation
The most important role of mitochondria is to generate energy for cellular respiration in
the form of ATP by phosphorylation of ADP. The key pathways localized to the inner
membrane and matrix include the tricarboxylic acid cycle, fatty acid β-oxidation and
pyruvate dehydrogenase which lead to oxidation of amino acids, fatty acids and
pyruvate [6]. The initial steps involve conversion of pyruvate (by pyruvate
dehydrogenase) or fatty acids (in β-oxidation pathway) to acetyl CoA. The acetyl-CoA is
oxidized to CO2 by the citric acid cycle also known as the tricarboxylic acid cycle
(TCA)/Krebs cycle. Oxidation of one pyruvate molecule generates three molecules of
nicotinamide adenine dinucleotide (NADH), one flavin adenine dinucleotide (FADH 2)
and one guanosine triphosphate (GTP) molecule [24, 25]. NADH and FADH2 are
cofactors that transfer electrons into the respiratory chain to drive ATP synthesis. The
respiratory chain is localized in cristae of the IMM. NADH is diffusible but impermeable
to inner membrane whereas FADH2 (from TCA cycle) is covalently bound to the
succinate dehydrogenase which is the only enzyme of TCA cycle located in the inner
membrane. GTP is readily converted into ATP. NADH and FADH2 generated by the
TCA cycle transfer electrons to O2 through four multimeric respiratory complexes (I-IV)
resulting in an electrochemical gradient across the membrane which in turn is used by
by the F0F1 complex (ATP synthase) to generate ATP. The coupled processes of the
electron

transport

chain-dependent

NADH

and

FADH2

oxidation

and

the

phosphorylation of ADP to ATP driven by electron transport chain (ETC) dependent
proton motive force (PMF) are termed oxidative phosphorylation [26-28].
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Oxidative phosphorylation is a highly sophisticated system evolutionarily developed to
increase recovery of energy contained in glucose molecules [29]. Oxidation of glucose
through glycolysis, citric acid cycle and oxidative phosphorylation theoretically
generates a maximum of 38 ATP molecules (3 ATP per NADH and 2 ATP per FADH2).
However, this number is not reached in reality due to the losses in energy, such as the
cost of moving two equivalents of NADH (generated in glycolysis) from cytoplasm to
matrix, translocation of Pi and ADP into the mitochondria, and ATP out of the
mitochondria. Furthermore, inefficiencies in oxidative phosphorylation due to leakage of
protons across of the mitochondrial membrane and slippage of the ATP synthase/proton
pump reduce the ATP yield. Therefore, the theoretical efficiency of oxidative
phosphorylation is not reached and the observed yield is closer to 30 ATP molecules
per one molecule of glucose (2.5 ATP per NADH and 1.5 ATP per FADH2) [30].
I. 3. Mitochondrial Electron Transport Chain
The electron transport chain (ETC) is comprised of multi-subunit enzyme complexes
and additional mobile electron carriers, ubiquinone (coenzyme Q10) in the inner
membrane and cytochrome c located in the intermembrane space [26, 28]. These
complexes diffuse in the inner mitochondrial membrane individually or are organized
into larger supercomplexes called respirasomes [31].
Electrons are transferred from complex I (NADH: ubiquinone oxidoreductase; EC
1.6.5.3) and II (succinate: ubiquinone oxidoreductase, EC 1.3.5.1) to ubiquinone, which
carries them to complex III (ubiquinol: cytochrome c oxidoreductase, EC 1.10.2.2). From
complex III, the mobile cytochrome c carries the electrons to complex IV (cytochrome c
oxygenase, EC 1.9.3.1) where molecular oxygen is reduced to water. However, other
9

enzymes

comprising

the

electron-transferring

flavoprotein

(ETF):

ubiquinone

oxidoreductase; s, n-glycerophosphate dehydrogenase; dihydroorotate dehydrogenase
provide electrons to the ETC at the ubiquinone and the reactions occur usually at a very
low rate. Additionally in the liver, electrons generated during oxidation of sulfurcontaining amino acids by sulfite oxidase can be fed into the ETC at cytochrome c [29].
Electrons are transferred via productive collisions from high redox potential molecules
such as NADH, FADH2 with ETC complexes. The energy lost as a result of the transfer
of electrons is utilized by complexes I, III and IV to pump protons from the mitochondrial
matrix into the IMS (Figure 1.2). The released energy generates a potential difference
(ΔΨm) and proton gradient (ΔpH) across the membrane. This electrochemical proton
gradient is used by the ATP synthase which allows the flow of H+ through the enzyme
back into the matrix to generate ATP from adenosine diphosphate (ADP) and inorganic
phosphate. Apart from the ATP synthesis, proton motive force is used for chemical,
osmotic and mechanical work such as mitochondrial Ca2+ uptake, ATP/ADP exchange
by the adenine-nucleotide translocator (ANT), import of nDNA-encoded preproteins,
functioning of mitochondrial antiporters (aspartate/glutamate, H+/K+, H+/Na+, 2H+/Ca2+)
and symporters (H+/pyruvate and Pi/ADP) [29, 32-34]. The proton motive force is
dominated by ΔΨm and the ΔpH component contributes approximately 15% to its total.
Therefore, ΔΨm can be considered as a crucial indicator of mitochondrial function and
metabolic activity [29, 35, 36].
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Figure 1.2. Schematic representation of mitochondrial electron transport chain.
The sites of proton pumping (red arrows) are located in complex I, III and IV. From each
NADH two electrons are passed into molecular oxygen (O2) resulting in translocation of
ten protons (H+). Six protons are pumped into IMS when succinate/FADH2 is used as an
electron donor. NADH, nicotinamide adenine dinucleotide; FMN, flavin mononucleotide;
Fe-S, iron-sulfur cluster; Q, ubiquinone; cyt c, cytochrome c; C, complex. Adapted from
[37].
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I. 3. 1. NADH: ubiquinone oxidoreductase
During oxidative phosphorylation complex I transfers two electrons from NADH to
ubiquinone with pumping of four protons from the matrix to the intermembrane space
[6]. Complex I is comprised of forty six unique protein subunits with an approximate total
size of 980 kDa. Despite such complexity, only fourteen subunits are essential for its
catalytic function: seven highly hydrophobic mtDNA-encoded subunits (ND1, ND2, ND3,
ND4, ND4L, ND5, ND6) and seven hydrophilic nuclear-encoded subunits (NDUFV1,
NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, NDUFS8). The function of the
remaining 31 additional proteins is largely unknown. Electron microscopy analysis
reveals that complex I assumes an L-shaped conformation and consists of a peripheral,
matrix-protruding arm and an inner membrane-embedded arm. The matrix protruding
arm contains NADH dehydrogenase activity with flavin mononucleotide (FMN) and an
inner membrane-immersed arm consisting of all mtDNA-encoded subunits with
ubiquinone-and rotenone-binding site [38, 39].
Fully assembled mammalian complex I accepts electrons from NADH into FMN cofactor
located in the NDUFV1 subunit. Then electrons are transported through the protein by
eight iron-sulfur clusters: N3 (NDUFV1), N1b (NDUFS1), N4 (NDUFS1), N5 (NDUFS1),
N6a (NDUFS8), N6b (NDUFS8) and N2 (NDUFS7). In six of the FeS clusters (N2, N3,
N4, N5, N6a, and N6b) iron atoms are coordinated to four sulfur atoms ([4Fe-4S]) and
the other two (N1a, N1b) display a [2Fe-2S] configuration. After reaching FeS N2
cluster, electrons are transferred to the coenzyme Q or ubiquinone-binding site [38, 40].
The Thermus thermophiles crystal structure studies predict that coenzyme Q binding is
located at subunits NDUFS2 and NDUFS7. Another study using site-directed
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mutagenesis of NDUFS2 and NDUFS7 subunits confirm this observation [41]. Complex
I inhibitors act at the terminal electron donating step by inhibition of ubiquinone
reduction. One of them is the naturally found plant alkaloid rotenone, commonly used to
study complex I dependent effects in the mitochondria. Photoaffinity labeling techniques
and mutagenesis studies from Y. lipolytica, R. capsulatus reveal that NDUFS2,
NDUFS7, ND1 and ND5 subunits contribute to the rotenone inhibition site within
complex I [42]. The net reaction of complex I activity is summarized below:
NADH + Q + 5H+matrix

NAD++ QH2 + 4H+IMS

Altered complex I activity during pathologic conditions is often observed in a variety of
diseases resulting from mutations in mtDNA that leads to decreased integrated
respiration [21, 43, 44]. Mutations in the subunits of complex I have been associated
with neurological and neuromuscular diseases, including Leigh syndrome [45-47],
Leber's hereditary optic neuropathy [48, 49] and even with etiology of Parkinson’s
disease [50, 51]. Moreover, enzymatic activity may be regulated by specific posttranslational modifications of particular subunits which include phosphorylation [52],
glutathionylation [53-55], acetylation/deacetylation [56] and even S-nitrosylation [57, 58].
I. 3. 2. Succinate: ubiquinone oxidoreductase
Complex II is the only enzyme that participates both in TCA cycle and ETC by
catalyzing the oxidation of TCA intermediate succinate to fumarate with the electron
transfer directly to the quinone pool. Complex II consists of four protein subunits and a
bound flavin adenine dinucleotide (FAD) cofactor, iron-sulfur clusters, and a heme
group [6]. The protein subunits are encoded by nuclear-DNA that include two
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hydrophilic subunits, SDHa and SDHb which protrude into matrix and two hydrophobic
subunits SDHc and SDHd embedded in inner membrane. The heme group does not
participate in electron transfer to coenzyme Q, but is important in decreasing production
of reactive oxygen species. The electrons from succinate are accepted at FAD cofactor
located in SDHa. Next, the electrons are transferred through three iron-sulfur clusters,
([2Fe-2S], [4Fe-4S] and [3Fe-4S]), within SDHb into membrane-anchored subunits that
contain the quinone-binding site [6, 59]. However, transfer of electrons through complex
II does not transport protons across the membrane as summarized in equation below:
FADH2 + Q

FAD + QH2

Molecules such as TTFA (thenoyltrifluoroacetone) bind to the ubiquinone pocket and
are speculated to play a protective role in blocking the unfavorable reverse electron flow
from complex II into I, which can result in superoxide generation by complex I [29, 60].
The activity of succinate:ubiquinone oxidoreductase is tightly regulated despite its
simple

structure.

However,

post-translational

modifications

such

as

acetylation/deacetylation [61], glutathionylation [62] and phosphorylation [63] in the
flavoprotein part of the complex (SDHa) result in altered enzymatic activity. On the other
hand, mutations in SDHa subunit have been reported to cause a classical mitochondrial
neurogenerative disease, encephalomyopathy in childhood while the mutations found in
the genes of the other three subunits have been associated with sporadic
paragangliomas and/or pheochromocytomas and the inherited autosomal cancersusceptibility syndromes [64]. Also, mev-1 mutation in C. elegans gene encoding the
homolog of SDHc subunit results in premature aging and hypersensitivity to oxidative
stress [65].
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I. 3. 3. Ubiquinone: cytochrome c oxidoreductase
Complex III or mitochondrial bc1 complex is a multi-subunit enzyme encoded by both
the mtDNA (cytochrome b) and the nuclear genome (remaining ten peptides). Structural
studies have shown that the functional complex III is present as a dimer wherein each
monomer contains three protein subunits with redox prosthetic groups: cytochrome b
(two b-type hemes, bLand bH); cytochrome c1 (c-type heme, c1); and the Rieske ironsulfur protein harbors a [2Fe-2S] cluster [66].
Complex III has two reaction centers for ubiquinol, Qo and Qi. Qo is located on the outer
face of the inner membrane while Qi is localized facing the mitochondrial matrix [67].
Electron transport through bc1 complex, termed Q cycle, involves a concerted oxidation
of QH2 coupled with proton pumping across the membrane. Initially, QH2 is oxidized at
the Qo site resulting in bifurcation of the electron transfer. One electron is given to the
[2Fe-2S] cluster within Rieske subunit, which is then oxidized by cytochrome c1.
Further, cytochrome c1 is oxidized by cytochrome c resulting in transfer of a single
electron and translocation of two protons into the IMS. The second electron bifurcated
at the Qo site, as a result of oxidation of QH2 results in formation of a semiquinone
which subsequently is oxidized by donating the electron to the chain of hemes bL and
bH. Reduced heme bH gives one electron to Qi site resulting in the formation of
semiquinone. The second half of the cycle is initiated again by a second round of QH2
oxidation at Qo resulting in another molecule of reduced cytochrome c, another two
protons translocation into the intermembrane space. The successive reduction of
hemes bL and bH causes the complete reduction of semiquinone at Qi to ubiquinone.
The quinone reduction at Qi involves an uptake of two protons from matrix. Therefore,
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as a result of the Q cycle, for every pair of electrons taken from QH2 to two molecules of
cytochrome c, four protons are translocated to the intermembrane space and two
protons are removed from the mitochondrial matrix [68]. The overall reaction is
summarized below:
QH2+ 2cyt-c (Fe3+ox) + 2H+matrix

Q + 2cyt-c (Fe2+red) + 4H+IMS

Two types of complex III-specific inhibitors have been reported based on their targets.
Myxothiazol and stigmatellin bind to the distinct pockets within the Qo site and block the
transfer of electrons into complex III from reduced QH2. Antimycin A (second class
inhibitor) blocks the electron transfer from bH heme to oxidized Qi site by binding to the
ubiquinone [69].
Complex III gene mutations cause exercise intolerance and cardiomyopathy [19].
Additionally, mutations in mtDNA-encoded cytochrome b have been reported to cause
septo-optic dysplasia [70] and multisystem disorders like deafness, mental retardation,
retinitis pigmentosa, cataract, growth retardation and epilepsy [71]. Furthermore,
Bjornstad syndrome (deafness, hair abnormalities) [72] and the Finnish lethal GRACILE
syndrome (growth retardation, amino aciduria, iron overload, lactic acidosis and
cholestasis) [73] are due to mutations in BCs1L assembly protein which assists in the
maturation of the Rieske protein.
I. 3. 4. Cytochrome c oxidase
Complex IV (cytochrome c oxidase) belongs to the heme-copper oxygen reductase
superfamily which catalyzes the complete reduction of dioxygen to water and
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translocates protons to the intermembrane space [8]. Complex IV can exist as a
monomer, which is sufficient for electron transfer and oxygen reduction but for proton
translocation across the inner membrane the cytochrome c oxidase must be present as
a dimer. Each monomer is composed of several metal prosthetic groups (two hemes
and two copper centers) and thirteen proteins. Among the thirteen proteins, three of
them are encoded by mtDNA (COX1, COX2, and COX3) and the other ten by nuclear
DNA. COX1 contains twelve transmembrane α helices that are organized in three
groups of four helices with a central pore. The first group contains heme a, the second
contains a heme a3-copper CuB center, and the third group is empty. Subunit COX2
contains a binuclear copper center CuA. The nuclear encoded subunits (COX4 -COX8)
are considered to contribute to the stability, assembly and regulation of the oxygenase.
However, their exact functions are only partially understood [6, 25, 74].
Electrons from reduced cytochrome c are transferred to the binuclear CuA center in
COX2 and then to heme a. Finally electrons are transferred to heme a3-CuB center from
heme a resulting in conversion of ½ O2 to H2O at the heme a3-CuB center which
involves a rapid four electron reduction along with immediate oxygen-oxygen bond
cleavage to avoid superoxide formation. Electron transfer through complex IV is coupled
with the translocation of four protons from the matrix to the intermembrane space [25,
29]. The net reaction is summarized below:
4cyt-c (Fe2+red) + 8H+matrix + O2

4cyt-c (Fe3+ox) + 4H+IMS + 2H2O

The oxygen binding site of complex IV also binds ligands such as carbon monoxide
(CO), nitric oxide (NO), cyanide anions (CN-), azide anions (N3-), and hydrogen sulfide
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(H2S), resulting in competitive inhibition of the oxidase activity, which in turn leads to
chemical asphyxiation [29].
Genetic mutations altering complex IV functionality and/or structure usually result in
very severe and often fatal metabolic dysfunctions. The majority of cytochrome c
oxidase disorders are caused by mutations in nuclear-encoded assembly proteins such
as SURF1, SCO1, SCO2, COX10 and COX15 [75] that result in oxidase deficiency with
variety of clinical phenotypes including Leigh syndrome, fatal infantile hypertophic
cardiomyopathy and other neuropathies [76, 77].
I. 4. Mitochondria as generators of reactive oxygen species
In most mammalian cells, mitochondria are important generators of Reactive Oxygen
Species (ROS) [78-80]. Small amounts of ROS can function as “signaling ROS” that
trigger ischemic preconditioning by activating protein kinases such as protein kinase C
(PKC) or p38 MAP kinase leading to the subsequent translocation of transcription factor
NF-κB to the nucleus where it regulates gene expression [81, 82]. However, excessive
generation of ROS act as “cytotoxic ROS” that damage cardiomyocytes ultimately
permeabilizing the mitochondrial membrane. Increased ROS from mitochondria
contribute to the pathological redox signaling, releasing H2O2 from the organelle to the
rest of the cell resulting in oxidative damage of target proteins which alters activity of
enzymes, kinases, phosphatases and transcription factors [79, 83].
In mitochondria, superoxide (O2•−) is produced by one-electron reduction of dioxygen
(O2). Theoretically, several electron donors and redox couples in the mitochondria can
thermodynamically favor the formation of O2•−. However, small-molecule electron
18

carriers like NADH, NADPH, CoQH2 and glutathione (GSH) do not react with O2 to
generate O2•−. Instead, mitochondria produce O2•− mainly at active sites of redox
prosthetic groups within proteins or when reduced electron carriers such as CoQH2 are
bound to proteins. Alterations in protein due to mutation, post-translational modification
or conformational changes enable O2 to interact more rapidly with the electron carrier
which increases dramatically the production of O2•− [84]. This makes the electron
transport chain a perfect candidate for ROS production. Indeed, it is now very well
documented that complex I and III are the main sites of superoxide generation during
pathologic conditions [85].
Better understanding of mitochondrial ROS production will lead to the rational design of
therapies to minimize oxidative damage by O2•−. However, direct measurement of O2•−
within mitochondria is a challenge because MnSOD rapidly dismutates it to form H2O2.
The difficulties in assessing mitochondria-generated superoxide can be overcome by
the measurement of H2O2 release from the mitochondria that has already exceeded the
threshold of ROS scavenging systems capacity [86-88].
I. 4. 1. Complex I-mediated ROS production
As mentioned earlier, Complex I comprises forty six polypeptides which includes FMN,
FeS clusters and likely two semiquinones. Oxygen mostly likely has access to electron
carriers mainly at FMN, CoQ sites and terminal FeS centers which can possibly donate
an electron reducing O2 to O2•− [89, 90]. Isolated complex I increases O2•− production in
the presence of NADH and inhibitor rotenone. Rotenone binds to the CoQ-binding site
of complex I and enhances O2•− generation I which suggests that the N2 Fe-S or the
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tightly bound quinones are the loci for O2•− release [91, 92]. It is now well understood
that complex I produces O2•− when O2 reacts with fully reduced FMN which in turn is
dependent on the NADH/NAD+ ratio. Excess NADH leads to the fully reduced state of
FMN, which favors the reduction of O2 at the flavin cofactor [93-95]. Hence inhibition of
the electron transport chain by chemicals, damage, mutation, ischemia, loss of
cytochrome c or decrease in ATP demand affects respiration thereby increasing
NADH/NAD+ ratio ultimately causing excessive ROS generation [84, 93, 96]. In contrast,
physiological respiring mitochondria on NADH-linked substrates produce less O2•− from
complex I because the NADH/NAD+ ratio is very low [97].
Reverse electron transfer (RET) is another mechanism by which complex I produces
large amounts of superoxide [84, 89, 97]. RET occurs when electrons from succinate, αglycerophosphate or fatty acid oxidation reduce the CoQ pool which along with
significant proton motive pushes electrons back from CoQH2 into complex I ultimately to
the FMN site resulting in reduction of NAD+ to NADH [98]. Under above mentioned
conditions complex I produces extensive amounts of superoxide, especially in brain,
heart, muscle and liver mitochondria [84, 89, 97]. Moreover, this generation of ROS is
abolished in the presence of rotenone, which confirms that electrons enter complex I
through the Q-binding site during RET [99]. However, the site in complex I of the RETlinked superoxide generation is unclear [100]. One possibility is that RET results in
higher generation of O2•− from reduced FMN by forcing electrons back from complex I to
FMN [84]. Additional RET-related O2•− production occurs at semiquinones formed in the
Q-binding site of complex I during proton pumping [94, 99]. However, other reports
provide evidence that the one-electron donor to oxygen in complex I is located prior to
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the Q-binding site [101]. Their results also suggest that the superoxide generation site
can be the iron-sulfur cluster N2, based on its physico-chemical properties and ability to
interact with endogenous ubiquinone. Notably, the ROS production from complex I is
considered to be directed into the matrix of the mitochondria [102].
I. 4. 2. Complex III-mediated ROS production
Complex III for a long time has been considered the dominant source of superoxide
production. Inhibition of the Qi center by antimycin A, results in large amounts of O2•−
release due to the reaction of O2 with ubisemiquinone bound to the Qo site. However,
the Qi center can also be a site of O2•− production especially when electron flow into Qo
is limited [91, 103]. Complex III exists as dimer which allows adequate residual electron
flow into the the complex. As a result, electrons tunnel between the b hemes located at
the Qi centers of each monomer [104] which increases ROS generation from the Qi
center [105, 106]. On the other hand, an altered Fe-S center [107] will inactivate the Qo
center which along with loss of cytochrome c, limits electron flow to Qo center which
further augments ROS release from complex III [94, 104]. Superoxide generated at the
Qo site in complex III is released into the intermembrane space but O2•− from Qi is
targeted to the matrix [108, 109]. Interestingly, under conditions of a high proton motive
force, as a result of reduced Q pool (from succinate), the main site of O2•− generation
remains at the complex I through RET mechanism [84].
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I. 4. 3. Other sites of ROS production in the mitochondria
Other sites in the mitochondria located outside the ETC contribute to O2•− production.
However, it is unclear whether they generate quantitatively significant amounts of
mitochondrial ROS when compared to the ETC generated ROS [110].
Studies on the lower organisms or from the in-vitro isolated mammalian complex II have
reported that the catalytic activity of electron transport chain complex II can contribute to
O2•− generation in the mitochondria. Two regions of this enzyme that are suspected for
ROS production are: the FAD cofactor which is modulated by FADH• semiquinone and
the Q-binding site [111-113]. However, the main source of complex II-driven superoxide
generation in intact mitochondria is based on the RET into the complex I, which results
in O2•− release from the sites within complex I. In addition, the damaged or mutated
complex II increases O2•− production by itself [84, 114, 115].
Enzymes containing flavin prosthetic groups in their redox active center are suspected
to generate O2•−. These enzymes function mainly by donating electrons into NADH or
ubiquinol. However, under conditions of high proton motive force, ubiquinol remains
highly reduced, which leads to a blockade of the electron transfer to NADH and in turn
to ubiquinol generating O2•−. For example, the α-ketoglutarate dehydrogenase (αKGDH)
contains a flavin center which produces ROS when its electron acceptor NAD+ is limiting
[116]. Furthermore, enzymes transferring electrons to the ubiquinol pool, such as
succinate dehydrogenase and electron transfer flavoprotein (ETF), increase superoxide
generation by the RET mechanism by donating electrons to CoQ [86]. Additionally, ETF:
CoQ reductase may produce ROS by itself directed to the intermembrane space [109].
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Another Q-linked enzyme located on the outer surface of the inner membrane is αglycerophosphate dehydrogenase

(αGPDH)

which

donates electrons from

α-

glycerophosphate to ubiquinol. This leads to increased ROS production, mainly by RET,
although some is released from the enzyme itself. However, the physiological relevance
of αGPDH contribution to O2•− generation is unclear due to a very low expression of this
enzyme in most of mammalian tissues, though it may be important in the brain [116,
117].
In addition, many other mitochondrial enzymes which are not connected to NADH or
CoQ can be induced to produce O2•− or H2O2. For example, adrenodoxin
reductase/adrenodoxin/ cytochrome P450 produces ROS in the mitochondrial matrix by
receiving electrons from the NADPH pool [118]. Another one which has recently been
reported is the mitochondrial intermembrane space protein, p66shc, which uses electron
transferred from reduced cytochrome c to generate peroxide that in turn appears to
activate the apoptotic program [119]. Last but not least, monoamine oxidase is a
flavoenzyme (containing FAD) located within the outer mitochondrial membrane, facing
the intermembrane space. In mitochondria, monoamine oxidase catalyzes oxidative
deamination of monomaines resulting in formation of aldehydes, ammonia and H2O2
[120]. However, their contribution to the overall production of ROS by mitochondria is
still unclear [110].
I. 4. 4. Mitochondrial ROS scavenging system
Mitochondrial ROS is measured using O2•−-sensitive dyes such as hydroethidine and
MitoSOXTM [121-123], spin trapping [88], by measuring the reaction of O2•− with
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compounds to form chemiluminescent products [124, 125] and also by measuring the
inactivation rate of aconitase [126]. However, the assessment of O2•− generation in
mitochondria is extremely difficult due to its extremely short half-life and also due to the
rapid dismutation into hydrogen peroxide (H2O2) which further diffuses out from the
mitochondria. H2O2 which diffuses out is typically measured by oxidation reaction of
H2O2 with non-fluorescent dye (eg. Amplex Red) and a peroxidase (Horse Radish
Peroxidase) to form a fluorescent product [86, 127, 128].
The process of dismutation of O2•− to H2O2 occurs either spontaneously or is catalyzed
by mitochondrial antioxidant systems that are capable of neutralizing excess ROS [79].
Tetrameric mitochondrial manganese superoxide dismutase (MnSOD or SOD2) located
in the matrix catalyzes the production of H2O2 from O2•− as shown in the following
reaction [129]:

O2•− +

O2•−

MnSOD
+

+ 2H

H2O2 + O2

Due to a high intra-mitochondrial concentration (3-10 µM) and reaction rate (k = 2.3x109
M-1s-1) of MnSOD, the steady-state superoxide content in matrix of normally respiring
mitochondria is very low [130]. However, in the presence of redox-active transition
metals like copper and iron, H2O2 can form very active and damaging hydroxyl radicals
(•OH). •OH radicals are highly unstable and reactive for which no scavenging enzyme
system exists [131]. These forms of ROS may cause direct damage to membrane lipids,
proteins and mitochondrial DNA [132, 133]. Therefore, mitochondrial matrix contains a
special system of peroxidases that remove H2O2 before it can react with active forms of
metals. These include peroxiredoxins, glutathione peroxidases and trace amounts of
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catalase [134, 135]. The glutathione peroxidase (GPx) reaction is coupled to the
glutathione disulfide-reduced glutathione couple (GSSG/GSH) and the rate of H2O2
removal depends on GSH concentration [136, 137].
GPx
H2O2+ 2 GSH

2H2O + GSSG

The above mentioned highly efficient antioxidant systems in the mitochondria neutralize
ROS under normal conditions. Probably this is why the normal respiring mitochondria
generate low levels of H2O2. However, damaged mitochondria during stress produce
high levels of ROS that exceed the capacity of the antioxidant system and can result in
cell death [87].
I. 5. Mitochondria regulate apoptosis and mitophagy
During stress, damage to mitochondria concomitantly activate both mitophagy and
mitochondrial apoptosis/permeabilization. The final outcome depends on the balance
between these pathways. Exposure to modest stress activates mitophagy wherein
damaged mitochondria are sequestered by autophagosomes and degraded before
apoptosis or necrosis can be triggered. However, during severe stress conditions
apoptosis is the major pathway to minimize tissue damage upon cell death [138].
I. 5. 1. Intrinsic apoptotic signalling
Apoptosis is programmed cell death. It results in chromatin condensation, DNA
fragmentation, cell shrinkage, and plasma membrane blebbing with release of apoptotic
bodies, which are phagocytized by other cells in the organism [139]. There are two
principal apoptotic pathways: the extrinsic or the death receptor-mediated pathway, and
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the intrinsic or the mitochondrial-mediated pathway. The extrinsic pathway is triggered
by tumor necrosis factor-α (TNF-α), TRAIL (TNF-related apoptosis-inducing ligand) and
Fas receptors which activate downstream caspase 8 and caspase 10 [140, 141]. The
intrinsic pathway involves mitochondria to intensify or augment the pathway by
responding to stress signals including loss of growth factors, hypoxia, oxidative stress,
and DNA damage [142].
Apoptosis by mitochondria is highly regulated by the BCL-2 family of proteins.
Antiapoptotic members of the family BCL-2 and BCL-XL promote survival. The proapoptotic BCL-2 family proteins are BH3-only proteins, which include BH3 interacting
domain death agonist (BID), BCL2/adenovirus E1B 19-kDa protein-interacting protein 3
(BNIP3), Nip3-like protein X (NIX), BCL2/adenovirus E1B 19-kDa protein-interacting
protein 3-like (BNIP3L),

p53 upregulated modulator of apoptosis (PUMA), and the

effector proteins the BCL2-associated X protein (BAX) and BCL2-antagonistic/killer
(BAK). The majority of the pro-apoptotic proteins are cytosolic, with the exception of
Bak, which is localized at the OMM [143]. The cytosolic BH3-only proteins neutralize the
antiapoptotic BCL-2 proteins thereby causing cell death by activating BAX and BAK
[144, 145]. Additonally, following apoptotic stimuli, Bid is cleaved by death receptordependent caspase-8, after which it translocates to the mitochondria and interacts
directly with BAX and BAK to induce their activation. Upon activation, BAK and BAX
undergo conformational changes forming homo-oligomers in the OMM. Homooligomerization of BAK and BAX, form pores in the OMM causing mitochondrial outer
membrane permeabiliation (MOMP) [146]. Permeabilization of the outer membrane
results in the release of pro-apoptotic proteins from the IMS such as cytochrome c,
26

second mitochondria-derived activator caspase (SMAC)/direct IAP-binding protein with
low pI (DIABLO), HtrA2/Omi, apoptosis-inducing factor, and endo-nuclease G into the
cytosol, which activates apoptosis [138, 147, 148]. In the cytosol, cytochrome c binds to
dATP, Apaf-1 and the initiator caspase 9 which forms an apoptosome activitaing
caspase 9 which in turn activates caspase-3, the ‘executioner’ of the apoptotic pathway
[149]. Smac/DIABLO and HtrA2/Omi promote caspase activation by neutralizing IAPs
(inhibitor of apoptosis proteins) in the cytosol [150, 151], whereas EndoG and AIF
initiate a caspase-independent pathway by translocation to the nucleus where they
trigger DNA fragmentation and chromatin condensation [152, 153].
In parallel, there exists a crosstalk between BCL-2 proteins and mitochondrial
permeability transition pore (MPTP). Opening of MPTP in the inner mitochondrial
membrane activates the intrinsic pathway leading to cell death [154]. Reports in the
literature suggest that MPTP contains a voltage-dependent anion channel (VDAC,
porin) in the OMM, the adenine nucleotide translocase (ANT) in the IMM and
cyclophilin-D in the matrix, although the exact structure of MPTP is still unknown [155].
Opening of the MPTP causes rapid influx of solutes and water into the mitochondrial
matrix. This collapses the proton gradient thereby disrupting ATP synthesis. MPTP
opening induces mitochondrial swelling and cell death through apoptosis or necrosis
and has been implicated in ischemia-reperfusion injury, cardiomyopathies, and
congestive heart failure [147, 156, 157]. It has been reported that BCL-XL can bind
directly to the components of MPTP controlling the pore opening and closing whereas
BCL-2 increases the calcium threshold which makes the mitochondria more resistant to
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MPTP. Also, BAX promotes MPTP opening through a mechanism which is different
from MOMP [158-160].
Apoptosis is an energy-dependent process, thus the presence of ATP is necessary to
execute the apoptotic program. Therefore, substantial ATP depletion limits caspase
activation and leads to necrosis. Necrosis is characterized by cell swelling, plasma
membrane disruption releasing cytosolic components which trigger an inflammatory
response [142]. During severe oxidative stress, apoptosis progresses to necrosis as a
result of ATP loss which inhibits energy-dependent processes (e.g. functioning of ion
pumps) resulting in swelling and rupturing of the cell membrane [161]. Rupture of the
plasma membrane can be facilitated by proteolytic degradation of crucial cytoskeletal
and membrane proteins, such as calpain-mediated cleavage of ankyrin and fodrin,
anchor proteins for Na+/K+-ATPase [162].
I. 5. 2. Mitochondria and mitophagy
BCL-2 and BCL-XL regulate autophagy via their interaction with activating molecule in
BECLIN1-regulated autophagy (AMBRA1) that activates the BECLIN1-VPS34-VPS15
complex which induces autophagy. Upon induction of autophagy, BCL-2 releases
BECLIN1 and AMBRA1. However, it is still unclear what triggers the dissociation of
AMBRA1 from BCL-2 [163-166]. Similarly, BNIP3, a pro-apoptotic BH3-only protein is a
potent inducer of mitophagy [167]. Another protein which regulates both apoptosis and
autophagy is the p53 tumor suppressor protein. Under physiological conditions, the E3
ubiquitin ligase mouse double minute 2 (MDM2) degrades p53 maintaining low levels.
In response to oxidative stress, p53 escapes degradation by an unknown mechanism
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and its levels increase in the cell. P53 causes cell death by regulating gene expression
and by direct action on the mitochondria. In the nucleus, p53 activates expression of
autophagic genes like AMP-activated protein kinase, tuberous sclerosis protein 2, and
sestrin1/2 [168, 169] along with proapoptotic genes which include Bax [170], Bak [170,
171], Noxa [172], and Puma [173]. It also represses the transcription of antiapoptotic
BCL-2, BCL-XL, and MCL-1 [171, 174, 175]. In parallel, p53 translocates to
mitochondria where it inhibits BCL-2/BCL-XL and activates BAX and BAK causing
MOMP [176-178].
The phosphatase and tensin homolog induced putative kinase 1 (PINK1)/Parkin
pathway is another important regulator of mitophagy. In normal healthy mitochondria
with an intact membrane, serine/threonine kinase PINK1 is rapidly imported and
cleaved by mitochondrial proteases. Upon collapse of the Δψm, the import and
degradation of PINK1 are blocked, and PINK1 accumulates on the outer mitochondrial
membrane which signals the cytosolic E3 ubiquitin ligase Parkin [179, 180]. Parkin
rapidly translocates to mitochondria where it ubiquitinates mitochondrial proteins like
VDAC1, MIRO, mitofusin-1 and mitofusin-2. Ubiquinated proteins signal induction of
mitophagy [181-183]. However, the exact mechanism on how accumulation of PINK1 on
the OMM activates and recruits Parkin is still unclear [138]. Alternatively, mitochondria
can also be cleared via an ubiquitin-independent pathway which involves direct binding
of ATG8 family proteins to autophagy receptors on the mitochondria [184, 185].
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I. 5. 3. Interplay between Mitophagy, Mitochondrial Biogenesis and Mitochondrial
dynamics
In response to mitophagy, cells compensate energy production without affecting
contractility using their reserve pool of mitochondria. However, excessive mitophagy
results in depletion of the bioenergetic reserve leading to cell death. Under such
conditions, the cell replaces the mitochondria cleared by mitophagy through a tightly
coupled process called mitochondrial biogenesis. The transcriptional coactivator
peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) is a key regulator
of mitochondrial biogenesis [186]. PGC-1α is induced at birth wherein there is a striking
increase in mitochondrial biogenesis [186, 187]. In addition, Parkin has been shown to
be a central regulator of both mitophagy and mitochondrial biogenesis. Recently, PARIS
(ZNF746), a Parkin substrate is shown to repress the expression of PGC-1α by binding
to insulin response sequences in the PGC-1α promoter. Activation of Parkin during
mitophagy promotes degradation of PARIS and subsequent activation of PGC-1α
transcription [188].
Mitochondria are highly dynamic organelles capable of changing both size and shape.
The main regulators of this process are the fission and fusion proteins [138]. Fission
produces mitochondria that are fragmented and discontinuous whereas fusion produces
elongated, tubular, interconnected mitochondrial network [189, 190]. Dysfunction or loss
of fusion proteins is lethal as it causes the total loss of mtDNA from the cells. In
mammals, the fusion proteins are the dynamin-related GTPases mitofusins (Mfn) and
optic atrophy protein 1 (Opa1). Mfn exists in two isoforms, Mfn1 and Mfn2, both
localized in the outer mitochondrial membrane (OMM) which interact with their
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homologous proteins in the adjacent mitochondria causing OMM fusion. Opa 1 is
located in the inner mitochondrial membrane (IMM) and plays a role in IMM fusion and
cristae remodeling [190]. On the other hand, mitochondrial fission 1 protein (Fis1) and
dynamin-related protein 1 (Drp 1) participate in fission. While Fis1 is transmembrane
protein which binds to the OMM, Drp1 is located in the cytosol and translocates to
mitochondria and interacts with Fis 1 in the event of mitochondrial fission [189]. The loss
of fusion responses predisposes toward cell death and following fission, the
mitochondrial fragments are selectively degraded through lysosomal machinery. A fine
balance exists between mitophagy and biogenesis that is responsible for mitochondrial
quality control [191-193]. However, the mechanisms through which mitochondrial
dynamics trigger cell death are not fully understood.
I. 6. Mitochondria and ischemia-reperfusion injury
Heart attack/ myocardial ischemia is a major cause of morbidity and mortality
worldwide. Myocardial ischemia exists when there is an inadequate supply of oxygen
and nutrients to the myocardium as a result of blockade of blood flow through coronary
arteries. The depletion of oxygen and metabolic substrates decreases the energy
available to cardiomyocytes and leads to cardiac injury (infarction) [5]. The extent of the
injury is determined by various factors including the duration of ischemia and the
severity of ischemia (zero-flow versus low-blood flow). Reperfusion following ischemia
to restore cardiac tissue survival also increases cardiac injury over and above that
sustained during ischemia and independently contributes to myocardial cell death. This
phenomenon is called reperfusion injury [78, 149, 194-197]. However, the cardiac
response to ischemia-reperfusion insult can be manipulated to decrease the severity of
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1. 6. 1. Mitochondrial damage during ischemia
Mitochondria are the cellular powerhouses that generate ATP for cell survival. But
during cardiac ischemia, they are both sources and targets of cellular damage. Ischemia
disrupts the ETC in mitochondria which leads to a decrease in respiration rate and an
increase in production of reactive oxygen species (ROS). Global ischemia in animal
models decreases the activity of complex I, complex III, cytochrome c content and
respiration through complex IV [5, 198]. Studies in different animal models have shown
that the consequences of ischemic damage depend on the duration of ischemia. Brief
periods of ischemia for 15 min did not damage the ETC; cardiac contractile function is
recovered with no myocyte cell death. This phenomenon is called “stunning” wherein
the myocardium is not contracting properly and is viable. The stunned myocardium
eventually will recover function if blood flow is restored [199, 200]. Ischemia for shorter
time periods (15-20 min) decreases complex I activity [201, 202] while prolonged
ischemia (30-45 min) results in damage distal to complex I. Longer periods of iscchemia
decreases activity of complex III, leads to loss of cardiolipin and cytochrome c content,
and impaired complex IV respiration rate [102, 203, 204].
Ischemia decreases complex I activity due to increased ROS generation as a result of
electron leakage from the complex [102, 201, 205-207]. Additionally, complex I undergo
ischemia-mediated post-translational modifications including phosphorylation [208] and
S-nitrosylation [57] (as discussed earlier in section I.3). However, there are conflicting
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reports regarding the ischemia-induced damage to NADH ferricyanide oxidoreductase
(NADH dehydrogenase, NFR) which is the proximal component of complex I. While
some reports have shown that the decreased NFR activity appears likely due to the loss
of the flavin mononucleotide (FMN) component [206, 207], other studies have pointed
out that the increased ROS production by complex I due to ischemia without apparent
decrease in NFR activity indicates a site of damage distal to NADH dehydrogenase part
of complex I [102, 209]. During ischemia, complex I is considered to be both the target
and a source of damage. Rotenone treatment immediately before ischemia decreased
damage to the distal parts of the ETC [210] by preserving complex IV respiration,
cardiolipin and cytochrome c content [210]. Consistent with the retention of cytochrome
c, proximal blockade of ETC during ischemia preserved the integrity of inner and outer
mitochondrial membrane [209]. In addition, complex I blockade with rotenone before
ischemia decreased ROS production and mitochondrial Ca2+ loading [85, 211, 212].
Therefore, it has been suggested that the proximal electron transport chain mediates
the damage to its distal part during the progression of ischemia [210].
Several studies have shown that myocardial ischemia does not damage complex II [5].
However, studies showed that in vivo regional or global ischemia/reperfusion resulted
in loss of protective glutathionylation of key sulfhydryl groups in the complex II which
results in decreased complex II enzyme activity [62]. Recent work by Quinlan et al.
demonstrated that complex II is an important contributor to physiological and
pathological ROS production [213]. This work suggests that the flavoprotein subunit of
complex II generates ROS in both the forward reaction with electrons supplied by
succinate, and the reverse reaction with electrons supplied from the reduced ubiquinone
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pool when complex III is inhibited [213]. Thus, complex II can also be a potential source
of damage during ischemia or early reperfusion due to distal blocks in the ETC.
Ischemia decreases complex III activity as a result of the functional inactivation of ironsulfur [2Fe-2S] protein subunit. Ischemic damage did not affect the remaining eleven
subunits of the complex. The electron paramagnetic resonance (EPR) signal from [2Fe2S] cluster decreases after ischemia without loss of the protein, suggesting that it is the
disruption of the cluster which decreases the complex activity [214]. Studies with
complex III blocker, myxothiazol decreased superoxide generation during simulated
ischemia in cardiomyocytes which highlights the role of complex III as a major site of
ROS production during ischemia [212]. As discussed in section I.3, the majority of ROS
produced in complex III originates from the Qo center. However, the Qi center also
releases superoxide when electron transfer into Qo is blocked. ROS generated from
complex III causes oxidative modification and depletion of cardiolipin and subsequent
release of cytochrome c from the inner membrane. Therefore, apart from complex III
damage, progressive loss of cytochrome c during ischemia sets a distal block in the
ETC resulting in impairment of Qo center which in turn increases ROS generation at the
Qi site [104, 105].
During ischemia, the activity of cytochrome c oxidase is decreased by two different
mechanisms. First, ischemia leads to posttranslational modifications of complex IV,
mainly phosphorylation of COXI, COXIVi1, and COXVb causes functional inactivation of
the complex [215]. Second, studies from different animal models (rabbit, rat, canine)
suggest that selective depletion of cardiolipin during ischemia affects the cytochrome c
oxidase enzyme activity [216-218]. Cardiolipin is a phospholipid enriched in the inner
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mitochondrial membrane and is the only phospholipid whose content decreases during
ischemia. Decrease in cardiolipin content corresponds to the decrease in intergrated
respiration through complex IV [219]. Potential mechanisms of overall cardiolipin loss
during ischemia include hydrolysis by phospholipase A2 or oxidative damage [220, 221].
The mechanism of cardiolipin oxidation may result from the formation of cytochrome ccardiolipin peroxidase, which can occur in pathologic settings, under conditions of
oxidative stress (increased H2O2) [222]. As mentioned earlier, the ROS generated from
Qi center (in complex III) most likely causes cardiolipin modifications [222], although
other sites of superoxide generation should not be excluded from the consideration.
Cardiolipin contains linoleic acid (C18:2) acyl groups with two unsaturated cis double
bonds. Oxidative damage to cardiolipin during ischemia generates peroxy-groups that
are unstable and decompose rapidly leading to direct depletion of cardiolipin from the
inner membrane [223]. Alternatively, the peroxy-acyl groups can form complexes with
proteins that cause delocalization of cardiolipin from the membrane [221]. Hence, the
peroxidation of cardiolipin, if not counteracted by synthesis of new cardiolipin leads to
increase in generation of monolysocardiolipin which activates pro-apoptotic factors
leading to cell death [224, 225]. However, the remaining cardiolipin in the inner
membrane that did not delocalize showed no signs of modification.
Cytochrome c is localized to the the inner membrane via its interactions with cardiolipin
[226]. Depletion of cardiolipin results in redistribution of cytochrome c from the inner
membrane into the inter-membrane space [227]. In normal conditions the outer
membrane is impermeable to cytochrome c, however during ischemia the integrity of
the outer membrane lipid bilayer is disrupted [149]. Results from the different
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experiments suggest that during ischemia, loss of BCL-2 triggers oligomerization of the
pro-apoptotic BAX and BAK in the outer membrane forming pores. This leads to an
increase in the permeability of the outer membrane allowing delocalization of
cytochrome c from the inter-membrane space into the cytosol following its detachment
from cardiolipin (two-step process) [228]. Consequently, cytochrome c and the
accompanying pro-apoptotic proteins including SMAC/DIABLO, HtrA2/Omi, apoptosisinducing factor and endo-nuclease G activate apoptotic pathways leading to cell death
[146, 229].
1. 6. 2. Mitochondrial damage during reperfusion
The restoration of blood flow to an organ or to tissue is termed reperfusion. The
presence of damaged mitochondria following ischemia persist during reperfusion
leading to reduced energy production, increased ROS and activation of cell death
programs by cytochrome c release [222]. Pathological ETC function as a consequence
of ischemic damage is supported by experimental evidence that blockade of complex I
with amobarbital or nitric oxide before ischemia followed by reperfusion improved
contractile recovery and decreased infarct size following reperfusion [211, 230-232].
Also, the distal blocks in ETC during ischemia due to damage of complex III and loss of
cytochrome c result in excessive ROS generation which causes increased cardiac injury
during reperfusion. Interestingly, the net release of ROS from ischemic damage can be
abolished by proximal blockade of the ETC with rotenone [210].
Amobarbital (Amytal®) is a short-acting barbiturate that reversibly inhibits complex I at
the rotenone-binding site [233, 234]. Amobarbital treatment during ischemia protects the
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distal electron transport chain by preserving respiration through complex III and
complex IV, improving complex I activity along with retention of cytochrome c within
mitochondria, all of which are measured following reperfusion [209, 230]. This
demonstrates that though rotenone and amobarbital are chemically distinct compounds,
inhibiting the rotenone binding site protected mitochondrial ETC from ischemic damage.
Moreover, this inhibition of electron transport during ischemia reduced calcium loading
during reperfusion. Diminished calcium loading along with lower ROS levels would
result in decreased susceptibility to MPTP opening and smaller cardiac infarction [211,
232]. Therefore, the reduction of electron flow through ETC applied before the ischemic
insult exhibits cardioprotection following reperfusion. Hence, ischemic damage to the
electron transport chain is considered an important link between ischemia and the
progression of cardiac injury during reperfusion [222].
There are conflicting reports on the damage caused to mitochondria during reperfusion.
Some studies suggest that ischemic damage to complexes I, III and IV further
deteriorates oxidative phosphorylation [201] and complex activities [201, 235] during
reperfusion, suggesting that additional mitochondrial injury occurs. Also, early in
reperfusion, a detectable burst ROS generation is recorded [194, 236-239]. Damage to
the ETC during ischemia increases net release of H2O2 during reperfusion with
glutamate as a substrate [102]. With succinate and rotenone the H2O2 generated
following ischemia from complex III is substantially increased [85, 88, 240]. Hence,
ischemic damage to the ETC augments oxidative injury during reperfusion, especially at
complex I and III wherein there is an increase in ROS generation due to distal blocks in
the ETC which could result in additional damage [201, 235]. In addition, post-ischemic
37

mitochondria generate reactive and damaging hydroxyl radical (•OH) measured by
electron spin resonance (ESR) spin-trapping [194, 241].
Prompt reperfusion or reoxygenation rapidly restores the substrates essential for ATP
generation, increases the oxygen supply and normalizes the extracellular pH to restore
cellular homeostasis. However, abrupt normalization concurrently causes reperfusion
injury [242]. Rapid normalization of the extracellular pH creates an extreme H+ gradient
across the plasma membrane that triggers Na+/H+ exchange leading to high Na+ influx
which in turn triggers Na+/Ca+2 exchanger in a “reverse mode,” resulting in intracellular
Ca+2 overload [243]. The increase in intracellular Ca+2, enhances mitochondrial calcium
overload triggering mitochondrial permeability transition (MPTP) that contributes to
additional cardiac injury during reperfusion [244, 245]. The MPTP can be blocked by
pharmacological inhibitor, cyclosporine A. Opening of the MPTP can lead to cell death
through apoptosis (release of cytochrome c) or necrosis (depletion of ATP) [246, 247].
Morphological and biochemical studies suggest that mitochondria are largely intact
following ischemia [204, 216]. However, during reperfusion increased calcium
availability enhances mitochondrial calcium loading as result of which mitochondria
“swell” and cause cell death [244, 248].
In contrast, experimental studies suggest that ischemic damage to the mitochondria
persists during reperfusion without apparent evidence of additional substantial damage
to the distal ETC caused by reperfusion. The decreased cardiolipin and cytochrome c
contents as well as cytochrome c oxidase respiration persist but do not worsen during
reperfusion [203, 223]. However, during ischemia, distal blocks formed as a result of
loss of cardiolipin and cytochrome c [216], functional inactivation of Fe-S peptide of
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complex III [214] result in decreased respiration through complex IV [204] following
reperfusion. Apart from this, ischemia increases ROS generation during reperfusion
from complex I even in the absence of complex I damage [78, 92, 219]. From these
studies it is clear that enhanced mitochondrial damage, increased ROS along with
calcium loading predispose MPTP pore opening during early reperfusion which
translates the ischemic mitochondrial damage into reperfusion injury [222]. Amobarbital
treatment before ischemia along with postconditioning during early reperfusion
improved calcium tolerance and inner membrane potential recorded following
reperfusion [249]. In another study, postconditioning (brief periods of ischemia) during
early minutes of reperfusion, inhibited MPTP opening by reducing oxidative stress at the
cellular level without any effect on oxidative phosphorylation or membrane polarization
[250]. These results suggest that reperfusion injury can be minimized if the
mitochondrial damage during ischemia is prevented.
Current therapeutic interventions to pre-condition, post-condition, or pharmacological
treatment to activate signaling pathways of protection in the heart are ineffective during
certain conditions including aging and diabetes due to defects in the signaling cascades
[251-253]. Hence direct therapeutic targeting of dysfunctional mitochondria will provide
the potential to bypass the upstream signaling defects and intervene directly with the
effector organelle. Novel mitochondrial-targeted therapy relies on understanding the
sites in the ETC that are damaged by ischemia and produce cell-injury during
reperfusion. The main objective of the current study is to delineate sites of ETC that are
responsible for ischemic damage. This will allow us to identify a key mechanism of
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CHAPTER II: Electron flow into cytochrome c and reactive oxygen
species from the electron transport chain convert cytochrome c to a
peroxidase during ischemia-reperfusion

II. 1. Introduction
Mitochondria are the cellular powerhouses that generate ATP for cell survival. But
during a pathological condition like cardiac ischemia, they are both sources and targets
of cellular damage [5]. The sequence of events leading to myocardial ischemic damage
involves increased generation of reactive oxygen species (ROS) [102], mitochondrial
membrane permeabilization [154], depletion of cytochrome c and activation of apoptotic
pathways [149]. Blockade of electron transport chain during ischemia decreases
myocardial damage. This supports the concept that ETC itself plays a major role in
ischemic

damage
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[209].

II. 1. 1. Localization of the segment of mitochondrial ETC responsible for ischemic
damage
Given the importance of ETC as a source of damage during ischemia, blocking it with
inhibitors to manipulate electron flow through the respiratory complexes allows one to
isolate the segment responsible for ischemic damage [254]. Experiments using an insitu global ischemic model with rotenone, an irreversible inhibitor of complex I, markedly
attenuated the ischemic damage to cardiolipin, cytochrome c and respiration through
complex IV. This observation provides evidence that proximal blockade of ETC during
ischemia protects distal respiration [210]. Similar to rotenone, a chemically distinct
compound, amobarbital competes for binding at the “rotenone-site” of complex I [233].
Amobarbital treatment immediately before ischemia decreases the net release of H 2O2
due to the preservation of oxidative phosphorylation and cytochrome c content [230].
Thus, the site within ETC that causes damage is located distal to complex I.
To localize the site of ischemic damage distal to complex I, antimycin A, an irreversible
inhibitor, is used to block the electron transport distal to complex III. Antimycin A,
inhibits the Qi center of complex III thereby causing a net increase in ROS production
from the semiquinone bound Qo site [109]. The ROS generated from the Qo site in
complex III is released into the intermembrane space [78, 108]. Antimycin A, given
immediately before ischemia, preserves complex IV respiration, cardiolipin and
cytochrome c content. This evidence suggests that the site of ETC responsible for
ischemic damage is located distal to quinol oxidation site of complex III [255].
Lastly, the contribution of complex IV in mediating ischemic damage was studied.
Isolated perfused rabbit hearts which underwent global ischemia for 30 min were used.
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Azide was given immediately before ischemia which blocked the ETC at complex IV.
Interestingly, treatment with azide did not protect the ischemia-mediated decrease in
respiration. Also, a decrease in cytochrome c content was observed similar to that of
untreated ischemic hearts [254]. This evidence strongly supports that the segment
located between the quinol oxidation site of complex III and complex IV is responsible
for the ischemic damage to the ETC [254]. One of the key components of this site is the
cytochrome c and cardiolipin complex located between complex III and complex IV
which can potentially play an important role in ischemia mediated cardiac injury and is
the focus of my research (Figure 2.1) [222].
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Figure 2.1. Schematic representation of the mitochondrial electron transport
chain localizing the ischemic defect. The segment located between the quinol
oxidation site of complex III and complex IV is responsible for the ischemic damage to
the ETC. Key components of this site are the cytochrome c and cardiolipin complex. Q,
ubiquinone; cyt c, cytochrome c; CL-cardiolipin. Adapted from [37].
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II. 1. 2. Cytochrome c-cardiolipin interactions
Cytochrome c is a small heme protein that transfers electrons between respiratory
complexes III and IV located in the inner membrane of mitochondria. Cytochrome c is a
positively charged protein with an iso-electric point of approximately pH 10, with
approximately 30% of the protein surface having binding sites for anionic lipids [256259]. Complex interactions of cardiolipin with cytochrome c are responsible for localizing
the later at the inner membrane. Various forces including electrostatic, hydrogen
bonding and hydrophobic interactions are responsible for the formation of cytochrome
c/cardiolipin complex. Under physiological conditions, electrostatic forces existing
between negatively charged phosphate groups of the cardiolipin and positively charged
lysine residues of cytochrome c are predominant [259]. Experimental studies have
shown that anionic phospholipids have contact sites on cytochrome c at residues Lys72
and Lys73 [256, 257]. Also, studies from interactions of the spin-labeled protein with
spin-labeled phospholipids have shown that Lys72, Lys86, and Lys87 residues of
cytochrome c are involved in cytochrome c-cardiolipin binding [226]. Recent studies
have shown that additional electrostatic binding sites on cytochrome c which interact
with membrane include Lys22, Lys25, His26, Lys27, and His33 [258]. Other than
electrostatic interactions, hydrogen bonding between protonated acidic phospholipids
and Asn52 stabilizes the protein binding with lipids [256, 257]. FRET studies depicted
that the interactions between cytochrome and lipids are classified into two modes: an
electrostatic low-affinity binding to deprotonated cardiolipin molecules and a high-affinity
binding to partially protonated cardiolipin stabilized by electrostatic and hydrogen
bonding. However, the type of interaction depends on pH, ionic strength, and the mole
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fraction of cardiolipin [260]. Another type of interaction in the cytochrome- cardiolipin
complex that are a result of nonpolar acyl residues of the lipid molecules and nonpolar
regions of cytochrome c (normally buried inside the protein) are the hydrophobic
interactions [259, 261, 262]. Thus, a single cardiolipin molecule interacts with
cytochrome c by electrostatic interaction of a negatively charged phosphate groups with
Lys72 as well as hydrophobic interaction by acyl chain insertion either in the channel
surrounded by Asn52, Lys72, and Lys73 or between the nonpolar polypeptide strands 6771 and 82-85 [260, 263]. Experimental evidence from nuclear magnetic resonance
studies suggests that the high affinity interactions between cytochrome c and cardiolipin
are also a result of partial unfolding and partial insertion of the protein into the
membrane [261, 264]. However, to a large extent, the interactions by insertion depend
on pH, ionic strength, lipid composition and lipid/protein ratio. Hence, a decrease in
cardiolipin content or alterations in the linoleate-fatty acyl chain saturation would
diminish the affinity of cytochrome c to cardiolipin [264].
II. 1. 3. Structural rearrangements and peroxidase activity of cytochrome c
Interactions of cytochrome c with negatively charged lipids in the membrane can disrupt
the native structure of cytochrome c resulting in an intermediate conformation, between
the native and the fully unfolded state, called a “molten globule” [265-268].
Exceptionally, solubilized cytochrome c is a heme-containing protein that reacts very
slowly with H2O2 (0.2 M-1s-1 at pH 7.0) [269] since the heme iron is occupied by ligands
in all the six coordination positions [270]. The heme iron in cytochrome c has two axial
bonds, one with His18 and the other with Met80 (Figure 2.2). In normal conditions, it is
the Met80 bond with heme that blocks the interaction of iron with NO, O2, CO and H2O2
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[271]. However, conditions including pH and temperature affect the heme binding to
Met80 ligand in cytochrome c. Several in-vitro studies that include oxidation by HOCl
[272], nitration of Tyr67 by ONOO- [273] or carboxy-methylation of Met80 [274] were
shown to disrupt the Fe-Met80 bond which facilitates the reactivity of iron thereby
inducing the peroxidase activity. This change in reactivity of iron is a two-step process
initiated with disruption of Fe-S(Met80) bond further resulting in rearrangements of the
protein’s tertiary structure [275]. The changes in the heme environment are detected by
looking at the CD spectra shifts in the 375-425 nm region (heme moiety), changes in the
UV region (250-280 nm) as well as the quenching of the Trp59 fluorescence due to the
closely located heme group. In addition, the disruption of the Fe-Met80 bond can be
detected by measuring its characteristic absorbance at 695 nm [264, 271]. In short,
structural changes along with loss of axial ligand (Met80) alter the redox catalytic
reactivity of cytochrome c by enhancing its peroxidase activity in the presence of
negatively charged phospholipid membranes [264, 271].
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Figure 2.2. Structure of the cytochrome c with native axial ligands. Cytochrome c
has two axial bonds, one with His18 and the other with Met80. Met, methionine; His,
histidine [264].
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The peroxidase function of cytochrome c requires direct physical interaction with
cardiolipin. In general, >80% of the cardiolipin is localized to the inner mitochondrial
membrane (IMM) wherein it is distributed at a ratio of 60:40 between the inner and the
outer leaflets [276-280]. In addition to binding cytochrome c in the outer leaflet of the
IMM, cardiolipin binds to other mitochondrial ETC proteins such as mitochondrial
respiratory complexes I, III, and IV [281, 282]. However during apoptosis, cardiolipin
content in the inner membrane decreases to 60% whereas its content in the outer
mitochondrial membrane increases to 40%. In apoptotic cells, the decrease in the inner
membrane cardiolipin levels is accompanied by changes in the intermembrane
distribution of CL wherein approximately only 30-40% of the cardiolipin is confined to its
inner leaflet [283, 284]. The mechanisms that are responsible for mitochondrial interand intramembrane cardiolipin translocation are not well understood. The transmigration
of cardiolipin during apoptosis involves two proteins: tBid and phospholipid scramblase3 (PLS-3) [284, 285]. Although, tBid is localized to the outer mitochondrial membrane, it
inserts into the inner and outer membrane through its cardiolipin-binding domain at the
contact and noncontact sites [286, 287]. t-Bid treated mitochondria undergo significant
changes in the intra- and intermembrane distribution of cardiolipin [279, 284]. PLS-3 is
another mitochondrial protein that plays a role in bidirectional translocation of cardiolipin
during apoptosis and is activated by calcium [285, 288]. During apoptosis, PLS-3
undergoes posttranslational modification, phosphorylation of a specific Thr21 residue by
protein kinase Cδ [289] leading to cardiolipin translocation through an unknown
mechanism. Thus, during apoptosis, phosphorylation and activation of PLS-3 and tBid-
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dependent pathway causes transmembrane redistribution of cardiolipin which is a
critical step for the mitochondria to initiate the apoptotic program [264].
II. 1. 4. Peroxidation of cardiolipin by cytochrome c
The peroxidase activity of cytochrome c utilizes cardiolipin as the substrate and is
mainly associated with participation in the execution of apoptosis [264]. The cytochrome
c-catalyzed peroxidation has substrate specificity and the preferred oxidation substrates
are polyunsaturated anionic phospholipids, particularly cardiolipin, phosphatidylserine,
and phosphatidyl-inositol’s. Another study showed that saturated and monounsaturated
cardiolipin molecules do not undergo peroxidation [224, 290-292]. Apoptosis induced by
γ-irradiation, exposure to staurosporine or actinomycin D in cultured cells, showed
accumulation of cardiolipin hydroperoxides [292-296]. Coinciding with this observation,
exposure of mice to total body irradiation, formed cardiolipin hydroperoxy derivatives
comprising (C18:2)3/(C18:2-OOH)1, (C18:2)2/(C18:2-OOH)2, (C18:2)1/(C18:2-OOH)3,
(C18:2-OOH)4 which are detected via mass spectrometry [292]. Interestingly, other
abundant phospholipids with polyunsaturated acyl chains phosphatidylcholines,
phosphatidylethanolamine, and phosphatidylinositol are not oxidized [292]. This
emphasizes the role of cytochrome c/cardiolipin peroxidase in determining the substrate
specificity for cardiolipin oxidation [264].
Lipid peroxides are highly unstable and they decompose rapidly leading to direct
depletion of cardiolipin from the inner membrane [223]. Alternatively, the peroxy-acyl
groups can form complexes with proteins that cause depletion of cardiolipin from the
membrane [221]. Depletion of cardiolipin results in translocation of cytochrome c from
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the inner membrane into the inter-membrane space [227]. In normal conditions the
outer membrane is impermeable to cytochrome c, however during pathological
situations; the integrity of the outer membrane lipid bilayer is disrupted by the activation
of cytosolic/mitochondrial phospholipases or insertion of pro-apoptotic proteins into the
outer membrane [149, 220, 297]. This leads to an increase in the permeability of the
outer membrane allowing release of cytochrome c and pro-apoptotic proteins (like Aif,
SMAC/DIALBO) from the inter-membrane space into the cytosol (Figure 2.3). In the
cytosol, cytochrome c binds to Apaf-I protein which activates caspase-9. Activated
caspase-9 in turn activates caspase-3 which is the “executioner” of the apoptotic
pathway [298]. Hence, the oxidation of cardiolipin, if not counteracted by synthesis of
new cardiolipin activates apoptosis leading to cell death. The remaining cardiolipin in
the inner membrane that did not delocalize showed no signs of modification [224, 225].
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Figure 2.3. Cartoon depicting consequences of cytochrome c peroxidase. Cyt c;
cytochrome c; CL, cardiolipin, AIF, apoptosis inducing factor
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In a study by Kagan et al., actinomycin D induced apoptosis in different cell models,
have shown that cytochrome c bound to cardiolipin acts as a peroxidase that selectively
oxidizes cardiolipin. Peroxidation of cardiolipin increases outer mitochondrial membrane
permeability, releasing of cytochrome c into the cytosol and thereby initiating the
apoptotic program by activating caspase 3/7 [276]. Also, in-vitro direct measurements of
peroxidase activity during induced oxidative stress in the liposomes are measured using
chemiluminescence and fluorescence based assays with luminol and Amplex Red
respectively. In addition, electron spin resonance spectroscopy of the EPE phenoxyl
radical also confirmed the formation of cytochrome c peroxidase [276]. In addition, work
by Vlasova et al. demonstrated that nitric oxide nitrosylates the heme of cytochrome c
and blocks the cytochrome c peroxidase activity thereby preventing oxidation of
cardiolipin [299].
Under physiological conditions, complex III reduces cytochrome c while complex IV
oxidizes it [6, 67]. Cytochrome c accepts electrons from complex III at a redox potential
of +250 mV (vs SHE) while it donates electrons to the CuA site in complex IV at a redox
potential of +285 mV (vs SHE) [300]. Any significant change of the redox potential of
cytochrome c disrupts the electron transfer between the complexes [300, 301].
However, under H2O2-induced oxidative stress in cardiolipin liposomes, the redox
potential of cytochrome c shifts negatively by 350-400 mV. This shift in redox potential,
switches off the cytochrome c function as an electron transporter. This alteration inhibits
the reduction of complex III by cytochrome c [301]. The peroxidase activity of
cytochrome is functionally well characterized in in-vitro and in non-physiological cell
death models [276, 301]. Although, its physiological relevance during diseased
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conditions is still unknown. To understand the mechanistic importance of cytochrome c
peroxidase formation and its ability to trigger apoptosis would be a great interest with
respect to disease models.
Hence, we intend to study the role of cardiolipin-cytochrome c peroxidase in ischemia,
which is unknown and is the focus of my research. During ischemia, we hypothesize
that excessive generation of ROS may oxidize the methionine residue (Met81) switching
on its peroxidase activity ultimately oxidizing the linoleic fatty acyl chains of cardiolipin.
This hypothesis is supported by experimental evidence (mass spectrometric data) which
showed an increase in the amount of the monolysocardiolipin (degradation product of
cardiolipin) in the samples generated following 30 min of ischemia when compared to
the control non-ischemic hearts [302].
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RESEARCH AIMS
Mitochondrial electron transport chain (ETC) contributes to its own damage during ISC.
Blocking ETC with inhibitors that disrupt electron flow through the respiratory complexes
have shown that the locus of ischemic damage is between complexes III and IV. One
key component of this site is the cytochrome c which interacts with cardiolipin.
Cardiolipin is an oxidatively sensitive phospholipid that is unique to mitochondria and is
modified during ischemia-reperfusion (ISC-REP) in the heart. Studies in nonphysiological cell stress models have shown that cytochrome c in its peroxidase mode
catalyzes oxidation of cardiolipin during oxidative stress.

However, the role of

cytochrome c peroxidase in ischemia is not yet known and is the focus of my research.
This project proposes to identify cytochrome c peroxidase as a key contributor to
mitochondrial driven ischemic injury which oxidizes cardiolipin resulting in cardiac injury.
As depicted in Figure 2.4, we hypothesize that during ISC, oxidants from complex I and
complex III modify cytochrome c and it creates an alternate route for electron transport.
Oxidation of the cytochrome c at the methionine-81 residue serves as the marker for the
peroxidase formation. As mentioned earlier, there is an increase in ROS production
during ischemia which is converted to H2O2. H2O2 acts as a substrate for cytochrome c
peroxidase or modified cytochrome c which causes the oxidation of cardiolipin to the
peroxidized form. Modification and depletion of cardiolipin disrupts normal physiology,
impairs electron transport, disrupts membrane integrity and augments cell death via the
release of cytochrome c from mitochondria. Identification of this innovative pathobiology
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during ISC-REP recognizes a novel therapeutic target, cytochrome c peroxidase, which
can be a focal point for new therapeutic interventions to decrease cardiac injury.

Specific aims:
1. Identify the oxidation of cytochrome c at the methionine-81 residue, a marker for
cytochrome c peroxidase, during ischemia-reperfusion.
2. Determine the contribution of ROS and electron flow through cytochrome c in
oxidizing cytochrome c at the methionine residue.
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Figure 2.4. Schematic of alternate route for electron transport by cyt c-CL
peroxidase during ISC-REP. ISC, ischemia; REP, reperfusion; Met, methionine; cyt c,
cytochrome c; CL, cardiolipin; CL-OOH, peroxidized cardiolipin.
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II. 2. Materials and Methods
II. 2. 1. Materials
All chemicals and reagents were purchased from Fisher Scientific, Pittsburgh, PA, or
stated otherwise, except the ones used in mitochondria isolation and mitochondriarelated functional assays, which were purchased from Sigma-Aldrich, Saint Louis, MO.
Animals
Animals were housed in the fully AAALAC-accredited Animal Research Facility at the
Virginia Commonwealth University. Experimental animals were purchased through, and
maintained by the Animal Research Facility (ARF) of Virginia Commonwealth
University. C57BL6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME).
Mice were given heparin (1000 U/kg; i.p.) followed by deep anesthesia with
pentobarbital (90 mg/kg; i.p.). Only mice which were 8-10 weeks old were used for the
experiments. All animal experiments were conducted under the guidelines on humane
use and care of laboratory animals for biomedical research published by the National
Institutes of Health (revised 2011).
II. 2. 2. Methods
II. 2. 2. 1. Preparation of mouse heart for perfusion
Male C57BL/6 mice (24.6 ± 0.9 g) were anesthetized with pentobarbital sodium (0.1
mg/g i.p.) and anti-coagulated with heparin (1000 U/g i.p.). Hearts were excised and
immediately immersed in a petri dish containing ice-cold (4°C) modified Krebs-Henseleit
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buffer solution (composition, in mM: 115 NaCl, 4.0 KCl, 2.0 CaCl2, 25 NaHCO3, 1.1
MgSO4•H2O, 0.9 KH2PO4, and 5.5 glucose; pH 7.4) oxygenated with 95% O2/5% CO2.
Any attached connective tissue was carefully removed using fine surgical scissors. The
heart was transferred to the perfusion apparatus and the aorta was carefully slipped
onto the grooved tip of the perfusion cannula and secured in place with a ligature.
Hearts were retrograde perfused via the aorta in the Langendorff mode with modified
Krebs-Henseleit buffer. The temperature of the perfusate and the heart were rnaintained
at 37 °C using a water jacket wamed by a water bath. Cardiac function was monitored
with a balloon inserted into the left ventricle, and data were recorded digitally using the
Powerlab recording system (AD Instruments, Colorado Springs, CO). Hearts mounted
on the Langendorff system were stabilized for 15 min by buffer perfusion after which
coronary flow, heart rate and perfusion pressure was recorded. After stabilization,
experimental hearts were either subjected to 45 min control perfusion (TC), or 25 min
global ischemia (ISC) by stopping the coronary flow at 37 oC followed by 30 min
reperfusion. Hearts were paced at 420 beats per min during the 15-min equilibration
period and after 10 min of reperfusion. Throughout the reperfusion period, continuous
timed samples of the coronary effluent were collected and kept on ice.
II. 2. 2. 2. Isolation of mitochondria, cytosol, and heart tissue homogenates
Adult male mice (body weight ~30 gram) were anesthetized by an intraperitoneal (i.p.)
injection of pentobarbital (90 mg/kg), followed by rapid removal of the heart for the
experiment. The heart was washed and placed in pre-chilled modified Chappell-Perry 1
(CP1) buffer (pH 7.4) with the following composition: 100 mM KCl, 50 mM 3-(Nmorpholino)

propanesulfonic

acid

(MOPS),
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1

mM

ethylene

glycol-bis(2-

aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 5 mM MgSO4⋅7H2O, and 1 mM
adenosine 5′-triphosphate disodium (ATP).
A single, combined population of total cardiac mitochondria was isolated using the
procedure described below. The entire mitochondrial isolation process was performed
on ice with chilled buffers and equipment. Hearts were excised and only ventricles were
used. Heart tissue was washed in the modified CP1 buffer. Further, the heart tissue was
dried with Whatman filter paper, weighed, and then thoroughly minced in a glass
beaker. The minced heart tissue was transferred to a glass tube for homogenization.
Next, the cardiac tissue was homogenized in 3 ml of CP1 buffer using a polytron tissue
blender (Kinematica, Bohemia, NY) for 2.5 s at a rheostat setting of 10,000 rpm. 50 µl of
the homogenate was saved as the heart tissue extract. The polytron homogenate was
centrifuged at 6,000 x g for 10 min at 4oC and supernatant was saved as a crude
cytosol for further purification. The homogenate pellet was re-suspended in 3 ml of CP1
buffer and incubated with 5 mg/g (wet weight) trypsin (#T0303, Sigma-Aldrich, Saint
Louis, MO) for 15 min at 4oC. Next, 3 ml of CP2 buffer [CP1 buffer containing 0.2%
bovine serum albumin (BSA) (#A7030, Sigma-Aldrich, Saint Louis, MO)] was added to
decrease the trypsin digestion. Digested tissue was then homogenized (two strokes)
with a tight Teflon pestle/glass tube homogenizer set at steady stirring speed of 600
rpm. From the remaining homogenate, the undigested tissue and heavier cell fractions
were separated by centrifugation at low speed 500 x g for 10 min at 4 oC. The
supernatant that contains the mitochondria was then transferred to a new tube and
centrifuged at 3000 x g for 10 min at 4oC. The pellet containing the mitochondria was
washed with 2 ml of KME buffer [100 mM KCl, 50 mM MOPS, and 0.5 mM EGTA] and
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centrifuged at 3000 x g for 10 min. Lastly, the mitochondrial pellet was re-suspended in
80-100 µl of KME and the protein concentration was measured by Lowry method using
BSA as a standard and sodium deoxycholate (Sigma-Aldrich, Saint Louis, MO) as a
detergent to solubilize the mitochondria.
Crude cytosolic fraction was supplemented with protease and phosphatase inhibitor
cocktails (Roche, Indianapolis, IN) and was further purified to separate any low-weight
cell fraction by ultra-centrifugation at 100,000 x g for 30 min at 4oC. Also, heart tissue
homogenate was supplemented with protease and phospatase inhibitor cocktails and
further lysed in a whole cell extraction buffer (WCE buffer: 20 mM Hepes pH 7.0, 300
mM NaCl, 10 mM KCl, 1 mM MgCl2, 20% glycerol, 1% Triton X-100) for 30 min at 4oC.
Cell debris was then removed from the lysates by centrifugation at 20,000 x g for 15 min
at 4oC. The protein concentrations of the cytosols and whole cell extracts were
determined using Bio-Rad protein assay (Bio-Rad, Hercules, CA) based on Bradford
dye-binding method.
II. 2. 2. 3. Measurement of oxidative phosphorylation in intact mitochondria
Polarographic measurement of oxygen consumption by intact mitochondria was
performed in a glass chamber equipped with a Clark-type oxygen electrode
(Strathkelvin Instruments, Glasgow, Scotland) as described below. The measurements
were performed at 30oC in 500 µl of a respiration buffer (80 mM KCl, 50 mM MOPS, 1
mM EGTA, 5 mM KH2PO4 and 1 mg/ml defatted BSA, at pH 7.4). For glutamate/malatedependent respiration (complex I) and succinate-dependent respiration (complex II),
150 µg of mitochondrial protein was used, and for TMPD (N,N,N′,N′-tetramethyl-p61

phenylenediamine)/ascorbate (complex IV), 50 µg of protein was used. Next, the
selected substrates for complex I (20 mM glutamate+5 mM malate), complex II (20 mM
succinate with 7.5 µM rotenone), or complex IV (1 mM TMPD/20 mM L- ascorbate with
7.5 µM rotenone) of the respiratory chain were added to the chamber. State 3
respiration was measured by the addition of 0.2 mM ADP (final concentration) followed
by state 4 respiration. After state 4 was attained, 2 mM ADP (final concentration) was
added to the chambers to measure the maximum rate of state 3 respiration. Finally,
0.04 mM uncoupler DNP (2, 4-dinitrophenol) was used to measure the uncoupled
respiration rate. In case of TMPD/ascorbate, only maximum rate of state 3 (2 mM ADP)
was measured. At the end of that measurement, 2 mM azide was added to determine
the specificity of complex IV-dependent oxygen consumption.
ADP-stimulated (state 3) and ADP-limited (state 4) respiration rates were defined and
calculated according to the method of Chance and Williams [303, 304]. Respiratory
control ratios (RCR) were calculated as a ratio of stimulated state 3 to state 4
respiration according to Estabrook [305].
II. 2. 2. 4. In-vitro modulation of electron transport chain
Isolated mitochondria were incubated with succinate and rotenone in the presence of
azide (to establish a distal block at complex IV) and compared with incubations from
succinate and rotenone with or without antimycin A (A.A) or thenoyltrifluoroacetone
(TTFA). 1 mg of isolated mitochondria was incubated with 20 mM succinate + 7.5 µM
rotenone with or without 10 mM TTFA or 10 mM antimycin A or 2 mM azide. Incubation
studies of mitochondria were carried out in MSM buffer for 50 min at 37oC with gentle
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rotation. Then, the mitochondrial protein was spun down at 3000 g for 15 min and the
pellet was re-suspended in immunoprecipitation buffer (Invitrogen).
Following incubations, cytochrome c was isolated from mitochondria using Dynabeads®
Protein G immunoprecipitation kit (Invitrogen) with cytochrome c primary antibody (BD
Biosciences). Immunocaptured cytochrome c was separated using SDS/PAGE
electrophoresis system, transferred to the PVDF membrane and blotted for Met(O)
[Cayman Chemical] and cytochrome c [BD Biosciences] (control for equal mitochondrial
protein loading) as explained later in Materials and Methods II. 2. 2. 6.
II. 2. 2. 5. Immunoprecipitation of cytochrome c
Cytochrome c was immunoprecipitated from isolated mitochondria using Dynabeads®
Protein G immunoprecipitation (IP) kit (Invitrogen). Initially, Dynabeads® were
completely resuspended by pipetting or by rotating on a roller for 5 minutes. Later, 50 µl
(1.5 mg) of Dynabeads® were transferred to an eppendorf tube. Next, the supernatant
was removed after immobilizing the beads on the magnet. To the Dynabeads®, 8 μg
anti-mouse cytochrome c antibody (BD Biosciences), diluted in antibody binding and
washing buffer [PBS buffer (Invitrogen)+0.02% Tween-20], was added and incubated
with antibody at RT for 120 min. by rotation. After incubation with the antibody, the
supernatant was removed after immobilizing beads with a magnet. The beads were
washed 2X with washing buffer. After removing the the final wash, 0.5 mg mitochondrial
protein suspended in IP buffer (Invitrogen) (20 µl saved as “Before IP”) was added to
the Dynabeads®-antibody complex and was incubated with rotation for 120 min. at RT
which allowed the antigen (Ag) to bind to the Dynabeads®-antibody complex. In the
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next step, the supernatant was recovered by immobilizing beads on the magnet and
transferred to a clean tube for further analysis (“After IP”). Following, the Dynabeads®Ab-Ag complex was then washed three times using washing buffer [PBS buffer, pH 7.4,
Invitrogen; catalog # 10010-023]. In order to avoid co-elution of the proteins bound to
the eppendorf tube wall along with the protein of interest, the Dynabeads®-Ab-Ag
complex was resuspended in washing buffer and transferred to a clean tube. Again, the
supernatant was removed and the elution buffer [50 mM glycine, pH 2.8] was added to
resuspend the Dynabeads®-Ab-Ag complex and incubated with rotation for 5 min. at RT
which dissociated the Ab-Ag complex. Finally, the supernatant containing eluted
antibody and antigen was transferred to a clean tube. For the eluted protein to be used
for Western Blotting, the pH of the eluate was adjusted by adding 1 µl of 2.8 M Tris pH
8.5 for 45 µl of eluate.
II. 2. 2. 6. Western blot analysis
Samples containing an equal amount of protein samples were mixed with Lammelli
sample buffer (Invitrogen, Carlsbad, CA) containing DTT (dithiotreitol) (Invitrogen,
Carlsbad, CA) and incubated at 95oC for 5 min. Immediately after, samples were loaded
on the gel. Proteins were separated using SDS/PAGE electrophoresis system
consisting of 4-20% gradient Tris-glycine pre-cast gels (Invitrogen, Carlsbad, CA). After
separation, gels were transferred to Immobilon-P PVDF (polyvinyldifluoridine)
membrane (Millipore) using transfer buffer with 10% methanol and a semi-dry transfer
apparatus (Bio-Rad). The blots were then incubated for 1 h at RT with 5% (w/v) non fat
dry milk (Bio-Rad) in TBS-Tween20 buffer (10 mM Tris, pH 7.5, 150 mM NaCl, and
0.1% Tween20). Next, the membranes were incubated overnight at 4oC with the primary
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antibody prepared in 5% BSA or 1% (w/v) non-fat dried milk in TBS-Tween buffer. Next
day, the blots were washed three times, 15 min each, with TBS-Tween buffer and were
incubated with a 1:50,000 dilution of anti-mouse or anti-rabbit IgG F(ab)2 fragments
conjugated with Horse Radish Peroxidase (HRP) in 5% BSA/TBS-Tween buffer for 1 hr.
Lastly, blots were washed three times, 15 min each, with TBS-Tween. The
immunoreactive proteins were visualized using Amersham ECL Plus western blotting
detection reagents (GE Healthcare Lifesciences, Piscataway, NJ) or SuperSignal Femto
maximum sensitivity substrate kit (Pierce). Protein bands on western blot were
quantified by densitometric analysis by the using ImageJ software (NIH, Bethesda).
II. 2. 2. 7. In solution enzymatic digestion of proteins
In-solution digestion of immunoprecipitated cytochrome c or commercial cytochrome c
(Sigma) was done using the trypsin or chymotrypsin enzyme. Initially, 5 µl of 0.5 M
tris(2-carboxyethyl)phosphine (TCEP) was added to the sample protein mixture which
was incubated at 37oC for 1 hr with shaking. Following 15 µl of 55 mM iodoacetamide
(IAM) was added to the protein mixture and incubated for 1 hr at 37oC with rotating in
the dark. Further the trypsin digestion buffer was prepared by adding 990 µl of 100 mM
ammonium bicarbonate (NH4HCO3) (pH 7.8) and 10 µl of 100 mM CaCl2 which
activates the enzyme to a 20 µg vial of sequencing Grade trypsin (Promega, #V511).
Chymotrypsin digestion buffer was prepared by adding 500 µl of 1 mM HCl, 495 µl of
100 mM NH4HCO3 (pH 7.8) and 5 µl of 100 mM CaCl2 to a 25 µg vial of Chymotrypsin
Sequencing Grade (Roche, No. 11418467001). Then 100 µl of trypsin/chymotrypsin
digestion buffer was added and the reaction was carried out at 37 oC for one day with
shaking. Next day, 200 µl of 10% TFA and 50 µl of 5% acetonitrile were added to stop
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the reaction and the solution was subjected to reverse phase chromatography solidphase extraction of peptides. The resulting peptide mixture was evaporated to dryness
using a speedvac and then re-suspended in 30 µl of 95/5 0.1% TFA (aq)/acetonitrile.
The samples were stored at -80oC until given for mass spectrometric analysis.
II. 2. 2. 8. Mass spectrometry analysis of immunoprecipitated cytochrome c
Peptide identification was performed using a Thermo (San Jose, CA) LTQ XL linear ion
trap mass spectrometer in Dr. Scott Gronert’s laboratory, Department of Chemistry,
Virginia Commonwealth University. The LTQ XL was interfaced with a Thermo Surveyor
capillary HPLC system. Peptides were separated on a reversed-phase, C18 column
(150 µm × 10 cm, 5 µm particles, 300 Ao pores; Column Technology, Fremont, CA) at a
flow rate of ~1 µl min-1 using 0.1% formic acid in water as mobile phase A and 0.1%
formic acid in methanol as mobile phase B. Peptides were injected and a Michrom
(Auburn, CA) CapTrap trapping column was used for rapid sample injection. The
gradient started from 2% B, then increased to 15% B over 5 min, then increased to 80%
B over 70 min, and finally increased to 95% B over 15 min. The eluted peptides were
introduced into the LTQ XL with a nanospray source operating at a spray voltage of 2.1
kV, a capillary voltage of 21 V, and a capillary temperature of 200°C. A full scan in the
m/z range 300-2000 was performed to obtain precursor ions, followed by four datadependent CID MS/MS scans for the four most abundant precursor ions in the full scan.
Dynamic exclusion was used, that is, if the same precursor ion was picked for
fragmentation twice within a 30 s window, it was excluded from further analysis for 180
s.

66

Database searching and data processing
Peptide sequences and modifications were identified using the BioWorks version 3.3.1,
SP1 implementation of Sequest (Thermo). No scan grouping was performed in
preparing peak lists for database searching. The protein sequence database used
consisted of the NCBI RefSeq version of the complete mouse proteome and reversed
versions of all sequences. Reversed sequences permit false discovery rate estimation.
Sequences were downloaded on June 27, 2011, and the final database contained
70499 entries. Only fully-tryptic and chymotryptic peptides were considered and up to
three missed cleavage sites were allowed. Fixed mass shifts were applied for alkylated
cysteines (+57 Da) and oxidized methionines (+16 Da). Sequest output was refined
using the Trans-Proteomic Pipeline (version 4.4; Institute for Systems Biology, Seattle,
WA) software package. Specifically, PeptideProphet was used, in semi-supervised
mode, to improve identification confidence. A PeptideProphet score threshold of 0.9
was applied.
II. 2. 2. 9. LC-MS/MS of cardiolipins
Isolated mitochondria (1 mg) in 50 µL of 100 mM potassium phosphate buffer were
mixed

with

1,2-dipalmitoyl-sn-glycero-3-phospho-N-methylethanolamine

(internal

standard) and extracted with 1 mL of chloroform:methanol, 2:1 containing 2 mM
butylated hydroxytoluene as an antioxidant. The lipids were given for mass
spectrometric analysis to the VCU Lipidomics Core, Department of Biochemistry and
Molecular Biology, Virginia Commonwealth University.
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For LC-MS/MS analyses, a Shimadzu LC-30 AD binary pump system coupled to a SIL30AC autoinjector and DGU20A3 degasser coupled to an ABI 4000 quadrupole/linear
ion trap (QTrap) (Applied Biosystems, Foster City, CA) operating in a triple quadrupole
mode was used. Q1 and Q3 were set to pass molecularly distinctive precursor and
product ions (or a scan across multiple m/z in Q1 or Q3), using N2 to collisionally induce
dissociations in Q2; the ion source temperature was 50°C. The lipids were separated by
reverse phase LC using a Supelco 2.1 (i.d.) x 150 mm Ascentis C18 column (Sigma, St.
Louis, MO) and a binary solvent system at a flow rate of 0.3 mL/min with a column
temperature of 60°C. Prior to injection of the sample, the column was equilibrated for
0.5 min with a solvent mixture of 30% mobile phase A (CH3OH/H2O, 50/50, v/v, with 2.5
mL triethylamine and 2.5 mL glacial acetic acid) and 70% mobile phase B (IPA/ H2O),
90/10, v/v, with 2.5 mL triethylamine and 2.5 mL glacial acetic acid). After sample
injection (typically 40 µL), the A/B ratio was maintained at 30/70 for 2.0 min, followed by
a linear gradient to 100% B over 7.0 min, which was held at 100% B1 for 4.3 min,
followed by a 0.6 min gradient return to 30/70 A/B. The column was re-equilibrated with
30:70 A/B for 1.0 min before the next run. Each cardiolipin was quantified during each
run by MRM analysis, and in addition, the structure was confirmed via a MS2 scan
within the linear ion trap during the elution of each peak.
II. 2. 3. Statistical analysis
Parameters were expressed as meanstandard error of the mean (SEM). The data
consisting of two groups were analyzed by two-tailed Student’s t-test. Differences among
multiple groups were compared by one-way analysis of variance with post hoc
comparisons performed using the Student-Newman-Keuls test. All analysis was
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executed using SigmaPlot ver.11 software (Systat Software Inc., Chicago, IL). A p<0.05
was considered statistically significant.
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II. 3. RESULTS
During ischemia, the ETC is a major target of ROS produced by specific sites of ETC
itself [5, 222]. As described in the background, previous work in the lab has shown that
the locus of ischemic damage is between complex III and IV [254]. One of the key
components of this site is the cytochrome c-cardiolipin complex which can potentially
convert to a peroxidase during pathological conditions. Cytochrome c is a small heme
protein located in the inner membrane of mitochondria that transfers electrons between
electron transport chain (ETC) complexes III and IV [30, 43]. Excessive generation of
reactive oxygen species (ROS) can oxidize a key methionine residue (Met81) of mouse
cytochrome c, disrupting the Fe-Met81 bond [264]. Oxidized cytochrome c attains
peroxidase activity as the heme catalytic center can now access H2O2, thereby
catalyzing the oxidation of the unsaturated linoleic (C18:2) acyl chains in cardiolipin to
form peroxy-groups [264, 276]. Hence, we propose that the oxidative stress condition of
ischemia-reperfusion results in the formation of oxidized cytochrome c. Secondly; we
will test the hypothesis that intra-mitochondrial ROS generation coupled with the
electron flow into the cytochrome c segment of the ETC is required to oxidize
cytochrome c.
To test this hypothesis, we used a Langendorff mouse model of ischemia and
reperfusion established in the laboratory [306]. In this model of ischemia-reperfusion,
the isolated, buffer perfused C57BL6 mouse hearts underwent either 45 min of buffer
perfusion or 25 min of ischemia and 30 min of reperfusion followed by isolation of
mitochondria. Cytochrome c was immunocaptured from the isolated mitochondria and
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the formation of methionine sulfoxide [Met(O)], a marker for cytochrome c peroxidase
formation, was assessed via semiquantitative immunoblotting. To test the second
hypothesis, mitochondria were incubated with specific substrates and inhibitors to
isolate particular segments of the ETC. Following incubations, cytochrome c was
immunocaptured and methionine sulfoxide [Met(O)] formation, was confirmed via
immunoblotting and mass spectrometry.
II. 3. 1. Immunoprecipitation of cytochrome c from isolated mitochondria.
To establish the formation of cytochrome c peroxidase activity in oxidative stress
conditions like ischemia-reperfusion, we have utilized immunoprecipitation as a technique
to specifically pull down cytochrome c from a complex mixture of proteins in isolated
mouse mitochondria. To confirm the specificity of the immunoprecipitation, freeze-thawed,
buffer-solubilized whole isolated mitochondria were probed with the cytochrome c antibody
immobilized on the Dynabeads® while negative control experiments were performed with
mouse IgG antibody and no antibody. Immunocaptured cytochrome c from all the samples
(cytochrome c antibody, IgG, no antibody) was subjected to SDS-PAGE followed by
immunoblotting with anti-cytochrome c antibody.
The specificity of immunocapture antibody to cytochrome c in the isolated mitochondria
was confirmed by comparing its immunodetection signal to the negative controls
(mouse IgG, and no IP antibody). As shown in Figure 2.5, cytochrome c bands were
absent in the negative controls whereas signal for cytochrome c was observed with
cytochrome c antibody used during immunoprecipitation. Also, the cytochrome c signal
was much enriched in the eluate containing immunocaptured cytochrome c when
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compared to supernatants collected “before IP” and “after IP”. This result demonstrates
that the immunocapture technique was successful to separate cytochrome c and the
cytochrome c antibody used for immunoprecipitation has high specificity to pull down
cytochrome c from complex mixtures of proteins (e.g. isolated mitochondria).
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Figure 2.5. Immunoprecipitation of cytochrome c from mitochondria. Western blot
showing detection of cytochrome c. Cytochrome c content in samples before-IP, afterIP, mouse IgG and no IP-cytochrome c antibody. Densitometry was measured using
ImageJ (NIH, Bethesda). Results were mean±SE. All results were compared using
one-way ANOVA test. *p<0.05 vs. control-no Ab. n= 4 in all groups. One representative
blot out of four independent experiments was shown.
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II. 3. 2. Quantification of immunoprecipitated cytochrome c using Dynabeads®.
Spectrophotometric analysis of cytochrome c content in the mitochondria revealed that
there is approximately 0.4 nmoles of cytochrome c/mg of isolated mitochondria [107,
203] which is equivalent to 4.8 µg of cytochrome c/mg of isolated mitochondria. In order
to determine the amount of immunocaptured cytochrome c from 0.5 mg of isolated
mitochondria, we have run a SDS-PAGE with the 5 µl of immunocaptured cytochrome c
(from total of 50 µl cytochrome c) along with known concentrations of commercial
equine cytochrome c (25ng, 50ng, 100ng, 500ng, 750ng, 1000ng, 2500ng).
From

the

semiquantitative

calibration

(Figure

2.6),

the

concentration

of

immunocaptured cytochrome c was projected to be approximately 40 ng from 5 µl of
immunocaptured cytochrome c. Hence, from 50 µl of immunocaptured cytochrome c, a
total of 400 ng/0.4 µg of cytochrome c was separated from 0.5 mg of isolated
mitochondria. Thus, the amount of successfully immunocaptured cytochrome c from 0.5
mg mitochondria was equivalent to 33.33 picomoles. However, the efficiency of the
immunocapture protocol depends upon the amount of isolated mitochondria,
cytochrome c antibody and the Dynabeads® utilized for the experiment.
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Figure 2.6. Semi-quantification of immunoprecipitated cytochrome c using
Dynabeads®. Western blot showing detection of cytochrome c. Immunocaptured
cytochrome c content in samples was determined by establishing a semiquantitative
range with known concentrations of commercial cytochrome c. Densitometry was
measured using ImageJ (NIH, Bethesda).
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II. 3. 3. Mass spectrometric analysis of cytochrome c containing the oxidized
methionine residue.
Murine cytochrome c has two methionines, one at 66 and the other at position 81. In order
to confirm the specific oxidation of Met81 which indicates formation of cytochrome c
peroxidase in a physiological model of isolated mouse mitochondria, we have used the
mass spectrometric approach to detect methionine sulfoxide modification.
As an initial control isolated mitochondria from mouse hearts were exposed to the oxidant,
hypochlorous acid (10 nM HOCl for 15 min). Cytochrome c was immunocaptured and
methionine sulfoxide [Met(O)] modification was determined. Isolated mitochondria from
mouse were exposed to HOCl after which cytochrome c was immunocaptured and
analyzed for oxidation of the Met-81 residue (axial ligand to the heme group) using mass
spectrometry and western blotting.
As shown in Figure 2.8A, western blotting of immunocaptured cytochrome c from
mitochondria exposed to HOCl show greater methionine sulfoxide formation compared
to control mitochondria. Recovery of peptides containing the key Met-residue has been
achieved with cytochrome c from the mouse species. Peptide fragment ions were
indicated by a, b, or c if the charge was retained on the N-terminus and by x, y or z if the
charge was maintained on the C-terminus. As shown in Figure 2.7, tryptic digest of
murine cytochrome c using collision-induced dissociation as the fragmentation method
yielded a short peptide MIFAGIK containing Met-81 (AA 81-87; MW 778.44) at the Nterminal end. The combined sequence coverage with trypsin proteolysis is around 58%
for the LTQ analysis. Previous studies have shown that b1 fragments cannot be
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detected using collision-induced dissociation [307]. Hence MIFAGIK containing a +16
mass shift associated with methionine oxidation was not detected because of the lack of
carbonyl group to initiate the nucleophilic attack on the carbonyl carbon located
between the first two aminoacids, as a result of which the cyclic intermediate cannot be
formed and thus cannot be identified [307].
In order, to generate a fragment ion encompassing Met-81, trypsin was replaced by
chymotrypsin and the peptide IPGTKMIF (AA 76-83; MW 906.51) was generated. With
the help of Dr. David Simpson from Dr. Scott Gronert’s lab, we have confidently
identified the peptide IPGTKMIF (Figure 2.8B), oxidized at methionine, using linear ion
trap mass spectrometer, with good coverage of fragment ions around Met-81. The
combined sequence coverage with chymotrypsin proteolysis is around 32% for the LTQ
analysis. As shown in the Figure 2.8B, the b-ions bracket the modification site for
unambiguous localization. Identification was further supported by a characteristic peak
for the neutral loss of methane sulfenic acid, which is common in peptides containing
oxidized methionine residues. The numerous water losses were consistent with the
presence of threonine and the most intense y-ion was consistent with the proline effect.
This work demonstrates the feasibility of cytochrome c analysis to identify site specific
oxidation of Met81 using mass spectrometry.
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Figure 2.7. Trypsin proteolysis results in “MIFAGIKK” with methionine at the
terminal residue. MS/MS spectrum of peptide containing residues 150-780 in the +1 or
+2 charge state. Blue peaks are y ions and red peaks are b ions. Black peaks were not
identified as b or as y ions.
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Figure 2.8. Detection of IPGTKMIF containing oxidized methionine from the MITO
treated with HOCl. (A) Western blot showing detection of Met(O) isolated mitochondria
treated with or without HOCl (B) Annotated tandem mass spectrum for chymotryptic
peptide IPGTKMIF, oxidized at methionine (measured precursor ion m/z = 922.4;
precursor ion determined to be singly charged).
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II. 3. 4. Cardiac function was decreased in mouse hearts following ischemiareperfusion
Next, we examined if ischemia-reperfusion oxidizes cytochrome c immunocaptured from
isolated from mouse hearts. To test this, the isolated, buffer perfused C57BL6 mouse
hearts either underwent 45 min of buffer perfusion (TC perfusion) or 25 min of ischemia
and 30 min of reperfusion (ISC-REP) following which the cardiac function, protein yield
and the mitochondrial function was measured.
During the entire perfusion on the Langendorff system, the cardiac function was
monitored in mouse hearts which underwent TC perfusion and ISC-REP. The left
ventricular developed pressure (LVDP) was recorded in both the groups. In the two
groups, LVDP was similar in each group at the end of equilibration perfusion, before
ISC-REP [TC perfusion: 84±4 mm Hg; ISC-REP: 86±12; p<0.05]. In ISC-REP hearts,
LVDP was markedly decreased during reperfusion compared with the pre-ischemic
value [TC perfusion: 74±7 mm Hg; ISC-REP: 26±7; p<0.05]. Thus, as shown in Figure
2.9, the % LVDP recovery during reperfusion was decreased to approximately 31±6% in
ischemia-reperfusion group. From the data it was clear that cardiac function was
substantially decreased during ischemia-reperfusion.
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Figure 2.9. Cardiac function was decreased in mouse hearts following ischemiareperfusion. Left ventricular developed pressure (LVDP) was recorded (as mm Hg) in
TC perfusion and ischemia (ISC)-reperfusion (REP) groups. Ischemia decreases the
recovery of LVDP during reperfusion compared with untreated hearts (A). Results were
presented as mean±SE. A difference of p<0.05 was considered significant. Results
were compared using t-test. *p<0.05 vs.TC perfusion. n=5 in all groups.
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II. 3. 5. Recovery of mitochondria from heart tissue was similar following
ischemia-reperfusion.
Following mitochondrial isolation, protein concentration was measured by the the Lowry
method using BSA as a standard and sodium deoxycholate as a detergent to solubilize
the mitochondria. The protein yield of isolated mitochondria following 25 min of
untreated ischemia and 30 min of reperfusion was similar to the protein yield in the time
control perfusion group (Figure 2.10). The protein yield averaged 21.0±2.0 mg/g wet
weight in TC perfusion vs. 24.7±0.7 mg/g in ISC-REP hearts (p=ns). Thus, any
differences between TC perfusion and ISC-REP (e.g. OXPHOS) were not due to a
preferential selection of “good” or “bad” mitochondria during the isolation process. This
was confirmed by the protein content between the two groups which provided a strong
evidence of a similar recovery of mitochondria following isolation from heart tissue.
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Figure 2.10. Ischemia-reperfusion did not alter the mitochondrial protein yield.
The protein content of the one population mitochondria isolated from C57BL6 mice was
unaltered in TC perfusion, ISC-REP groups (A). Results were presented as mean±SE.
n= 5 in all groups.
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II.

3.

6.

Glutamate+malate

and

TMPD+ascorbate

dependent

oxidative

phosphorylation was decreased following ischemia-reperfusion.
The rates of oxidative phosphorylation were studied in mitochondria isolated from time
control perfusion and ischemia-reperfusion groups using substrates that feed electrons
to different entry points in the ETC. Glutamate+malate was used as the complex I
substrate and TMPD/ascorbate (with rotenone) as electron donor to complex IV via
cytochrome c. As shown in Figure 2.11, mitochondrial respiratory function was
substantially decreased following ischemia and reperfusion. The maximal rates of
oxidative phosphorylation were obtained by addition of saturating 2 mM ADP when
glutamate+malate or TMPD/ascorbate were used as substrates. The maximal rate of
respiration using a complex I substrate, glutamate+malate, (complex I→complex
III→complex IV) was decreased by approximately 50% (TC: 438±36 nAO/min/mg
protein;

ISC-REP:

221±17,

p<0.05).

TMPD/ascorbate-dependent

(complex

IV)

respiration was lowered by approximately 25% (TC: 1560±62 nAO/min/mg protein; ISCREP: 1184±88, p<0.05) following ischemia-reperfusion. Respiratory control ratios
(RCRs) were reduced after ISC-REP with glutamate+malate as a substrate (Table 2.1).
As a next step, the rates of uncoupled respiration by addition of 2, 4-ditrophenol (DNP)
were measured. DNP is a protonophore that carries protons across the mitochondrial
membrane. In its presence, the electron transport chain works independently from the
phosphorylation apparatus. The use of DNP tests the relative contributions of the
electron transport chain and ATP synthase/ANT/Pi transporter to the decreased rate of
oxidative phosphorylation. The DNP-uncoupled respiration with the glutamate+malate
was reduced to a similar extent when compared to the respiration rates without the
84

uncoupling agent (2 mM ADP rates) (Table 2.1). This observation suggests that the
decrease in respiration was not caused by defects in ATP synthase, adenine nucleotide
translocase (ANT) or phosphate (Pi) transporter, but was indeed localized to the
electron transport chain.

85

Figure 2.11. Glutamate+malate and TMPD+ascorbate dependent oxidative
phosphorylation was decreased following ischemia-reperfusion. Oxygen
consumption by intact mitochondria was measured by Clark-type electrode at 30 oC as
described in Materials and Methods. Incubations contained: 20 mM glutamate with 5
mM malate (A) or 1 mM TMPD/20 mM L-ascorbate with 7.5 µM rotenone (B). Maximum
rates of state 3 respiration with 2 mM ADP were shown (A). For TMPD/Asc-dependent
respiration azide-sensitive data were depicted (B). Results were expressed as
nanoatoms of atomic oxygen/min/mg of mitochondrial protein and were presented as
mean±SE. * p<0.05 vs. TC perfusion. All results were compared using t-test. n=5 in all
groups.
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Table 2.1. Rates of oxidative phosphorylation in heart mitochondria isolated from
TC perfusion and ISC-REP groups.

Table 2.1. Ischemia-reperfusion affects mitochondrial oxidative phosphorylation.
Mitochondria were isolated and rates of respiration were recorded. Based on state 3
and state 4 rates, respiratory control ratios (RCRs) were calculated. During recording of
2 mM ADP-dependent maximal state 3 rate, uncoupler 2,4-dinitrophenol (DNP) was
added to establish relative contribution of phosphorylation apparatus to the observed
defects in integral respiration. Results were presented as mean±SE. Values of state 3,
state 4, 2 mM ADP and DNP rates are expressed in nanoatoms of atomic
oxygen/min/mg of mitochondrial protein. A difference of p<0.05 was considered
significant. All results were compared using t-test. *p<0.05 vs. TC perfusion. n=5 in all
groups.
ADP,
adenosine
di-phosphate;
TMPD,
N,N,N′,N′-tetramethyl-p
phenylenediamine; RCR, respiratory control ratio; DNP, 2,4-dinitrophenol.
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II. 3. 7. Cytochrome c from ISC-REP hearts exhibit increased methionine
modification
Mitochondria were isolated from the Langendorff perfused mouse hearts that underwent
45 min buffer perfusion (TC perfusion) or 25 min of ischemia and 30 min of reperfusion
(ISC-REP). Isolated mitochondria from TC perfusion and ISC-REP hearts were
subjected to immunoprecipitation to capture cytochrome c using Dynabeads® Protein G
immunoprecipitation

kit

loaded

with

cytochrome

c

primary

antibody.

The

immunocaptured cytochrome c was blotted for methionine sulfoxide [Met(O)] and
cytochrome c (control for equal mitochondrial protein loading). Met(O) formation was the
mechanistic indicator for cytochrome c peroxidase formation. As shown in Figure 2.12,
the densitometry ratio of Met(O) to cytochrome c in ISC-REP hearts showed
approximately 80% increase in the methionine sulfoxide formation when compared to
TC perfusion [Ratio Met(O)/cyt c; normalized to TC perfusion; TC perfusion: 1.0±0.0;
ISC-REP: 1.8±0.24; p<0.05]. This data supports the formation of cytochrome c
peroxidase indicated by an increased Met(O) signal during pathological setting of
ischemia-reperfusion.
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Figure 2.12. Ischemia-reperfused hearts show increased Met(O) compared to
buffer perfused hearts. Western blot showing detection of Met(O) and cytochrome c at
12 kDa in buffer perfused (TC) and ischemia-reperfused (ISC-REP) hearts. MITO from
buffer perfused (TC) and ischemia-reperfused (ISC-REP) hearts were subjected to IP
and the eluate containing cytochrome c was subjected to SDS-PAGE and
immunoblotted for Met(O) and cytochrome c (control for equal mitochondrial protein
loading). Densitometry was measured using ImageJ (NIH, Bethesda) and expressed as
ratio of Met(O) signal to cytochrome c signal. Results were expressed as mean±SE.*
p<0.05 vs. TC perfusion. All results were compared using one-way ANOVA test. n=5 in
all groups. Met(O), methionine sulfoxide.
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II. 3. 8. Mass spectrometric analysis to detect oxidized Met81 in control and
ischemia-reperfused samples
Studies to identify and analyze IPGTKMIF peptide in cytochrome c immunocaptured from
control and ischemia-reperfused were carried out using mass spectrometry. However,
basal oxidation of methionine in IPGTKMIF peptide was observed even in the control
samples. A quantification approach with Tandem Mass Tag (TMT) labeling that
irreversibly reacts with the primary amines (-NH2) groups was used to label the
peptides of immunocaptured cytochrome c from control and ischemia-reperfused
samples. Moreover, isobaric labeling with TMT tag was not compatible with
immunocapture technique as the cytochrome c separated through this procedure is in
the glycine solution which is a primary amine and thus will provide a lot of background
signal. The approach to separate glycine from cytochrome using 5KDa filters was
unsuccessful as the peptides were no longer detectable via mass spectrometry
probably due to considerable loss of protein. In addition, thioglycolate and N 2 bubbling
of the solutions used for immunocapture were also tested to reduce artifactual oxidation
which might have occurred through sample handling. However, all these approaches
could not prevent basal oxidation of methionine in control samples. One alternative, to
quantify oxidation of methionine between control and ischemia-reperfused samples is to
do an on-bead digestion of cytochrome c with chymotrypsin which will eliminate the
problem of glycine for TMT-labeling.
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II. 3. 9. Distal blockade of electron transport chain increases formation of
cytochrome c peroxidase
Given the importance of ETC as a source of ischemic damage, blocking it with inhibitors
that manipulate electron flow through the respiratory complexes has shown that the
segment located between complex III and complex IV is responsible for the ischemic
damage [254]. One of key components of this site is the cytochrome c and cardiolipin
complex located between complex III and complex IV which most likely plays an
important role in ischemia mediated cardiac injury [254]. Hence, we hypothesize that
during ischemia-reperfusion, an increase in intra-mitochondrial ROS generation coupled
with the electron flow into the cytochrome c segment of the ETC is required to oxidize
cytochrome c at the methionine residue converting to a peroxidase. To test this
hypothesis, isolated mitochondria from C57BL6 mice were incubated with specific
substrates and inhibitors to isolate particular segments of the ETC in such a way that the
cytochrome c segment has access either to the ROS or electron flux or both.
For the experiment, mitochondria were incubated with succinate and blockers including
rotenone, theonyl trifluoroacetic acid (TTFA), antimycin A and azide. Succinate feeds
electrons into the ETC through complex II. Rotenone binds to the CoQ-binding site of
complex I and prevents reverse electron transfer from complex II to complex I. TTFA
blocks complex II at the distal portion of the compex and increases ROS from complex
II. Antimycin A, inhibits the Qi center of complex III thereby causing a net increase in
ROS production from the Qo site. The ROS generated from the Qo site in complex III is
released into the intermembrane space (IMS). Azide inhibits electron transport in
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complex IV by binding tightly with the iron coordinated in Cyt a3 thereby increasing ROS
release from upstream complex I and complex III.
The isolated mitochondria from C57BL6 mice hearts were incubated with the following
combinations of substrate and inhibitors in order to test the importance of ROS and
electron flux into cytochrome c in generating modified cytochrome c. As shown in Figure
2.13, (A) succinate + rotenone: Rotenone inhibits reverse electron transfer to complex I.
This group was the control incubation (B) succinate + rotenone + TTFA: TTFA blocks at
complex II. Here, in this group there would be increase in ROS from complex II and
electron flux is blocked prior to complex III (C) succinate + rotenone + antimycin A:
Antimycin A inhibits the Qi center of complex III. Therefore, in this group there would be
an increase in ROS from complex III but no electron flux into cytochrome c (D) succinate +
rotenone + azide: Azide inhibits electron transport in complex IV. From this group there
would be an increase in ROS from complex III along with electron flux through cytochrome
c. Following incubations, cytochrome c was immunocaptured using Dynabeads® Protein
G immunoprecipitation kit. Cytochrome c and methionine sulfoxide [Met(O)], a marker for
cytochrome c peroxidase formation, were immunoblotted.
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Figure 2.13. Schematic of mitochondrial incubations with substrates to test the
contribution of ROS and electron flow to oxidize cytochrome c: Isolated
mitochondria
were
incubated
for
50
min
with
succinate+rotenone,
succinate+rotenone+TTFA, succinate+rotenone+A.A, succinate+rotenone+azide. TTFA,
Thenoyltrifluoroacetone; A.A, Antimycin A; cyt c, cytochrome c; Met(O), methionine
sulfoxide.
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Incubation of isolated mitochondria with the ETC blockers antimycin A and azide, blocks
electron flow at complex III and complex IV respectively, causing increase in ROS
production from complex I and complex III. However, distal blockade of complex IV with
azide showed approximately 200% increase in the signal as a result of Met(O) formation
compared to TTFA (blocks complex II) or A.A (blocks complex III) [Ratio Met(O)/cyt c;
normalized

to

succ+rot;

succ+rot+TTFA:

1.04±0.38;

succ+rot+A.A:

0.87±0.16;

succ+rot+azide: 3.46±1.10 p<0.05 vs. succ+rot+TTFA or succ+rot+A.A]. Azide not only
increases ROS from complex III but also allows electron flow to cytochrome c as shown
in Figure 2.14. This data suggests that both ROS and the electron flux into cytochrome
c were needed to increase the formation of Met(O), which is the marker for cytochrome
c peroxidase formation.
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Figure 2.14. ROS and electron flow into cytochrome c was essential for its
modification. Western blot showing detection of methionine sulfoxide [Met(O)] and
cytochrome c at 12 kDa. Isolated mitochondria were incubated for 50 min with
succinate+rotenone,
succinate+rotenone+TTFA,
succinate+rotenone+A.A,
succinate+rotenone+azide and then subjected to IP. The eluate containing
immunoprecipitated cytochrome c was subjected to SDS-PAGE and immunoblotted for
Met(O) and cytochrome c (control for equal mitochondrial protein loading). Densitometry
was measured using ImageJ (NIH, Bethesda) and expressed as ratio of Met(O) signal
to cytochrome c signal (lower panel). Results were expressed as mean±SE, n=5-7 for
each group. All results were compared using one-way ANOVA test. *p<0.05 vs.
Succ+Rot. One representative blot out of seven independent experiments is shown.
Succ, succinate; Rot, rotenone; TTFA, Thenoyltrifluoroacetone; A.A, Antimycin A; cyt c,
cytochrome c; Met(O), methionine sulfoxide.
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II. 3. 10. Cardiolipin content was decreased following distal blockade of electron
transport chain.
Cardiolipin, a key mitochondrial inner membrane phospholipid, plays a crucial role in
ischemia mediated cardiac injury [5, 216]. Experiments performed with different animal
models using global ischemia showed an overall decrease in the cardiolipin content [203,
216, 302, 308]. Ischemia increases ROS production resulting in cytochrome c
peroxidase formation which causes the oxidation and depletion of cardiolipin. Depletion
of cardiolipin delocalizes cytochrome c from the inner mitochondrial membrane into the
cytosol thereby activating cell death [264, 276].
As shown in Figure 2.13, blockade at cytochrome oxidase of the ETC allows cytochrome
c to have access to both ROS and electron flux which results in the oxidation of
methionine residue of cytochrome c turning it to a peroxidase. Further, we asked if the
formation of cytochrome c peroxidase as a result of distal blockade of ETC in isolated
mitochondria consequently altered the content or composition of cardiolipin. Isolated
mitochondria were incubated in KME buffer containing succinate and rotenone with or
without azide for 90 min. Phospholipids from the mitochondrial incubations were extracted
and quantified using LC/MS/MS analysis.
As shown in Figure 2.15, the content of cardiolipin was significantly decreased, by
approximately 20%, in incubations containing succinate+rotenone+azide when compared
to incubations containing succinate+rotenone [succ+rot: 48±1 nmol/mg protein;
succ+rot+azide: 39±2; p<0.05 vs. succ+rot]. This data suggests that the formation of
cytochrome c peroxidase ultimately results in loss of cardiolipin in isolated mitochondria.
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Figure 2.15. Content of cardiolipin was decreased following incubation of
mitochondria with succinate+roteonone+azide. Quantification of cardiolipin content
by phosphate measurement per mg mitochondrial protein (nmol/mg protein) in isolated
mitochondria incubated with Succ+Rot and Succ+Rot+Azide for 90min. Results were
expressed as mean±SE, n=3 for each group. All results were compared using t-test.
*p<0.05 vs. Succ+Rot. Succ, succinate; Rot, rotenone.
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II. 4. SUMMARY
 Ischemia-reperfusion increases the formation of methionine sulfoxide, a mechanistic
indicator for cytochrome c peroxidase formation.
 Increase in ROS generation along with electron flow through cytochrome c is
essential to convert cytochrome c to a peroxidase.
 As a result of increase in cytochrome c peroxidase activity with distal blockade of
ETC, cardiolipin is selectively depleted from the mitochondrial membrane.
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II. 5. DISCUSSION
Cell culture and in-vitro studies identified a novel function of cytochrome c during nonphysiological stress conditions [264, 276, 301]. During oxidative stress, cytochrome c
converts to a peroxidase and specifically oxidizes the polyunsaturated molecular
species of cardiolipin. As a result cardiolipin oxidation and depletion, pro-apoptotic
proteins, including cytochrome c and Smac/Dialbo are released into the cytosol both of
which cause cell death via the caspase dependent pathways [276]. Inhibition of
cytochrome c peroxidase by nitric oxide prevents cardiolipin oxidation and cytochrome c
loss [299], suggesting that the peroxidase is a potential site that generates
mitochondrial damage. However, the molecular switch that disrupts the electron
shuttling function of cytochrome c and converts it to a peroxidase was not identified. In
addition, the physiological relevance of the cytochrome c peroxidase is unknown. Thus,
the focus of this study was to identify the role of cytochrome c peroxidase during a
pathological condition such as ischemia-reperfusion. This work demonstrates that during
ischemia-reperfusion, an increase in intra-mitochondrial ROS generation coupled with
the electron flow through the cytochrome c segment of the ETC oxidizes cytochrome c
at the methionine residue which confers peroxidase activity, resulting in depletion of
cardiolipin.
Cardiolipin, a phospholipid unique to mitochondria, is located in the inner membrane
and is required for the optimal activity of ETC complexes [264]. The close proximity to
the ETC makes cardiolipin, containing highly enriched oxidatively sensitive linoleic acid
(C18:2) groups, a prime target for ROS generated during ischemia [309]. During
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ischemia, ROS from complex III along with electron flow through cytochrome c depletes
cardiolipin leading to a decrease in complex IV activity [203, 216, 310]. In addition,
cardiolipin depletion results in the loss of cytochrome c from the inner membrane which
in turn enhances ROS production from the ETC after ischemic damage. Under normal
physiologic conditions, cytochrome c shuttles electrons from complex III to complex IV.
However, under pathological oxidative stress conditions, methionine is oxidized
disrupting the binding of Met81 to the heme of cytochrome c resulting in the formation of
cytochrome c peroxidase [264, 271].
The changes in the cytochrome c heme environment were detected in in-vitro studies by
CD spectra shifts in the 375-425 nm region (heme moiety), changes in the UV region
(250-280 nm) as well as the quenching of the Trp59 fluorescence due to the closely
located heme group [264, 271]. In addition, the disruption of the Fe-Met81 bond can be
detected by measuring its characteristic absorbance at 695 nm [264, 271]. Yet, the
cause for the changes in absorbance or fluorescence cannot be confidently attributed to
cytochrome c oxidation. For example, the loss of the 695-nm absorption in cytochrome
c may also be due to the nitration of tyrosine residues, which is not a consequence of
sulfhydryl oxidation in Met81 [273]. However, the changes in absorbance/fluorescence
can only indicate oxidation of the sixth heme ligand at Met81 but there is no direct
evidence supporting this speculation. Moreover, the sphectrophotometric approaches
were used mainly for in-vitro studies wherein cytochrome c was the only protein present
and so any changes in absorbance/fluorescence can only be attributed to the alterations
in cytochrome c. However, these approaches cannot be used at a tissue level for
characterizing cytochrome c peroxidase due to the complex mixture of proteins involved
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which would make it impractical to attribute the changes in absorbance/fluorescence
specifically to cytochrome c.
Murine cytochrome c has two methionines, one at position 66 and the other at position 81,
whereas in the equine cytochrome c, methionines are located at positions 65 and 80.
Oxidation of Met81 (in mouse) or Met80 (in horse) results in formation of cytochrome c
peroxidase. In-vitro radiolysis of equine cytochrome c showed that Met80 is the prime
target for oxidation [311]. In-vitro studies using HOCl to oxidize cytochrome c were
shown to disrupt the Fe-Met80 bond of equine cytochrome c mainly by oxidation of
Met80. Oxidation of Met80 facilitates the reactivity of heme center to H2O2 thereby
inducing the peroxidase activity [272]. The mass spectrometry approach provided direct
evidence that methionine residues are oxidized to methionine sulfoxide and that Met80
oxidation was more favored than Met66 (72% Met80 vs. 23% Met65) [272]. This suggests
that methionine 80 (the heme ligand) in cytochrome c is the preferred site of oxidation.
In addition, the HOCl oxidized cytochrome c exhibited an increase in peroxidase activity
as seen by an increase in ability to oxidize tyrosine to tyrosyl radical (measured by EPR
spectroscopy) [272] .
Though, the immunoblotting for methionine sulfoxide from HOCl- treated mitochondria
supports the formation of cytochrome c peroxidase (Figure 2.8A), identification of site
specific oxidation of Met81 from mouse hearts would unequivocally confirm the cytochrome
c peroxidase formation. Hence, in order to confirm the specific oxidation of Met81, we have
utilized the mass spectrometric approach. In our study, we have shown at a tissue level
that the cytochrome c immunocaptured from HOCl treated mitochondria showed site
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specific oxidation of Met81 which is inline with the earlier observation with in-vitro HOCl
oxidation of commercial cytochrome c (Figure 2.8A).
Actinomycin D or staurosporine induced apoptosis in cell culture models showed that
cytochrome c bound to cardiolipin acts as a peroxidase that resulted in cardiolipin
peroxidation and apoptosis [276]. Also, in-vitro direct measurements of peroxidase
activity in the liposomes was measured using chemiluminescence, fluorescence and
electron paramagnetic resonance based assays which determine cytochrome c
peroxidase activity in the presence of H2O2 [276]. However, these studies functionally
measure cytochrome peroxidase activity but could not characterize the cytochrome c
peroxidase formed as a result of oxidative stress. Also, the role of Met81 oxidation in
cytochrome c peroxidase formation was unclear in these studies. Moreover, the
cytochrome c peroxidase activity was well characterized in in-vitro liposomal systems
[271, 276, 299, 312] or non-physiological cell stress models [276] and its physiological
relevance is still unknown. Thus, the main objective of the present study was to identify
the cytochrome c peroxidase formation at a tissue level during pathological condition such
as ischemia-reperfusion.
Myocardial ischemia damages the mitochondrial electron transport chain resulting in
decreased rates of mitochondrial respiration [5, 102, 203, 204, 222]. In our study, 25min ischemia followed by 30-min reperfusion led to a significant decrease in
glutamate+malate- and TMPD-dependent respiration (Figure 2.11) which was
consistent with previous studies [102, 201, 206]. During ischemia, mitochondria are the
major contributors of ROS production [5, 222]. Complex I and complex III are the major
sites for ROS generation during ischemia. Antimycin A, given immediately before
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ischemia, preserved complex IV respiration, cytochrome c content whereas treatment
with azide did not protect the ischemia-mediated decrease in respiration and loss of
cytochrome c [254]. This allows us to speculate that the locus of ischemic damage is
located between complex III and complex IV and that increased ROS and electron flow
to this segment both contribute to the ischemic damage. Key component of this locus is
the cytochrome c which can potentially convert into the peroxidase during ischemiareperfusion.
To identify the formation of cytochrome c peroxidase during ischemia-reperfusion, the
immunocapture approach was used to specifically separate cytochrome c (Figure 2.5)
from isolated mitochondria and asess the methionine sulfoxide formation. Oxidation of
Met81, loosens the iron coordination of cytochrome c providing access of the heme
catalytic center to small molecules like H2O2. As a result, cytochrome c converts to a
peroxidase which will reduce H2O2 to H2O and simultaneously generate peroxidized
cardiolipin. Hence, Met(O) formation is the mechanistic indicator for cytochrome c
peroxidase formation. In this study, we have demonstrated that ischemia-reperfused
hearts show an approximate 80% increase in the methionine sulfoxide formation
(Figure 2.12) which supports the role of cytochrome c peroxidase during physiological
oxidative stress conditions. Further studies will be required to study the contribution of
cytochrome c peroxidase during ischemia or during early reperfusion.
Blockade of the ETC at complex I decreases ROS generation and prevents cardiolipin
depletion [210] which suggests that when electron flow into the cytochrome c-cardiolipin
segment is limited it may inhibit peroxidase activity of cytochrome. In the present study,
mitochondrial incubation with succinate+rotenone+TTFA did not increase the formation
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of cytochrome c peroxidase. This observation suggests that the complex II generated
ROS did not contribute to the peroxidase formation. The mitochondrial incubation with
succinate+rotenone+antimycin A also did not increase peroxidase formation which
suggests that the increase in ROS due to complex III blockade was not sufficient to
convert cytochrome c to a peroxidase. Interestingly, incubation of mitochondria with
succinate+rotenone+azide significantly increased the methionine sulfoxide signal as a
result of cytochrome c peroxidase formation. This observation suggests that along with
the increase in ROS from complex III, electron flow into cytochrome c was essential for
oxidizing cytochrome c at the methionine residue resulting in formation of cytochrome
peroxidase. Thus, from this study we have demonstrated that distal blockade of
cytochrome c-cardiolipin segment with azide showed increase methionine sulfoxide
formation when compared to proximal blockade of ETC with TTFA or Antimycin A
(Figure 2.14). This highlights the importance of electron flow through the cytochrome c
segment as a key factor which influences peroxidase formation along with increased
ROS during ischemia-reperfusion.
Experiments performed with different animal models using global ischemia or in-vivo
ischemia showed an overall decrease in cardiolipin content [203, 216, 302]. The
increase in ROS production during ischemia is converted to H2O2 which acts as a
substrate for cytochrome c peroxidase causing the oxidation of cardiolipin to the
peroxidized form. Cardiolipin can undergo oxidation at the unsaturated cis double bonds
of the linoleic (C18:2) fatty acyl chains that will give rise to peroxy-groups:
(C18:2)3/(C18:2-OOH)1, (C18:2)2/(C18:2-OOH)2, (C18:2)1/(C18:2-OOH)3, (C18:2-OOH)4
[292]. Furthermore, hydrolysis of the peroxidized cardiolipin results in formation of
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monolysocardiolipin (degradation product) [229]. Alternatively, the peroxy-acyl groups
can interact directly with proteins leading to covalent cardiolipin-protein complexes.
Also, inter-molecular dimerization of cardiolipin by peroxyl bond formation undergoes
decomposition and finally generates a secondary peroxidation product, 4-hydroxy-2nonenal (HNE) [313]. In addition, HNE forms Michael adducts by interacting with the
nucleophilic groups in cysteine, histidine or lysine residues of the proteins. Also, HNE
can interact with ε-NH2 groups of Lys residues forming Schiff-bases [314]. The
decomposed cardiolipin or cardiolipin interacting with proteins is no longer extractable
by organic solvents and thus cannot be detected [308].
In this study, we have shown that incubation of isolated mitochondria for 50 min with
succinate+rotenone+azide enhanced peroxidase formation as detected by increase in
Met(O) signal but did not alter cardiolipin content (data not shown). Further
mitochondrial incubation with succinate+rotenone+azide for 90 min resulted in depletion
of cardiolipin (Figure 2.15). This suggests that peroxidase formation occurs earlier than
peroxidation of cardiolipin. In addition, the data confirms that the increase in ROS
generation along with the electron flow through cytochrome c enhanced the peroxidase
activity of cytochrome c leading to the depletion of cardiolipin from the mitochondria
(Figure 2.15). Moreover, we were not able to detect any monolysocardiolipin, a
degradation product of cardiolipin. So, it is possible that the oxidized cardiolipin is
degraded via hydrolysis or modified to form Michael adducts or Schiff’s bases. Future
studies to support the depletion of cardiolipin via degradation will include blotting for
HNE in the mitochondrial incubations.
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Ischemia decreased cardiolipin content in rabbit heart mitochondria whereas the content
of other phospholipids was preserved [203]. Also, ischemia did not alter the composition
of cardiolipin that remained in the mitochondrial membrane [203]. This is consistent with
our study using distal blockade of ETC wherein cardiolipin content was decreased but
the remaining cardiolipin composition was not altered (Figure 2.15). In our study, the
cytochrome c peroxidase formation was increased during ischemia-reperfusion (Figure
2.12) that recapitulates the role of cytochrome c peroxidase in the depletion of
cardiolipin in rabbit mitochondria [203]. Rotenone or amobarbital treatment immediately
before in-situ ischemia markedly improved respiration and attenuated the loss of
cardiolipin and cytochrome c from the mitochondria [230, 255]. Antimycin A, given
before ischemia, preserved complex IV respiration and cytochrome c content [254]. On
the other hand, azide treatment before ischemia resulted in decreased respiration and
cytochrome c content [254]. These observations from ex-vivo ischemia-reperfusion
studies strongly supports that the blockade of electron flow into cytochrome c protects
mitochondria and preserves cardioipin content which conceptually correlates to the
observations from the in-vitro mitochondrial incubations from our study.
In summary, the present study showed that cytochrome c converts to cytochrome c
peroxidase during ischemia-reperfusion. The increase in ROS generation and electron
flow through the cytochrome c segment were required for the cytochrome c peroxidase
activity that results in depletion of cardiolipin from the mitochondria (Figure 2.16).
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Figure 2.16. Schematic showing the formation of cytochrome c peroxidase during
ischemia-reperfusion. Electron flow into cytochrome c and reactive oxygen species
from electron transport chain oxidize cytochrome c during ischemia-reperfusion
converting it into a peroxidase. Cytochrome c peroxidase, converts H 2O2 to H2O inturn
peroxidising cardiolipin thereby depleting it from the mitochondrial membrane. Depletion
of cardiolipin delocalizes cytochrome c into the cytosol activating apoptotic cascades.
The peroxidized cardiolipin also alters the mitochondrial dynamics thereby triggering cell
death.
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CHAPTER III: Apoptosis signaling kinase-1 inhibitor decreases
mitochondrial damage during ischemia-reperfusion

III. 1. Introduction
Living organisms, during their lifetime, are exposed to ROS which is released as a
consequence of several physico-chemical stressors. While small amounts of ROS have
an important function as signal mediators, their overproduction in cells causes
pathological redox signaling which induces oxidative stress ultimately leading to cell
death [315-317]. In order to maintain homeostasis, cells have defense mechanisms to
counteract the excessive production of ROS. One of the major intracellular defense
mechanisms against the oxidative stress is the thioredoxin (Trx) system [318].
III. 1. 1. Thioredoxin/ Thioredoxin reductase system
Thioredoxin system contains thioredoxin, NADP (H) and thioredoxin reductase; together
they maintain a reduced intracellular redox state by the reduction of protein thiols.
Cytosolic thioredoxin-1 (Trx1) and mitochondrial Trx2 are the two major isoforms of
thioredoxin encoded by two distinct genes. Trx, an antioxidant protein, contains an
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active site with two cysteine residues which under reduced conditions exist as thiols.
However, during oxidative stress conditions, the thiols are reversibly oxidized to form an
intramolecular disulfide bond [319, 320]. Studies from thioredoxin genetic mouse
models suggest that thioredoxin is essential for survival. Thioredoxin-knockout mice
have shown that Trx is essential for the early development and morphogenesis of the
mouse embryo [321]. Thioredoxin-overexpressor transgenic mice are more resistant to
oxidative stress with longer life spans, compared to the wild-type mice [322].
The thioredoxin-interacting protein TXNIP, also known as VDUP1 (vitaminD3 upregulatedprotein-1) or TBP-2 (thioredoxin-binding protein-2), binds to both thioredoxin
isoforms (Trx1, Trx2) and negatively regulates Trx ability to scavenge ROS (Figure
3.1) [323-325]. On the other hand, Trx is bound directly to apoptosis signal-regulating
kinase 1 (ASK1) that inhibits ASK1 kinase activity [319, 326, 327]. Under oxidative
stress conditions, TXNIP localized primarily in the nucleus, translocates to cytosol and
mitochondria where it binds to and oxidizes Trx1 and Trx2, thereby reducing Trx1/Trx2
binding to ASK1 and allowing for ASK1 phosphorylation/activation (Figure 3.1) [324,
328, 329]. The interaction between Trx and ASK1 depends on the redox state of Trx,
which is supported by experimental studies wherein ASK1 fails to interact with the
oxidized form of Trx or with a Trx mutant in which both active site cysteines are
replaced with serine residues [330].
ASK1 belongs to the mitogen-activated protein kinase (MAPK) kinase kinase family that
activates the MAPK kinase 4 (MKK4)/MKK7-JNK and MKK3/6-p38 pathways through a
ROS-dependent mechanism in response to various stress conditions including
ischemia-reperfusion injury, oxidative stress, tumor necrosis factor-α (TNF-α),
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lipopolysaccharide (LPS), endoplasmic reticulum stress and calcium overload [331336]. Activation of these pathways induces cellular responses such as apoptosis,
differentiation, cell survival, and production of inflammatory cytokines [337, 338].
Sustained activation of ASK1 induces apoptosis mainly through mitochondriadependent caspase activation [330, 339, 340]. TNFα-induced apoptosis in mouse
embryonic fibroblasts (MEFS) from ASK1 deficient mice demonstrated that ASK1 is
required for the execution of ROS-induced apoptosis through JNK/p38 pathways [337].
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Figure 3.1. Schematic depicting the activation of ASK1 signaling cascade during
oxidative stress conditions. TXNIP localized primarily in the nucleus, translocates to
cytosol and mitochondria where it binds to and oxidizes Trx1 and Trx2, thereby reducing
Trx1/Trx2 binding to ASK1 and allowing for ASK1 phosphorylation/activation. ASK1
activation leads to cell death via p38, JNK or mitochondrial dependent pathways.
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ASK1 is constitutively oligomerized through its C-terminal coiled-coil (CCC) domain,
which is necessary for its basal activity [341, 342]. Under physiological conditions, Trx
inhibits the homo-oligomeric interactions through the N-terminal coiled-coil (NCC)
domain of ASK1 [343]. However, during oxidative stress conditions, Trx dissociates
from ASK1. ASK1 activates itself by homo-oligomerization of ASK1 through its NCC
domain thereby resulting in autophosphorylation at the threonine 845 residue (Figure
3.2) [342]. Post-translational modification of ASK1, including phosphorylation, regulates
ASK1 activity. Akt directly phosphorylates ASK1 at Ser83 and negatively regulates
ASK1 [344, 345]. Moreover, calcium/calmodulin-dependent protein kinase type II
(CaMKII), in response to calcium influx, also phosphorylates ASK1 and activates the
ASK1-p38 pathway [336]. In addition to phosphorylation, ubiquitination is shown to
stabilize ASK1 and is important for the net activation of ASK1 and ROS-induced cell
death [346]. On the other hand, two protein phosphatases, protein phosphatase 5 and
serine/threonine

protein

phosphatase

(PP2Cε)

dephosphorylating Thr845 residue [347, 348].
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inactivate

ASK1

by

directly

Figure 3.2. Schematic model of ROS-induced activation of ASK1 regulated by Trx.
ASK1 is constitutively oligomerized through its C-terminal coiled-coil (CCC) domain. Trx
inhibits the homo-oligomeric interactions through the N-terminal coiled-coil (NCC)
domain of ASK1. During oxidative stress conditions, Trx dissociates from ASK1. ASK1
activates itself by homo-oligomerization of ASK1 through its NCC domain thereby
resulting in autophosphorylation at the threonine 845 residue [319]. Trx, thioredoxin;
ASK1, Apoptosis signaling kinase 1.

113

III. 1. 2. ASK/p38/JNK activation during ischemia reperfusion injury
It is well understood that increased ROS production during ischemia-reperfusion
contributes to cardiac injury. One of the mechanisms through which ischemiareperfusion contributes to cell death is via the ROS-dependent activation of JNK/p38
pathways [349, 350] . JNK and p38 are differentially activated during ischemiareperfusion. The p38 pathway is rapidly activated during ischemia and remains active
during reperfusion whereas JNK is activated only during reperfusion [351-353]. Cloning
and transfection experiments using cell culture and mouse gene knockout experiments
have shown that ASK1 is the upstream regulator for JNK and p38 [354, 355].
Downstream to ASK1, MKK4 and MKK7 regulate JNK [356-358], while MKK3 and
MKK6 regulate p38 [356, 359].
Recent studies in cardiac myocytes have confirmed that ischemia preferentially
activates ASK1 and thereby MKK6-p38 pathway but does not activate JNK [360]. ASK1deficient cardiomyocytes are resistant to H2O2- or calcium-induced cell death [361].
Also, ASK1 overexpression negatively regulates heat shock transcription factor-1 (HSF1) [362]. In turn, HSF-1 protects heart against ischemia-reperfusion injury [363, 364] by
inhibiting H2O2-induced JNK activation and apoptosis [365]. Compared to young
animals, cardiomyocyte apoptosis and infarct size during ischemia-reperfusion is
increased in aging animals due to inhibition of Trx activity and subsequent disruption of
Trx-ASK1 interactions [366]. As a result of increased afterload in chronic models of
heart failure, as in transverse aortic constriction [367] or altered regional mechanical
stress [368], the effects of increased ASK1 are observed weeks after the insult.
However, following increased ROS generation and intense neurohormonal activation as
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a result of cardiac decompensation, the protection of ASK1 deletion against adverse
cardiac remodeling is evident 2 to 4 weeks after transverse aortic constriction or nonreperfused acute myocardial infarction [367, 368]. In the cardiomyopathic hamster
model, adenovirus transfection of a dominant-negative ASK1 mutant gene suppressed
heart failure progression by preventing cardiomyocyte apoptosis [369]. Together, all
these studies suggest that ASK1 couples increase in ROS production to induction of cell
death pathways.
A study by Watanabe et al., with ASK1-/- (knock-out) mice has shown a >50% decrease
in infarct size following ischemia-reperfusion [361]. Another study by Liu et al., showed
that cardiac-specific and inducible overexpression of ASK1 in the heart led to a 2-fold
increase in infarct size after 60 minutes of regional myocardial ischemia and reperfusion
[367]. Interestingly, in the absence of ischemia, cardiac specific overexpression of ASK1
had no baseline effects in the mice [367]. This observation highlights the role of ASK1
as a cellular redox sensor that is activated by ROS rather than a simple chemical
mediator of cardiac injury. All the above studies suggest that ASK1 activation through
p38/JNK pathways contributes to the pathogenesis of myocardial ischemia-reperfusion
injury. Thus, any manipulations to inhibit ASK1/p38/JNK pathways should provide
cardioprotection against ischemia-reperfusion injury.
III. 1. 3. Pharmacological inhibitors of ASK/p38/JNK pathway
Many recent studies using inhibitor molecules have shown that the components of the
ASK1-MAPK are potential therapeutic targets for decreasing cardiac injury during
ischemia-reperfusion [351, 370, 371]. Among such compounds, p38 inhibitors have
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been extensively studied. In-vitro treatment with a p38 inhibitor prior to ischemia
protected the cardiac cells from ischemia/reperfusion injury [372-374]. Ex-vivo [375-377]
and in-vivo studies [378-380] with p38 inhibitor treatment during pre-ischemia reduced
infarct size and improved left ventricular (LV) function. However, inconsistent findings
are also reported in which inhibitor treatment prior to ischemia failed to reduce the
infarct size [381, 382]. Although p38 inhibitors are efficient in reducing cardiac injury in
animal models, the outcomes from clinical use are disappointing due to their toxicity
[383-386]. Recently, pre-treatment with an inhibitor of JNK, D-JNKI-1, at the time of left
coronary artery occlusion was shown to markedly decrease infarct size after reperfusion
[370]. In addition, an upstream kinase such as ASK1 is an alternative therapeutic target
which regulates the stress responses through the JNK and p38 pathways and may
provide less toxic pharmaceutical treatment options [387]. In a very recent study by
Toldo et al., treatment with ASK1-inhibitor (ASK1-i), GS-459679, at reperfusion led to a
significant dose-related reduction in infarct size, inhibition of apoptotic cell death, and
preservation of left ventricular dimension and systolic function at both 24 hours and 7
days [388].
Mitochondria are both the targets and sources of damage during cardiac ischemia and
reperfusion [5, 222]. Myocardial ischemia disrupts the electron transport chain that
results in decrease in the rate of the integrated respiration and increase in ROS
generation [5, 222]. This in turn predisposes mitochondria to MPTP opening,
cytochrome c release and activation of apoptosis [147, 154, 228]. In view of the
substantial reduction in cardiac injury observed in the in-vivo model with ASK1-i
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treatment [388], it is of great interest to understand the potential role of mitochondria in
the observed cardioprotection during ischemia-reperfusion.
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RESEARCH AIMS
ASK1 (apoptosis signal regulating kinase 1) is a MAPK (mitogen-activated protein
kinase) kinase kinase, and its activation during ischemia (ISC)-reperfusion (REP)
increases cardiac injury through p38 and JNK pathways [320, 360]. ASK1 is considered
as a cytosolic protein (c-ASK1) [320]. Mitochondrial localized ASK1 (m-ASK1) has
recently been identified [389]. ASK1 is deactivated when it is bound on its endogenous
inhibitor, a reduced thioredoxin (Trx). ISC damages the ETC and increases the
production of reactive oxygen species (ROS) which oxidizes Trx thereby activating
ASK1 [319]. Earlier work showed that the selective small molecule inhibitor of ASK1
(ASK1-i) given at reperfusion led to a significant dose-related reduction in infarct size
measured in-vivo at both 24 hours and 7 days [388].
Damage to the mitochondrial electron transport chain (ETC) from ischemia (ISC)
increases oxidant production and favors mitochondrial permeability transition (MPTP)
during REP [5, 222]. In view of the substantial reduction in cardiac injury observed in the
in vivo model, the potential role of mitochondria in the protection from ASK1-i treatment
was studied.

Specific aim:
1. To identify whether mitochondria contribute to the cardioprotection confered by
ASK1 inhibition at reperfusion in the in-vivo model of ischemia-reperfusion.
III. 2. Materials and Methods
III. 2. 1. Materials
118

All chemicals and reagents were purchased from Fisher Scientific, Pittsburgh, PA, or
stated otherwise, except the ones used in mitochondria isolation and mitochondriarelated functional assays, which were purchased from Sigma-Aldrich, Saint Louis, MO.
Animals
Animals were purchased and housed as mentioned in Materials and Methods II. 2. 1.
III. 2. 2. METHODS
III. 2. 2. 1. Preparation of mouse heart for perfusion
Hearts from male C57BL/6 mice were excised and perfused using a Langendroff
perfusion system as explained in Material and Methods II. 2. 2. 1.
III. 2. 2. 2. Lactate dehydrogenase (LDH) assay
Lactate dehydrogenase catalyzes the oxidation of lactate as shown in the following
reaction:
Lactate + NAD+ ↔ pyruvate + NADH + H+
During ischemia, deficiency of oxygen and metabolic substrate depletes cellular ATP
which leads to loss of cellular integrity. As a result, intracelluar enzymes such as LDH
and creatine kinase were released into the extracellular space.
For the assay, the following solutions are made fresh and kept on ice until used: 100
mM phosphate (pH 7.5), 125.3 mM pyruvate and 11.3 mM NADH. Coronary effluent
collected during 30 min of reperfusion was tested for LDH release. Reaction was started
by adding 0.20 ml of effluent to 0.76 ml of 100 mM phosphate buffer which was
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incubated for 5 min. Following 30 µl of 11.3 mM NADH was added and the baseline
reading was recorded. Finally 10 µl of 125.3 mM pyruvate was added and the oxidation
of NADH was monitored as a decrease in absorption at 340 nm.
III. 2. 2. 3. Isolation of mitochondria, cytosol, and heart tissue homogenates
Following perfusion, mitochondria were isolated from the hearts as described in
Materials and Methods II. 2. 2. 2.
III. 2. 2. 4. Measurement of oxidative phosphorylation in intact mitochondria
Oxygen consumption in isolated mitochondria was measured using a Clark-type oxygen
electrode at 30°C as explained in Materials and Methods II. 2. 2. 3.
III. 2. 2. 5. Measurement of mitochondrial membrane potential
Membrane potential of intact mitochondria (ΔΨm) was measured using the fluorogenic
indicator, tetramethylrhodamine methyl ester (TMRM) dye (Invitrogen, Carlsbad, CA) as
described below. TMRM is a lipophilic cation which accumulates in the mitochondria in
proportion with membrane potential according to the Nernst equation. As the dye
accumulates in the mitochondria it exhibits a red shift in both its absorption and
fluorescence emission spectra. When mitochondria were uncoupled, TMRM was mostly
in the medium exhibiting excitation spectra at 546 nm whereas when mitochondria were
coupled or polarized, TMRM accumulates inside the mitochondria exhibiting excitation
spectra at 573 nm. These properties were used to dynamically monitor ΔΨ m of isolated
mouse heart mitochondria using a ratio fluorescence approach (573/546). Emission
intensity at 590 nm was recorded by LS55 Fluorescence Spectrometer (PerkinElmer,
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Waltham, MA). Freshly isolated mitochondria (200 µg) were incubated in respiration
buffer (100 mM KCl, 50 mM MOPS, 5 mM KPi, 1 mM EGTA) with 0.1 µM TMRM with
stirring at 30°C. Mitochondria were polarized and depolarized by sequential addition of 5
mM glutamate + 1.25 mM malate (state 2 respiration) and 0.5 mM ADP (state 3
respiration: uses protons to produce ATP from ADP by complex V). The membrane
potential was re-generated by adding 1 nM oligomycin which inhibits complex V
(state4oligomycin) followed by titration with 25 µM DNP resulting in complete uncoupling of
of the mitochondria (ΔΨ0). The difference between state 4oligomycin and ΔΨ0 is termed
ΔΨmax which should correspond to the the physiological ΔΨm (theoretical value is -160
mV).
III. 2. 2. 6. Mitochondrial H2O2 net production
Mitochondria-generated H2O2 was measured by the enzymatic oxidation of the
fluorogenic indicator Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine) (Invitrogen,
Carlsbad, CA) in the presence of horseradish peroxidase (HRP) (Sigma-Aldrich, Saint
Louis, MO) which produces the fluorescence product, resorufin as described below. The
fluorescence of resorufin (Ex = 530 ± 25nm; Em = 585 ± 30nm) was measured by LS55
Fluorescence Spectrometer (PerkinElmer, Waltham, MA) with stirring at 30 oC. Isolated
mouse mitochondria (20µg) were incubated in buffer MMC (120 mM KCl, 5 mM
KH2PO4, 1 mM EGTA; chelex treated buffer; (all from Sigma-Aldrich, Saint Louis, MO))
along with 25 µM Amplex Red and 0.25 units/ml HRP. Glutamate (6.67 mM) + Malate
(3.33 mM) and succinate (6.67 mM) were used as complex I and complex II substrates
along with their respective inhibitors rotenone (5 µM) and antimycin A (10 µM) to
generate maximal complex I dependent and complex III dependent H 2O2 production.
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The amount of H2O2 generated was calculated based on the standard curve with known
H2O2 concentrations. To show specificity of the assay, bovine liver-derived catalase
(Sigma-Aldrich, Saint Louis, MO) was added to the reaction mixture incubated with
succinate in the presence of antimycin A which quenches > 90% of the signal from H2O2
generation.
III. 2. 2. 7. Determination of Calcium Retention Capacity
Calcium Retention Capacity (CRC) was defined as the amount of Ca 2+ required to
trigger a massive Ca2+ release by isolated cardiac mitochondria as described by Ichas
et al [390]. Mitochondrial tolerance to calcium loading, CRC, is an indicator of the
resistance of mitochondria to mitochondrial permeability transition pore opening (MPTP)
following matrix Ca2+ accumulation. Extra-mitochondrial Ca2+ concentration was studied
in the single-cell ﬂuorimeter (LS 55; PerkinElmer, Waltham, MA) by monitoring the
decrease in extra-mitochondrial Ca2+ concentration using the fluorescent probe
Calcium-Green 5N (Invitrogen, Carlsbad, CA) at excitation/emission wavelengths of
500/530 nm respectively. Calcium-Green fluorescence units were used to calculate the
amount of mitochondrial Ca2+ uptake by converting the signal to [Ca2+], expressed as
nmol CaCl2/mg mitochondrial proteins, using an exponential standard curve established
with increasing amounts of Ca2+. Freshly isolated mitochondria (250 μg proteins) were
incubated in CRC buffer (150 mM sucrose, 50 mM KCl, 2 mM KH 2PO4 and 20 mM
Tris/HCl, pH 7.4) along with 0.5 mM calcium green and 5 mM succinate for 60 sec with
stirring at 30 °C. Pulses of calcium (20 nmoles) were added at 60 sec intervals and the
progressive uptake of Ca2+ by mitochondria was monitored until mitochondrial Ca 2+
release caused by MPTP opening was observed. CRC, an index of MPTP sensitivity,
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was calculated as total amount of Ca2+ taken up by mitochondria prior to triggering
massive Ca2+ release.
III. 2. 2. 8. Spectrophotometric measurement of activity of mitochondrial enzymes
Enzyme

activities

of

detergent-solubilized

mitochondria

were

measured

spectrophotometrically at 30 oC as described below. Frozen mitochondria were thawed
and solubilized in MSM/EDTA buffer (220 mM mannitol, 70 mM sucrose, 5 mM MOPS,
2 mM EDTA, pH 7.4) containing 0.5% cholate. The final protein concentration of
solubilized mitochondria was 1 µg/µl. Calculated enzyme activities were expressed as
nmol/min per mg of mitochondrial protein or 1/min/mg in case of complex IV.
III. 2. 2. 8A. NADH-ubiquinone oxidoreductase (complex I)
Complex I activity was measured as a decrease in reduced nicotinamide adenine
dinucleotide (NADH) added exogenously. Oxidation of NADH results in decreased
absorbance at 340 nm which was monitored. Solubilized mitochondria (15 µg) were
incubated in 1ml buffer containing 50 mM KH2PO4 pH 7.4, 0.1 mM EDTA, 0.2% defatted BSA (w/v), 0.015% sonicated asolectin, 0.2 mM NADH, 20 µg of antimycin A.
After 2 min of equilibration, 0.05 mM oxidized decylubiquinone (DUQ) was added and
the decrease in NADH concentration was monitored. Enzyme activities were calculated
using an extinction coefficient of 6.22 mM-1cm-1 for NADH. Rotenone was used as a
specific inhibitor of NADH-ubiquinone oxidoreductase activity. Thus, final rotenonesensitive complex I activity was determined by subtracting the rate measured in the
presence of 7.5 µM rotenone from the rate obtained without inhibitor.
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III. 2. 2. 8B. NADH-ferricyanide reductase (NFR)
NFR assay measures activity of the rotenone-insensitive proximal portion of complex I,
which has a functional NADH dehydrogenase activity with non-covalently bound flavinmononucleotide (FMN) molecule. NFR activity was recorded as a decrease in
absorbance at 340 nm due to the oxidation of exogenously added NADH. The reaction
is carried out in 1ml buffer at pH 7.4 containing 50 mM KH2PO4, 0.1 mM EDTA, 0.2%
de-fatted BSA (w/v), 0.015% sonicated asolectin, 0.66 mM K3Fe(CN)6 (potassium
ferricyanide, an artificial electron acceptor from FMN), 2 mM NaN3 and 0.2 mM NADH.
After the acquisition of a baseline reading, reaction was initiated by addition of 5 µg of
mitochondrial protein and the NFR activities were calculated using an extinction
coefficient of 6.22 mM-1cm-1 for NADH. Actual rates of NFR complex were obtained after
substracting the baseline rates obtained in the absence of mitochondria.
III. 2. 2. 8C. Succinate-decylubiquinone oxidoreductase (complex II)
Complex II activity was determined by monitoring the reduction of 2, 6dichlorophenolindophenol (DCPIP), a potent acceptor of electrons from complex IIdependent

reduced

quinols.

The

reduction

of

DCPIP

was

measured

sphectrophotometrically as a decrease in absorbance at 600 nm. Buffer at pH 7.4
containing 50 mM KH2PO4, 1 mM EDTA, 0.1% de-fatted BSA (w/v), 2 mM NaN3, 30 µl
of DCPIP (of OD of 30 µl in 1 ml of H2O being about 1.8), 0.05 mM oxidized DUQ
(saturating amounts of exogenous ubiquinone), and 10 µg of mitochondrial protein in a
total volume of 1ml was incubated for 3 min. After the equilibration period, reactions
were started by the addition of 20 mM succinate, and the decrease in absorbance at
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600 nm was monitored. Rates were calculated using DCPIP extinction coefficient of 21
mM-1cm-1. Theonyltrifluoroacetone (TTFA) was used as a specific inhibitor of succinateubiquinone oxidoreductase activity. TTFA-sensitive rates were calculated by subtracting
the rate measured in the presence of 1 mM TTFA from the rate without the inhibitor.
III. 2. 2. 8D. Ubiquinol: cytochrome c oxidoreductase (complex III)
Complex III activity was measured as an increase in absorbance at 550 nm due to the
reduction of cytochrome c. Reaction buffer (1 ml) at pH 7.4 containing 50 mM KH2PO4,
0.05 mM EDTA, 0.125% de-fatted BSA (w/v), 2 µg of mitochondrial protein extract, 3
mM NaN3 and 0.06 mM cytochrome c was equilibrated for 1 min. After equilibration, the
reaction was initiated by adding 0.1 mM reduced decylubiquinol (DUQ). Rates were
calculated using an extinction coefficient of 19.1 mM-1cm-1 for reduced cytochrome c.
Antimycin A-sensitive activity was measured by subtracting the rates measured in the
presence antimycin A (20 mM) from the rate obtained without the inhibitor.
III. 2. 2. 8E. Cytochrome c oxidase (complex IV)
Complex IV activity was determined by monitoring the oxidation of exogenously added
reduced cytochrome c which was measured as a decrease in absorbance at 550 nm.
Reaction buffer at pH 7.4 containing 50 mM KH2PO4, 0.015% asolectin, 80 µl of 0.89
mM reduced cytochrome c in a final volume of 1 ml was incubated for 8 min. After the
equilibration period, reactions were started by adding 2 µg of mitochondrial protein. The
decrease in absorbance at 550 nm was monitored and the reaction follows substrate
dependent first order kinetics. Rates were calculated and were expressed as 1/min/mg
of mitochondrial protein.
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Reduced cytochrome c was prepared by adding sodium dithionate (Na 2S2O4) to 5 ml of
3 mM oxidized cytochrome c followed by vigorous vortexing. The Na2S2O4 treated
cytochrome c solution was seperated on Amersham PD-10 column (GE Healthcare Life
Sciences, Piscataway, NJ) to remove Na2S2O4 from the solution. Collected 3 mM
reduced cytochrome c was diluted with distilled H2O to a final volume of 10 ml. Reduced
cytochrome c concentration was measured spectrophotometrically and calculated using
its extinction coefficient 19.1 mM-1cm-1. One batch of the obtained reduced cytochrome
c was used for all the samples assayed.
III. 2. 2. 8F. Citrate synthase
In Krebs cycle, the formation of citrate from acetyl coenzyme A and oxaloacetate is
catalyzed by citrate synthase which is an enzyme specific for the mitochondrial matrix.
Citrate synthase activity assay measures of the rate of generation of mercaptide ion
when citrate reacts with 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB, Ellman’s reagent).
The formation of yellow mercaptide ion was quantified spectrophotometrically by
measuring the absorbance at 412 nm. Mitochondrial protein extracts (2 µg) were added
to the reaction mixtures containing 0.1 mM DTNB and 0.34 mM acetyl CoA in a final
volume of 1 ml, and the baseline reading was taken. Next, the reactions were started by
adding 0.5 mM oxaloacetic acid (OAA) and the increase in absorbance at 412 nm was
recorded. Activities were calculated using an extinction coefficient of 13.6 mM-1cm-1 for
mercaptide ion, a result of a side reaction of DTNB with CoA-SH, a product of citrate
synthase-mediated reaction.
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III. 2. 2. 9. Western blot analysis
Proteins were separated using SDS/PAGE electrophoresis system, transferred to the
PVDF membrane as explained in Materials and Methods II. 2. 2. 6. The membrane is
incubated with the cytochrome c (BD Biosciences) or α-Tubulin (Abcam) primary
antibodies followed by Horse Radish Peroxidase (HRP) conjugated anti-mouse or antirabbit secondary antibody. The immunoreactive proteins were visualized using
Amersham ECL Plus western blotting detection reagents (GE Healthcare Lifesciences,
Piscataway, NJ) and measured as explained in Materials and Methods II. 2. 2. 6.
III. 2. 3. STATISTICAL ANALYSIS
Data were expressed as the mean ± standard error of the mean and the statistical
analysis were performed as mentioned in Materials and Methods II. 2. 3.
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III. 3. RESULTS
Studies from transgenic mouse models have shown that ASK1 is central to ischemiareperfusion injury [361, 380]. Pharmacological treatment with ASK1-inhibitor (ASK1-i),
GS-459679, at the onset of reperfusion decreases infarct size and improves cardiac
function measured at 24 hr and 7 days [388]. Since cardiac mitochondria are both
sources and targets of ischemic damage, we hypothesized that ASK1 inhibition would
change the response of mitochondria to the ischemic insult resulting in cardioprotection
observed in-vivo. Ischemic insult affects the electron transport chain, which in turn leads
to decrease in the rate of integrated respiration [5].
In our experiments, we have used a Langendorff mouse model of ischemia and
reperfusion that is established in our laboratory [306]. In this model of ischemiareperfusion, the isolated, buffer perfused mouse hearts underwent 25 min of ischemia
and 30 min of reperfusion followed by isolation of mitochondria. Four groups of mice
were studied. Time control perfusion and untreated ischemia-reperfusion mice were
control groups, and were treated with vehicle (DMSO).

ASK1-i (10 µM final

concentration) was given either before ischemia and during early reperfusion or during
early reperfusion alone (Figure 3.3). Cardiac function was monitored and lactate
dehydrogenase (LDH) release during reperfusion was measured as the index of cell
death in all the four groups. Mitochondria were isolated and oxidative-phosphorylation
was measured using glutamate, succinate and TMPD/ascorbate as substrates.
Mitochondrial susceptibility to MPTP opening was studied using the the calcium
retention capacity (CRC) assay. Mitochondrial membrane potential was measured using
the TMRM assay. The Amplex Red assay was used to measure H 2O2 release from the
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mitochondria. Spectrophotometric assays to determine changes in ETC complex
activites were performed. Additonally, changes in specific protein levels were measured
using Western blotting.
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Figure 3.3. Experimental Protocol. ASK1-i was first dissolved in DMSO as vehicle,
then diluted into Krebs-Henseleit (K-H) buffer to reach final concentration 10 uM.
DMSO (0.001%) was added into K-H buffer for time control and ischemia-reperfusion
hearts. EQ, equilibration; ISC-ischemia; REP- reperfusion.
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III. 3. 1. ASK1-i treatment improves cardiac function in mouse hearts following
ischemia-reperfusion
Cardiac function was monitored in hearts that underwent TC perfusion, ISC-REP,
ASK1-i before and after ISC, ASK1-i during reperfusion. The left ventricular developed
pressure (LVDP) and diastolic pressure were recorded. In the four groups, the LVDP
was similar in each group at the end of equilibration perfusion (Figure 3.4) [TC
perfusion: 84±3 mm Hg; ISC-REP: 79±7; ASK1-i before and after ISC: 74±5; ASK1-i
during reperfusion: 75±5; p=ns]. In untreated ISC-REP hearts and ASK1-i treatment
before and after ISC, LVDP was markedly decreased during reperfusion compared with
the pre-ischemic value [ISC-REP: 26±5 mm Hg; ASK1-i before and after ISC: 15±5;
p<0.05 vs. TC perfusion]. In contrast, ASK1-i administration only during early
reperfusion significantly increased LVDP during 60 min reperfusion compared with the
untreated hearts or ASK1-i treatment before and after ISC [ASK1-i during reperfusion:
42±3 mm Hg; p<0.05 vs. ISC-REP] (Figure 3.4).
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Figure 3.4. ASK1-i treatment during reperfusion improves cardiac function in
mouse hearts following ischemia-reperfusion. Left ventricular developed pressure
(LVDP) was recorded (as mm Hg) in TC perfusion, ISC-REP, ASK1-i before and after
ischemia, ASK1-i during reperfusion groups. There were no differences in LVDP among
the four groups at 15 minutes of equilibration (EQ) before the onset of ischemia (A).
ASK1-i treatment during reperfusion improved the recovery of LVDP during reperfusion
compared with untreated hearts (B). Results were presented as mean±SE. All results
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISCREP. n= 6-7 in all groups.
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There were no differences in diastolic pressure between groups (TC perfusion, ISCREP, ASK1-i before and after ISC, ASK1-i during reperfusion) at the end of the 15 min
equilibration perfusion (15 min) [TC perfusion: 9±2 mm Hg; ISC-REP: 9±1; ASK1-i
before and after ISC: 9±1; ASK1-i during reperfusion: 8±1; p=ns] (Figure 3.5).
Ischemia-reperfusion markedly increased diastolic pressure in untreated hearts [ISCREP: 31±8 mm Hg; p<0.05 vs. TC perfusion]. ASK1-i treatment before ischemia had no
effect on the increased diastolic pressure [ASK1-i before and after ISC: 49±7 mm Hg;
p<0.05 vs. TC perfusion] whereas ASK1-i administration during early reperfusion
significantly decreased diastolic pressure during 60 min reperfusion compared with the
untreated hearts or ASK1-i treatment before and after ISC [ASK1-i during reperfusion:
17±5 mm Hg; p<0.05 vs. ISC-REP] (Figure 3.5). Thus, from the data it was clear that
cardiac function following ischemia-reperfusion were substantially improved by ASK1-i
given during early reperfusion.
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Figure 3.5. ASK1-i treatment during reperfusion improves cardiac function in
mouse hearts following ischemia-reperfusion. Diastolic pressure was recorded (as
mm Hg) in TC perfusion, ISC-REP, ASK1-i before and after ischemia, ASK1-i during
reperfusion groups. There were no differences in diastolic pressure among the four
groups at 15 minutes of equilibration (EQ) before the onset of ischemia (A). ASK1-i
treatment during reperfusion lowered diastolic pressure during ischemia and reperfusion
compared with untreated hearts (B). Results were presented as mean±SE. All results
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISCREP. n= 6-7 in all groups.
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III. 3. 2. ASK1-i treatment decreases cardiac injury in mouse hearts following
ischemia-reperfusion
To assess myocardial cell damage, we examined the lactate dehydrogenase (LDH)
release into the coronary effluent during the 30 min reperfusion period. Ischemiareperfusion increased total LDH release into the coronary effluent when compared to
TC perfusion [TC perfusion: 198±89; ISC-REP: 890±65; p<0.05] (Figure 3.6). ASK1-i
given before ischemia and during the initial 10 minutes of reperfusion attenuated
myocardial injury as observed from the decrease in LDH release during reperfusion
[ASK1-i before and after ISC: 560±83; p<0.05 vs. ISC-REP]. Remarkably, treatment
only during early reperfusion was as protective as given before ischemia as it
decreased LDH release during reperfusion to a similar extent [ASK1-i before and after
ISC: 533±61; p<0.05 vs. ISC-REP] (Figure 3.6). Thus, the in-vitro model used for the
study of mitochondrial function recapitulates the in-vivo observation of cardioprotection
by treatment only during reperfusion.
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Figure 3.6. ASK1-i treatment decreases cardiac injury in mouse hearts following
ischemia-reperfusion. LDH release, a marker for myocardial injury, was measured and
expressed as mU/min/ g wet tissue. ASK1-i treatment decreased the amount of LDH
release compared to untreated hearts. Results were presented as mean±SE. All results
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion, #p<0.05 vs. ISCREP. All results were compared using one-way ANOVA test. n=6-7 in all groups. LDH,
lactate dehydrogenase.
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III. 3. 3. ASK1-i treatment during ischemia-reperfusion does not alter the protein
yield or citrate synthase activity in the mitochondria.
Following, mitochondrial isolation, protein concentration was measured by Lowry
method using BSA as a standard and sodium deoxycholate as a detergent to solubilize
the mitochondria. Citrate synthase activity was quantified in cholate-solubilized frozenthawed mitochondria by measuring the rate of 5,5′-dithiobis (nitrobenzoic acid)-reactive
reduced coenzyme A (412 nm).
The protein yield of isolated mitochondria following 25 min of untreated ischemia and 30
min of reperfusion was similar to the protein yield in the time control perfusion group
(Figure 3.7A). The protein yield averaged 26.2±2.4 mg/g wet weight in TC perfusion vs.
25.0±1.5 mg/g in ISC-REP hearts respectively (p=ns). As shown in Figure 3.7A, the
yields of mitochondria were also similar in ASK1-i treated groups [ASK1 before and
after ISC: 21.9±1.5; ASK1 during reperfusion: 26.4±0.8; p=ns vs. ISC-REP].
To assess whether the relative purity of the mitochondria following isolation was similar
in TC perfusion, ISC-REP and ASK1-i treated groups, activity of citrate synthase, the
marker enzyme for mitochondrial matrix, was measured. From isolated mitochondria in
all the four groups, the specific activity of citrate synthase was similar in all groups
(Figure 3.7B) [TC perfusion: 3445±194; ISC-REP: 3277±232; ASK1-i before and after
ISC: 3314±265; ASK1-i during reperfusion: 3239±183; p=ns].
Thus, following ischemia-reperfusion or ASK1-i treatment during ISC-REP, there is an
unchanged protein yield of mitochondria along with similar marker enzyme activity. This
confirms that neither ischemia-reperfusion nor the treatment with ASK1-i significantly
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modified the recovery and purity of the mitochondria. In order to understand the role of
ASK1 on mitochondrial functioning during ischemia reperfusion, we proceeded with the
measurement of oxidative phosphorylation in untreated and ASK1-i treated groups.
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Figure 3.7. ASK1-i treatment in mouse hearts following ischemia-reperfusion did
not alter the mitochondrial protein yield and citrate synthase activity. The protein
content of the isolated mitochondria from C57BL6 mice was similar in TC perfusion,
ISC-REP, ASK1-i before and after ischemia, ASK1-i during reperfusion groups (A). As a
mitochondria-specific enzymatic marker, citrate synthase activity was measured in all
samples tested (B). Results were presented as mean±SE. All results were compared
using one-way ANOVA test. n= 6-7 in all groups.
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III. 3. 4. ASK1-i treatment improved oxidative phosphorylation following ischemiareperfusion in heart mitochondria.
In order to investigate if ASK1 influences cardiac mitochondrial respiration, the rates of
oxidative phosphorylation were studied in mitochondria isolated from four groups: time
control perfusion, untreated ischemia-reperfusion, ASK1-i given either before ischemia
and during early reperfusion or during early reperfusion alone using different substrates
that donate electrons to the electron transport chain. Glutamate+malate was used as a
complex I substrate, succinate (in the presence of rotenone) as a complex II substrate,
and TMPD/ascorbate (with rotenone) as an electron donor to complex IV via
cytochrome c. As shown in Figure 3.8, mitochondrial respiratory function was
substantially decreased following ischemia and reperfusion. The maximal rates of
oxidative phosphorylation were obtained by addition of saturating 2 mM ADP when
glutamate+malate, succinate or TMPD/ascorbate was used as the substrate. The
maximal rate of respiration using a complex I substrate, glutamate+malate, (complex
I→complex III→complex IV) was decreased by approximately 50% (TC: 417±32
nAO/min/mg protein; ISC-REP: 202±12, p<0.05) (Figure 3.8A). Succinate-dependent
(complex II→complex III→complex IV) maximal integrated respiration rates showed a
significant decrease, approximately 30% (TC: 617±65 nAO/min/mg protein; ISC-REP:
425±23, p<0.05) (Figure 3.8B) whereas TMPD/ascorbate-dependent (complex IV)
respiration was lowered by approximately 30% (TC: 1776±167 nAO/min/mg protein;
ISC-REP: 1275±43, p<0.05) (Figure 3.8C) following ischemia-reperfusion. Consistent
with previously published data [102, 209], ISC-REP increased uncoupling of the
mitochondria indicated by augmented state 4 rates when using different substrates
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(Table 3.1). Augmented uncoupling of respiration following ISC-REP is the result of
increased permeability of the inner mitochondrial membrane. Respiratory control ratios
(RCRs) were reduced after ISC-REP independently of the substrates used (Table 3.1).
As a next step, the rates of uncoupled respiration by addition of 2, 4-ditrophenol (DNP)
were measured. DNP is a protonophore that carries protons across the mitochondrial
membrane. In its presence, the electron transport chain works independently from the
phosphorylation apparatus. Therefore, the use of DNP allows us to test the relative
contributions of electron transport chain and ATP synthase/ANT/Pi transporter to the
decreased rates of oxidative phosphorylation. The DNP-uncoupled respiration with
glutamate+malate and succinate was reduced to a similar extent when compared to the
ADP stimulated maximal rates (Table 3.1). This result suggests that the decrease in
respiration was not caused by defects in ATP synthase, adenine nucleotide translocase
(ANT) or phosphate (Pi) transporter, but was indeed localized to the electron transport
chain.
Treatment with ASK1-i before ischemia and during reperfusion improved the maximal
ADP-stimulated glutamate respiration rate by approximately 50% (300±21 nAO/min/mg
protein, p<0.05) compared to ISC-REP (Figure 3.8A). Furthermore, the maximum state
3 rates with glutamate+malate in the presence of DNP uncoupler were improved 55%
(375±18 nAO/min/mg protein, p<0.05 vs. ISC-REP) which was comparable with the
results without DNP (Table 3.1). Apparently, the phosphorylation aparatus did not
contribute to the improvement of complex I-dependent respiration. Also, succinate-and
TMPD/ascorbate-dependent respiration rates were not significantly improved following
ASK1-i treatment before ischemia and during early reperfusion (Table 3.1).
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Remarkably, administration of ASK1-i only during reperfusion was sufficient to protect
the maximal complex I mitochondrial oxidative phosphorylation (381±13 nAO/min/mg
protein, p<0.05) compared to ISC-REP (Figure 3.8A). Respiratory control ratios (RCRs)
were improved following ASK1-i treatment only during reperfusion independently of the
type of substrates used (Table 3.1). Furthermore, the DNP-uncoupled respiration on
glutamate+malate and succinate was improved to the similar extent (Table 3.1) which
suggests that the increase in respiration was due to protection of the electron transport
chain. Remarkably, the ASK1-i treatment during early reperfusion alone was
comparable to the regimen that included ASK1-i pre-treatment before ischemia.
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Figure 3.8. ASK1-i treatment during reperfusion improves glutamate+malate,
succinate and TMPD+ascorbate dependent oxidative phosphorylation following
ischemia-reperfusion. Oxygen consumption by intact mitochondria was measured by
Clark-type electrode at 30 oC as described in Materials and Methods. Incubations
contained: 20 mM glutamate with 5 mM malate (A), 20 mM succinate with 7.5 µM
rotenone (B), or 1 mM TMPD/20 mM L-ascorbate with 7.5 µM rotenone (C). Maximum
rates of state 3 respiration with 2 mM ADP are shown (A and B). For TMPD/Ascdependent respiration azide-sensitive data are depicted (C). Results were expressed as
nanoatoms of atomic oxygen/min/mg of mitochondrial protein and were presented as
mean±SE. * p<0.05 vs. TC perfusion, #p<0.05 vs. ISC-REP. All results were compared
using one-way ANOVA test. n= 6-7 in all groups.
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Table 3.1. Rates of oxidative phosphorylation in heart mitochondria isolated from
TC perfusion, ISC-REP and ASK1-i treated groups.

ASK1-i treatment during ischemia-reperfusion affects mitochondrial oxidative
phosphorylation. Mitochondria were isolated and rates of respiration were recorded.
Based on state 3 and state 4 rates, respiratory control ratios (RCRs) were calculated.
During recording of 2 mM ADP-dependent maximal state 3 rate, uncoupler 2,4dinitrophenol (DNP) was added to establish relative contribution of phosphorylation
apparatus and the ETC. Results were presented as mean±SE. Values of state 3, state
4, 2 mM ADP and DNP rates were expressed in nanoatoms of atomic oxygen/min/mg of
mitochondrial protein. All results were compared using one-way ANOVA test. *p<0.05
vs. TC perfusion; #p<0.05 vs. ISC-REP. n=6-7 in all groups. ADP, adenosine diphosphate; TMPD, N,N,N′,N′-tetramethyl-p phenylenediamine; RCR, respiratory control
ratio; DNP, 2,4-dinitrophenol.
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III. 3. 5. Mitochondrial membrane potential was similar/unaffected by ASK1-i
treatment during ischemia-reperfusion.
Mitochondrial membrane potential (ΔΨm) is an integral component of cellular energy
homeostasis and normal cellular function. It is a major indicator of mitochondrial
membrane intactness which reflects the pumping of protons across the inner membrane
during the process of electron transport and oxidative phosphorylation [36]. TMRM
(tetramethylrhodamine methyl ester) is a permeant cationic fluorescent probe whose
accumulation in the mitochondria depends on high trans-membrane potential (the matrix
being negative) maintained by functional mitochondria [36]. However, dissipation of the
mitochondrial transmembrane potential by protonophores (DNP) or inhibitors of electron
transport chain eliminates the selective mitochondrial association with TMRM dye.
Therefore, the intactness of the inner mitochondrial membrane was measured by
dynamic changes in the TMRM fluorescence signal in mitochondria isolated from ASK1i treated and untreated groups [36].
The maximum membrane potential that the mitochondria could generate (ΔΨmax), was
expressed as a difference between fully polarized mitochondria in the presence of 1 nM
oligomycin (state 4oligomycin) and fully uncoupled mitochondria following addition of 25 µM
DNP (Ψ0). Addition of oligomycin inhibits proton translocation through ATP synthase.
Due to the activity of ETC in the presence of excess of substrates, the protons were still
being moved from matrix to the intermembrane space. Therefore, the measured state
4oligomycin represents the maximal inner membrane polarization state. Values of ΔΨmax
from TC perfusion, ISC-REP and ASK1-i treatment groups (Figure 3.9) indicate that

145

even though ISC-REP and ASK1-i treatment altered glutamate+malate respiration, they
did not affect the ability to generate normal proton motive force in mitochondria.
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Figure 3.9. ASK1-i treatment during ischemia-reperfusion did not alter the
maximum mitochondrial potential, ΔΨmax. ΔΨm was measured in 200 µg of intact
mitochondria using 0.1 µM TMRM, a fluorescent dye that accumulates in polarized
mitochondria. (A) ΔΨmax, maximum potential that mitochondria were capable to
generate defined as the difference in membrane potential between fully polarized
mitochondria in the presence of 1 nM oligomycin (state 4 oligomycin) and fully uncoupled
mitochondria after sequential titration with 25 µM DNP (Ψ0). All results were compared
using one-way ANOVA test. *p<0.05 vs. TC perfusion. n=6-7 in all groups. RFU, relative
fluorescence units.
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III. 3. 6. ASK1-i treatment does not decrease the net H2O2 release following
ischemia-reperfusion
To assess ROS production in the isolated heart mitochondria, we measured net H2O2
release from these organelles. In normally respiring mitochondria superoxide generation
from the electron transport chain is low [80]. Due to this reason, the isolated intact
mitochondria were supplied with excess quantity of metabolic substrates which results
in the depletion of ADP and establishment of higher ROS-generating state 4 of
mitochondrial respiration.
The maximal capacity of complex I to produce H2O2 by inhibition of complex I with
rotenone was studied. Specific inhibitors were present during the time of incubation of
isolated mitochondria with respiration substrates. As shown in Figure 3.10, ischemia
significantly increased the maximal capability of complex I to generate H 2O2 [TC
perfusion: 103±12 pmol/mg protein/30min; ISC-REP: 213±22; p<0.05]. On the other
hand, ASK1-i treatment during ischemia and early reperfusion showed a trend towards
increase in the maximal complex I H2O2 production which was not significant when
compared to ISC-REP [ASK1-i before and after ISC: 275±37 pmol/mg protein/30min]
(Figure 3.10). However, this increasing trend was not observed in the mouse hearts
which underwent ASK1-i treatment only during reperfusion [ASK1-i during reperfusion:
187±29 pmol/mg protein/30min; p<0.05 vs. ASK1-i before and after ISC] (Figure 3.10).
The maximal capacity of complex III to generate H2O2 was determined using succinate
in the presence of rotenone and antimycin A. From Figure 3.11, it is clear that
ischemia-reperfusion increased the maximal capability of complex III to H2O2 net
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release [TC perfusion: 654±62 pmol/mg protein/30min; ISC-REP: 1010±87; p<0.05]. On
the other hand, ASK1-i treatment during ischemia and early reperfusion significantly
increased the maximal complex III H2O2 production when compared to ISC-REP [ASK1i before and after ISC: 1528±118 pmol/mg protein/30min] (Figure 3.11). Conversely,
mouse hearts which underwent ASK1-i treatment only during reperfusion did not
additionally increase the ROS release from complex III when compared to ISC-REP
group [ASK1-i during reperfusion: 1013±63 pmol/mg protein/30min; p<0.05 vs. ASK1-i
before and after ISC] (Figure 3.11).
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Figure 3.10. ASK1-i treatment does not decrease the maximal net H2O2 production
from complex I following ischemia-reperfusion. Intact mitochondria were isolated
and incubated with glutamate+malate+rotenone followed by measurement of H2O2 net
production using Amplex Red and HRP. Results were expressed as pmol/mg/30min
and were presented as mean±SE. All results were compared using one-way ANOVA
test. *p<0.05 vs. TC perfusion; $p<0.05 vs. ASK1-i before and after ischemia. n=6-7 in
all groups.
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Figure 3.11. ASK1-i treatment does not decrease the net H2O2 production from
complex III following ischemia-reperfusion. Intact mitochondria were isolated and
incubated with succinate+rotenone+antimycin A followed by measurement of H2O2 net
production using Amplex Red and HRP. Results were expressed as pmol/mg/30min
and were presented as mean±SE. All results were compared using one-way ANOVA
test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISC-REP; $p<0.05 vs. ASK1-i before and
after ischemia. n=6-7 in all groups.
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III. 3. 7. ASK1-i treatment during ischemia-reperfusion decreases MPTP
susceptibility in mitochondria.
Damage to the electron transport chain from ischemia increases the production of
reactive oxygen species and predisposes to the onset of mitochondrial permeability
transition (MPTP) [246]. As shown in Figure 3.10 and 3.11, the production of reactive
oxygen species was not affected by ASK1-i treatment. MPTP is triggered during
reperfusion by calcium overload leading to subsequent opening of the permeability
transition pore followed by increased permeability of the inner and outer mitochondrial
membranes.

This increase in membrane permeability results in cellular necrosis

(increased infarct size) as well as the release of mitochondrial proteins that activate
programmed cell death pathways [246].
Calcium Retention Capacity (CRC) was used to assess the susceptibility to MPTP
opening in isolated mitochondria. Representative original tracings of CRC are shown for
TC perfusion and ISC-REP groups in the upper panel of Figure 3.12A. From the
tracings, it is clear that ischemia-reperfusion increases the mitochondrial susceptibility
to undergo MPTP, manifest by a decreased tolerance of mitochondria to exogenous
calcium before MPTP occurs. The release of calcium from the mitochondrial matrix
indicated MPTP opening. In TC perfusion group, CRC averaged 640±32 nmol CaCl2/mg
protein which was markedly decreased during ISC-REP to 344±11 nmol CaCl2/mg
protein [p<0.05] (Figure 3.12B). Remarkably, treatment with ASK1-i before ischemia
and during reperfusion significantly decreased mitochondrial susceptibility to calciuminduced MPTP as shown by their improved CRC [ASK1-i before and after ISC: 480±16
nmol CaCl2/mg protein; p<0.05 vs. ISC-REP] (Figure 3.12B). However, treatment only
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during reperfusion was as protective as treatment that was given before ischemia as
noticed in the improved CRC indicating decreased sensitivity to MPTP opening [ASK1-i
before and after ISC: 451±12 nmol CaCl2/mg protein; p<0.05 vs. ISC-REP] (Figure
3.12B).
Differences between TC perfusion, ISC-REP and ASK1-i treatment groups were not due
to a preferential selection of “good” mitochondria in the ASK1-i treated groups during
the isolation process. This was confirmed by the protein content or the citrate synthase
activity between the three groups which provided a strong evidence of a similar
recovery of mitochondria from all the four groups.
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Figure 3.12. ASK1-i treatment decreases MPTP susceptibility in mitochondria
following ischemia-reperfusion. The upper panel shows a representative original
tracing of CRC measurement during time control (TC) perfusion and ischemia (ISC)reperfusion (REP) (A). The number of calcium pulses to elicit MPTP opening was
markedly decreased after ischemia-reperfusion compared with time control. ASK1-i
treatment given before and after ischemia, during reperfusion alone improved CRC
when compared with untreated hearts (B). Data were expressed as mean ± SE. All
results were compared using one-way ANOVA test. * p<0.05 vs. TC perfusion, # p<0.05
vs. ISC-REP. N= 6-7 in all groups.
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III. 3. 8. ASK1-i treatment during ischemia-reperfusion decreases cytochrome c
release from mitochondria into cytosol
Mitochondrial electron transport chain (ETC) is both the source and target for ischemic
damage [5, 222]. The sequence of events leading to mitochondrial ischemic damage
involves damage to ETC, increase in mitochondrial membrane permeability, depletion of
cytochrome c and activation of apoptotic pathways [5, 79, 156, 222]. From the earlier
data, it is clear that ASK1-i treatment improved oxidative phosphorylation through ETC
(Figure 3.8) and decreased the susceptibility to MPTP opening (Figure 3.12). As a next
step, we would like to test whether the ASK1-i treatment has any effect on the
cytochrome c release from the mitochondria into the cytosol. Therefore, we measured
cytochrome c content in cytosols from hearts subjected to ISC-REP with or without
ASK1-i treatment or TC perfusion.
Western blot analysis revealed a significant increase in release of cytochrome c into the
cytosols of ISC-REP hearts (Figure 3.13) which is consistent with the earlier published
data. ISC-REP enhanced the release of cytochrome c from the mitochondria when
compared to TC perfusion [densitometric ratio of cyt c/α-tubulin; TC perfusion:
0.286±0.090; ISC-REP: 0.818±0.223; p<0.05]. In contrast, from the densitometric
measurements, both ASK1-i treatment before and after ischemia [ratio of cyt c/α-tubulin;
ASK1-i before and after ISC: 0.211±0.082; p<0.05] and during reperfusion alone [ratio
of cyt c/α-tubulin; ASK1-i during reperfusion: 0.276±0.110; p<0.05] significantly reduced
the cytochrome c release into the cytosol from the mitochondria when compared to ISCREP (Figure 3.13). Therefore, this data suggests that ASK1-i treatment improves
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complex I, II and IV-dependent respiration in ischemic mitochondria by decreasing
susceptibility to MPTP opening thereby retaining cytochrome c in the mitochondria.
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Figure 3.13. ASK1-i decreases cytochrome c release from mitochondria into
cytosol. Mitochondrial protein extracts (10 µg) from TC perfusion, ISC-REP, ASK1-i
treated groups were resolved by SDS-PAGE and immunoblotted against cytochrome c
and porin (mitochondrial loading control). Data were expressed as mean±SE. All results
were compared using one-way ANOVA test. *p<0.05 vs. TC perfusion, #p<0.05 vs. ISCREP. A representative blot from six independent experiments is shown.
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III. 3. 9. Complex III maximal enzymatic activities were increased upon ASK1-i
treatment during reperfusion
Various reports indicate that the initial site of ischemic damage to the ETC is complex I
and with increasing duration of the insult, it progresses to complex III and IV [5, 222].
Therefore, as a next step, maximal activities of complex I, II and III were measured to
investigate if ASK1-i treatment during ischemia and reperfusion or reperfusion alone
protects against damages to complexes. As an internal ‘loading’ control, the activity of
matrix-localized citrate synthase (one of the Kreb’s cycle enzymes) was also assayed.
Spectrophotometric analysis of individual respiratory chain complexes is achieved by
total disruption of both mitochondrial membranes using freeze-and-thaw technique and
additional solubilization with 0.5 % sodium cholate. This technique dissects the entire
electron transport chain into single complexes therefore their maximum enzymatic
activity (zero order) in the presence of excess substrates (electron donors and
acceptors) was measured.
Citrate synthase rates were equal and within a normal range (2500-3000 nmol/min/mg)
among all the four groups, indicating similar relative purity of mitochondria isolated from
the heart tissue (Table 3.2). Measurement of ubiquinol: cytochrome c oxidoreductase
(complex III) activity has shown that ISC-REP decreased complex III enzymatic activity
by approximately 30% (TC perfusion: 7403±335 nmol/min/mg protein; ISC-REP:
5385±392; p<0.05) when compared to the TC perfusion which localizes the defect
within the electron transport chain (Figure 3.14). This data along with OXPHOS data
and Western blotting for cytochrome c suggests that the slower rates of
glutamate+malate, succinate and TMPD/ascorbate respiration in ISC-REP mitochondria
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were likely atleast in part due to the impaired enzymatic activity of complex III or
cytochrome c loss. Interestingly, ASK1-i treatment during early reperfusion showed a
significant improvement, approximately 30% (7892±341 nmol/min/mg protein; p<0.05),
when compared to ISC-REP group (Figure 3.14).
As depicted in Table 3.2, ischemia did not affect the maximal activity of complex I in
mitochondria isolated from mice hearts with or without ASK1-i treatment during
ischemia-reperfusion.

Additionally,

the

rotenone-insensitive

activity

of

NADH

dehydrogenase (NFR), the proximal part of complex I was measured. ISC-REP did not
decrease maximal enzymatic rates of NFR in ASK1-i treated and untreated groups.
Complex II activity was not decreased by ischemia when compared to the TC perfusion
and ASK1-i treatment has no effect on the basal enzymatic rates.
Decrease in ETC activities may be caused by changes in expression of particular
subunits of respiratory complexes. ETC activity can also be affected by the loss,
damage or functional inactivation of protein subunits [214]. ETC activities can also
modulated

by

post-translational

modifications,

including

S-nitrosylation

or

phosphorylation [22, 61, 208, 215]. Identification of the mechanistic reason for
improvement in the complex III activity with ASK1-i treatment during reperfusion will be
one of the future directions of this project.
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Figure 3.14. ASK1-i treatment during reperfusion improves the maximal activity of
complex III in heart mitochondria. Integrity of isolated mouse heart mitochondria was
disrupted by freeze-and-thaw procedure followed by solubilization with 0.5% (final v/v)
cholate in MSM/EDTA buffer and adjusted to final protein concentration of 1 μg/ul. All
enzymatic activities were measured spectrophotometrically using over-saturating
amounts of specific substrates and inhibitors (zero rate kinetics) as outlined in Materials
and Methods and expressed as nanomole of substrate decreased or product increased
per minute per mg of mitochondrial protein [nmol/min/mg]. Data are presented as
mean±SE. A difference of p<0.05 was considered significant. *p<0.05 vs. TC perfusion,
#p<0.05 vs. ISC-REP. All results were compared using one-way ANOVA test. n=6-7 in
all groups.
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Table 3.2. ETC-related enzyme activities of the isolated mitochondria from TC
perfusion, ISC-REP, ASK1-i treated groups.

ASK1-i treatment during reperfusion increases maximum activity of complex III
following ischemia-reperfusion. Complex I, II and IV activities were not altered in all
the four groups. Mitochondria were isolated, cholate-solubilized and enzymatic activities
of individual ETC complex and of citrate synthase were determined
spectrophotometrically as described in Materials and Methods. All results were
expressed in nmol/min/mg or 1/min/mg in case of complex IV. Values were expressed
as mean±SE (in nmol.min-1.mg protein-1); n=6-7 experiments. Complex I,
NADH:decylubiquinone oxidoreductase; NFR, NADH:ferricyanide oxidoreductase;
Complex II, succinate-ubiquinone oxidoreductase; Complex III, ubiquinol-cytochrome c
oxidoreductase; Complex IV, cytochrome c oxidase; CS, citrate synthase. ISC-REP,
ischemia-reperfusion; ASK1-i, apoptosis signaling kinase 1 inhibitor. All results were
compared using one-way ANOVA test. *p<0.05 vs. TC perfusion; #p<0.05 vs. ISC-REP.
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III. 4. SUMMARY
 ASK1-i treatment during ISC-REP limits damage to mitochondria by:
1. Preservation of oxidative phosphorylation
2. Increased resistance to mitochondrial permeability transition.
3. Attenuation of damage to the respiratory chain.
4. Decrease in release of cytochrome c from mitochondria.
 Interestingly, treatment at the onset of REP with a cell-permeable small molecule
inhibitor of ASK1 limits mitochondrial-driven cardiac injury.
 This is the likely the mechanism of the sustained myocardial salvage previously
observed in-vivo in a preclinical model of STEMI treated by reperfusion.
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III. 5. DISCUSSION
ASK1 belongs to the mitogen-activated protein kinase (MAPK) kinase kinase family that
activates the MAPK kinase 4 (MKK4)/MKK7-JNK and MKK3/6-p38 pathways through a
ROS-dependent mechanism during ischemia-reperfusion [320, 331, 360]. Studies from
ASK1 genetic mouse models suggest that ASK1 contributes to the pathogenesis of
myocardial ischemia-reperfusion injury [361, 367]. Hence, pharmacological treatment
using inhibitor molecules for components of the ASK1-MAPK pathway may potentially
decrease cardiac injury during ischemia-reperfusion [388]. In a recent study,
pharmacological treatment with ASK1-inhibitor (ASK1-i) at reperfusion led to a
significant dose-related reduction in infarct size, inhibition of apoptotic cell death, and
preservation of cardiac function at both 24 hours and 7 days [388]. Since cardiac
mitochondria are both sources and targets of ischemic damage, we hypothesized that
mitochondria could have a possible role in the cardioprotection observed in the in-vivo
pretreatment with ASK1-i inhibitor. In the current study, we found that the cellpermeable small molecule inhibitor of ASK1 given at the onset of reperfusion protects
mitochondrial ETC, decreases susceptibility to MPTP opening and retains cytochrome c
in the mitochondria thereby decreasing mitochondrial driven cardiac injury. Thus, this
study provides a major translationally relevant pharmacologic strategy to attenuate the
cardiac injury which starts at the time of reperfusion.
Mitochondria sustain progressive damage during myocardial ischemia including the
electron transport chain, leading to decreased rates of oxidative phosphorylation [203,
204]. Ischemia decreased complex I activity due to increased ROS generation as a
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result of electron leakage from the complex [102, 201, 205-207]. Additionally, complex I
undergoes ischemia-mediated post-translational modifications including phosphorylation
[208] and S-nitrosylation [57]. Ischemia-induced damage to NADH ferricyanide
oxidoreductase (NADH dehydrogenase, NFR), a component of the complex I, appears
likely due to the loss of the flavin mononucleotide (FMN) component [206, 207]. During
ischemia, complex II activity was decreased due to loss of protective glutathionylation of
key sulfhydryl groups [62] whereas complex III activity was decreased as a result of the
functional inactivation of iron-sulfur protein subunit [214]. Moreover, ischemia damages
cytochrome c oxidase by phosphorylation of COXI, COXIVi1, and COXVb subunits
causing functional inactivation of the complex [215] and also by selective depletion of
cardiolipin [216-218]. While the complex I defect occurs early, as ischemia continues
damage increases and involves complex III and cytochrome oxidase.
In our study, 25-min ischemia followed by 30-min reperfusion led to a significant
decrease

in

glutamate+malate-,

succinate-

and

TMPD-dependent

respiration.

Respiratory control ratios (RCRs) were reduced after ISC-REP independently of the
type of substrates used due to slight increase in state 4 and a significant decrease in
state 3 rates (Table 3.1). The decrease in integrated respiration was consistent with
previous studies of ischemia-reperfusion [102, 201, 206]. The decrease in integrated
respiration was not a result of alterations in the phosphorylation apparatus, which
consists of ATP synthase, adenine nucleotide and phosphate transporters (DNP rates in
Table 3.1), thereby localizing the damage to the ETC. Indeed, we observed that
complex III activity was decreased (Table 3.2). From the observations including
decreased complex III activity (Table 3.1 and Figure 3.14) along with the loss of
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cytochrome c (Figure 3.14), it is clear that the distal part of ETC was the key target of
ischemic damage.
Ischemic damage to the electron transport chain facilitates ROS generation and sets the
stage for myocardial injury during reperfusion. Complex I, in ETC, is one of the major
sites for ROS generation during ischemia. The predicted sites of ROS generation from
complex I are the FMN, iron sulfur cluster N2, and the two tightly bound ubiquinones
[85, 92, 94, 95, 101, 219]. Ischemia increased maximal ROS generation from complex I
following blockade with rotenone which localizes the the site for ROS generation
proximal to the ubiquinone binding site (Figure 3.10) [92]. In this study, the increased
production of H2O2 with succinate as the substrate in the presence of rotenone indicates
that complex III remains a key site for ROS generation during ischemia (Figure 3.11)
[85, 109, 207, 240]. In addition, the blockade of distal ETC with antimycin A increases
ROS generation from complex III (Figure 3.11) [78, 219]. Most of the ROS generated at
complex III are from the Qo center, whereas the Qi center can be a site for ROS
generation, especially when electron flow into the Qo center of complex III is limited [85,
105]. Moreover, increase in ROS production from complex I and complex III can also
occur due to blocks in distal ETC including cytochrome c peroxidase formation, damage
to complex III (Figure 3.14) and cytochrome c loss (Figure 3.13) with ischemiareperfusion [219]. Under these conditions, eventhough there was no complex I damage
(Table 3.2) [78, 85, 219], complex I and complex III generate ROS due to increased
relative reduction and electron leak [78, 85, 92] which augments the impact of direct
ischemic damage to ETC.
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In the present study, ischemia-reperfusion increased the susceptibility to MPTP opening
(Figure 3.12). Increased calcium availability during reperfusion enhances mitochondrial
calcium loading [244, 245, 391] which in concert with mitochondrial oxidative damage
(ROS) predisposes to the onset of MPTP during reperfusion [154, 197]. Opening of
MPTP releases cytochrome c and other pro-apoptotic proteins that cause cell death
[147, 148]. Moreover, ischemia also depletes cardiolipin that provides binding sites on
the inner membrane for cytochrome c [260, 264, 275] as a result of the peroxidase
activity of cytochrome c. Depletion of cardiolipin [216, 219] or the oxidative modification
of cardiolipin [223, 271, 296, 309, 392] diminishes the affinity of cytochrome c for
cardiolipin delocalizing cytochrome c from the inner mitochondrial membrane to the
intermembrane space [224, 227]. In normal conditions the outer membrane is
impermeable to cytochrome c. However, during ischemia, the loss of BCL-2 triggers
oligomerization of the pro-apoptotic BAX and BAK in the outer membrane forming pores
[146, 229]. This leads to an increase in the permeability of the outer membrane allowing
delocalization of cytochrome c from the inter-membrane space into the cytosol [149].
Furthermore, loss of cytochrome c also inhibits respiration, leading to further increase in
ROS production from complex I [94, 102, 393]. This oxidative damage to mitochondrial
ETC, further increases susceptibility to MPTP (Figure 3.12) that leads to the loss of
cytochrome c (Figure 3.13) [228, 394] potentially creating a vicious cycle of
mitochondrial-driven oxidative injury leading to activation of apoptotic cascades. Thus
ischemic damage to the ETC promotes MPTP opening as a mechanism of
mitochondrial-dependent cardiac injury during reperfusion, translating ischemic
mitochondrial damage into reperfusion injury.
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ASK1 is a serine/threonine protein kinase bound directly to thioredoxin and regulates
cell death via p38 and c-Jun N-terminal kinase pathways [395]. During oxidative stress,
thioredoxin is oxidized which dissociates from ASK1 resulting in activation of ASK1
through phosphorylation of Thr845 [395]. The inhibitor of ASK1 (ASK1-i), GS-459679,
competes with the binding pocket of Trx in ASK1 thereby inhibiting ASK1 activation and
decreasing cell death. Treatment with ASK1-inhibitor (ASK1-i), at reperfusion led to a
significant dose-related reduction in infarct size, inhibition of apoptotic cell death, and
preservation of left ventricular dimension and systolic function at both 24 hours and 7
days of reperfusion [388]. The protective effects of ASK1 inhibition during early
reperfusion [388] were highly consistent with ASK1 genetic models wherein ASK1knock out mice decreased infarct size [361] and ASK1 overexpressor mice showed 2fold increase in infarct size [367] following ischemia-reperfusion. Interestingly, cardiac
overexpression of ASK1 in the absence of ischemic injury had no effects in the mice,
which proves that ASK1 acts as a cellular sensor, rather than a simple mediator of injury
[395].
In this study, we have shown that treatment with ASK1-i before ischemia and during
reperfusion significantly improved glutamate respiration whereas the succinate-and
TMPD/ascorbate-dependent respiration rates were not (Table 3.1). Interestingly, ASK1-i
treatment pre- and post-ischemia decreased susceptibility to MPTP opening (Figure
3.12) thereby preventing cytochrome c release from mitochondria (Figure 3.13). We
have also shown that, ASK1-i treatment during ischemia and early reperfusion showed
a significant increase in the levels of net H2O2 generated from complex I and III (Figure
3.10, 3.11) measured following ISC-REP. This suggests that physiological interaction of
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Trx with ASK1 is important for the Trx antioxidant defense system to scavenge ROS
release during ischemia [396-398] which probably is a reason why treatment before and
after ischemia showed an additional significant increase in ROS release from complex I
and complex III compared to ISC-REP.
Prevention of ischemic damage to the ETC by pharmacologic intervention before
ischemia salvages myocardium during reperfusion [209, 231, 399, 400]. However, the
clinical potential of these approaches are obviously limited because of the
unpredictability of clinical ischemic events. Thus, pharmacologic treatment at the onset
of reperfusion has great clinical relevance for the reduction of myocardial injury during
reperfusion [401, 402]. Remarkably, administration of ASK1-i only during reperfusion
protected maximal respiration through complex I, complex II and compex IV (Figure
3.8). Interestingly, pre-treatment with ASK1-i significantly increased the complex III
activity (Figure 3.14). In addition, pre-treatment with ASK1-i inhibits MPTP opening
(Figure 3.12) thereby decreases apoptosis by preventing cytochrome c release (Figure
3.13) from mitochondria. To summarize, these results support the observed increased
rates of integrated respiration following

ASK1-i treatment during reperfusion was

indeed due to protection from damage to the distal ETC. Sites of protection include
complex III and retention of cytochrome c as a result of decreased susceptibility to
MPTP opening. Hence, the ASK1-i treatment during early reperfusion alone protected
mitochondria from ETC driven myocardial injury comparable to the regimen that
included ASK1-i pre-treatment before ischemia.
Differences in the above mentioned observations in mitochondrial respiration, ETC
complex activities and MPTP susceptibility between control, treated and untreated
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groups were not due to a preferential selection of “good” mitochondria in the treatment
groups during the isolation process. The reason for the above conclusion was because
neither the protein content (Figure 3.7A) nor the citrate synthase activity (marker for
matrix) (Figure 3.7B) differed between the four groups which provided a strong
evidence of a similar recovery and relative purity of mitochondria from the heart
irrespective of ASK1-i treatment. This finding is consistent with published work that the
protein yield or the activity of citrate synthase, a mitochondrial matrix marker enzyme,
was unaltered [102, 204, 214].
Complex III (ubiquinol: ferricytochrome c oxidoreductase, EC 1.10.2.2) is a dimeric
complex with a molecular mass of 485 kDa that is involved in the transfer of electrons
from ubiquinol to oxidized cytochrome c coupled to proton translocation [403]. Each
monomer consists of 11 subunits, three of which, namely, cytochrome b, cytochrome c1
and the iron-sulfur protein (ISP), have prosthetic groups involved in the electron transfer
[66]. Myocardial ischemia decreased complex III activity following in-vivo coronary
occlusion in the canine model [206] and following global ischemia in the isolated rat
heart [201, 214]. Electron paramagnetic resonance (EPR) signal from the ISP subunit
containing the [2Fe-2S] cluster decreases after ischemia suggesting that it is the
disruption of the cluster that decreases complex III activity. The content of the ISP
subunit, cytochromes b and c1 were unchanged by ischemia [214]. Thus, ischemia
decreases complex III activity as a result of the functional inactivation of iron-sulfur
protein subunit without degradation of the ISP subunit or the remaining eleven subunits
of the complex. In addition, ischemia depletes inner membrane enriched phospholipid,
cardiolipin [5, 204, 216]. During ischemia excessive generation of ROS converts
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cytochrome c to a “peroxidase” leading to oxidation and depletion of cardiolipin. Fusion
of mitochondria from ischemic-reperfused hearts with cardiolipin-liposomes resulted in
an almost full restoration of complex III activity which highlights the importance of
cardiolipin for optimal activity of complex III [404].
ASK1-i treatment during reperfusion improved ETC function by restoring complex III
activity. Hence, it can be predicted that the functional inactivation of ISP subunit is a
reversible phenomenon. Future studies may include studying the EPR signal of ISP
subunit to identify the functional restoration of the ISP catalytic site and the relationship
to the improved complex III activity. In addition, it would be interesting to study if ASK1-i
treatment restored complex III activity by preserving cardiolipin content. Future studies
are required to study the contribution of ASK1-i treatment in preventing cytochrome c
peroxidase formation thereby preserving the cardiolipin content which can be probable
mechanism through which both complex III activity and cytochrome c content are
restored. Also, ASK1 is a MAPK kinase kinase and its possible role in phosphorylation
of complex III subunits need to be elucidated. Hence, another possible mechanism
through which the inhibitor of ASK1 improves complex III activation is by preventing
phosphorylation of complex III subunits thereby decreasing its damage.
Ischemia-damaged mitochondria remain as sources of ROS production and the
activators of apoptosis as reperfusion continues [5, 222]. In order for the post-ischemic
myocyte to fully recover from ischemia, these damaged mitochondria must eventually
undergo repair or removal, through the processes of mitochondrial remodeling or
autophagy [138, 192, 193]. Moreover, an approach such as ASK1-i treatment during
reperfusion modulates ETC during the course of reperfusion by improving mitochondrial
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function, retaining cytochrome c leading to a decrease in the signal for mitophagy.
Decreasing mitophagy will prevent the transition to the post-infarction ischemic
cardiomyopathy state. We anticipate that the ASK1-i-mediated protection of
mitochondria during ischemia favors a pro-survival mitochondrial phenotype and
prevents the maladaptive remodeling of the mitochondria by preserving fusion proteins
throughout reperfusion. The preservation of fusion proteins will favor the maintenance of
mitochondrial membrane potential and bioenergetic function, and will also decrease the
stimulus for activation of mitophagy thereby decreasing tissue injury observed after
prolonged reperfusion.
In summary, the major finding of the present study was that pharmacological inhibition
of ASK1 protects the heart during reperfusion via the modulation of mitochondria that
sustained

damage

during

ischemia.

This

mitochondrial-based

mechanism

of

cardioprotection enhanced the functional integrity of the inner mitochondrial membrane
retaining cytochrome c thereby decreasing cell death (Figure 3.15).
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Figure 3.15. Postulated mechanismof cardioprotection with ASK1-i during
ischemia-reperfusion. The cell-permeable small molecule inhibitor of ASK1 given at
the onset of reperfusion protects mitochondrial ETC, decreases susceptibility to MPTP
opening and retains cytochrome c in the mitochondria thereby decreasing mitochondrial
driven cardiac injury. ASK1, apoptosis signaling kinase 1; MPTP, mitochondrial
permeability transition pore opening, Trx, Thioredoxin; ROS, reactive oxygen species.
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CHAPTER IV: CONCLUDING REMARKS

Excessive generation of ROS during oxidative stress conditions oxidize methionine
residues in proteins forming methionine sulfoxide and can result in loss of protein’s
function [405, 406]. Cytochrome c is a small heme protein that transfers electrons
between respiratory complexes III and IV located in the inner membrane of
mitochondria. Excessive generation of reactive oxygen species (ROS) oxidizes a key
methionine residue (Met81) of cytochrome c converting it into a pathological peroxidase
[264, 271, 406]. Cytochrome c peroxidase oxidizes and depletes cardiolipin releasing
pro-apoptotic proteins into the cytosol activating cell death cascades [264, 276]. In order
to maintain homeostatis, living organisms have developed a complex and cyclic defense
system, the methionine sulfoxide reductase system, comprising enzymatic and nonenzymatic antioxidants to restore the cytochrome c function [407, 408].
Methionine sulfoxide reductases (MSR) are redox repair enzymes which reduce both
free and protein bound Met(O) back to methionine (Met) in the presence of thioredoxin
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[407, 408]. Oxidized Trx is inactive and unable to bind to ASK1 thereby activating ASK1
and causing cell death via p38/JNK pathways [319, 327, 396]. The oxidized thioredoxin
formed is reduced by thioredoxin reductase at the expense of NADPH. Thioredoxin
reductases (TrxR) are oxido-reductases that reduce the active site disulfide in Trx
maintaining the pool of reduced Trx [409]. Reduced Trx can bind to ASK1 at the Nterminal coiled coil (NCC) domain and inactivates ASK1 by directing it for ubiquitination
and degradation [319, 326, 327]. The net result is the catalytic scavenging of ROS by
NADPH (Figure 4.1). Hence, it is clear that the cytochrome c and ASK1 cause cell
injury through an inter-connected mechanism which is not yet explored during ischemiareperfusion.
Isoforms of MSRB, MSRB2 and MSRB3B, contain an N-terminal mitochondrial targeting
sequence, localizing them to mitochondria [405, 407]. In a recent study, mouse MSRA
was shown to be important in cytochrome c repair and protection against cataract [410].
Another study showed that cytosolic MSRA protects the heart from ischemiareperfusion damage [411]. These studies highlight the pathological role of methionine
sulfoxidation in causing cell death and the importance of redox enzymes, methionine
sulfoxide reductases, in decreasing cell injury.
Through this study we propose a novel pathway through which mitochondria trigger cell
death during ischemia-reperfusion. Excessive generation of ROS and limited NADPH
availability, during ischemia-reperfusion burdens and interferes with the methionine
redox enzyme system. As a result the cytochrome c oxidized at methionine residue
during ischemia is not effectively repaired by MSRB. Oxidized cytochrome c converts to
a peroxidase creating an altered electron flow thereby oxidizing and depleting cardiolipin
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from the mitochondrial membrane. In addition, high levels of ROS that exceed the
capacity of the antioxidant system may lead to an increase in oxidized thioredoxin pool
that activates ASK1 and result in cell death.
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Figure 4.1. Schematic of the antioxidant defense system created by oxidation and
reduction of methionine residues. ROS is oxidized to Met(O) which is reduced back
to Met by MSRB, with the formation of a disulfide bond. The oxidized MSRB is reduced
by thioredoxin, forming a disulfide bond. Oxidation of thioredoxin activates ASK1.
Oxidized thioredoxin is reduced by thioredoxin reductase containing a selenocysteine
residue which is then reduced by NADPH. The net result is that ROS is reduced at the
expense of NADPH. Met, methionine; MSRB, methionine sulfoxide reductase B; Trx,
thioredoxin; TrxR, thioredoxin reductase; NADPH, nicotinamide adenine dinucleotide
phosphate.
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